CNO Financial (CNO) 10-K 23 Feb 18 2017 FY Annual report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2017	Feb. 08, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CNO Financial Group, Inc.
Entity Central Index Key	1,224,608
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Filer Category	Large Accelerated Filer
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Amendment Flag	false
Entity Public Float			$ 3.5
Entity Common Stock, Shares Outstanding		166,876,131

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Investments:
Fixed maturities, available for sale, at fair value (amortized cost: 2017 - $20,702.1; 2016 - $19,803.1)	$ 22,910.9	$ 21,096.2
Equity securities at fair value (cost: 2017 - $491.1; 2016 - $580.7)	511.7	584.2
Mortgage loans	1,650.6	1,768
Policy loans	116	112
Trading securities	284.6	363.4
Investments held by variable interest entities	1,526.9	1,724.3
Other invested assets	853.4	589.5
Total investments	27,854.1	26,237.6
Cash and cash equivalents - unrestricted	578.4	478.9
Cash and cash equivalents held by variable interest entities	178.9	189.3
Accrued investment income	245.9	239.6
Present value of future profits	359.6	401.8
Deferred acquisition costs	1,026.8	1,044.7
Reinsurance receivables	2,175.2	2,260.4
Income tax assets, net	366.9	789.7
Assets held in separate accounts	5	4.7
Other assets	319.5	328.5
Total assets	33,110.3	31,975.2
Liabilities for insurance products:
Policyholder account balances	11,220.7	10,912.7
Future policy benefits	11,521.3	10,953.3
Liability for policy and contract claims	530.3	500.6
Unearned and advanced premiums	261.7	282.5
Liabilities related to separate accounts	5	4.7
Other liabilities	751.8	611.4
Investment borrowings	1,646.7	1,647.4
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable – direct corporate obligations	914.6	912.9
Total liabilities	28,262.8	27,488.3
Commitments and Contingencies
Shareholders' equity:
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)	1.7	1.7
Additional paid-in capital	3,073.3	3,212.1
Accumulated other comprehensive income	1,212.1	622.4
Retained earnings	560.4	650.7
Total shareholders' equity	4,847.5	4,486.9
Total liabilities and shareholders' equity	$ 33,110.3	$ 31,975.2

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parentheticals) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Investments:
Fixed maturities, available for sale, amortized cost	$ 20,702.1	$ 19,803.1
Equity securities cost	$ 491.1	$ 580.7
Shareholders' equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000,000	8,000,000,000
Common stock, shares issued (in shares)	166,857,931	173,753,614
Common stock, shares outstanding (in shares)	166,857,931	173,753,614

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Insurance policy income	$ 2,647.3	$ 2,601.1	$ 2,556
Net investment income:
General account assets	1,285.4	1,204.1	1,203.6
Policyholder and other special-purpose portfolios	265.9	121.1	30
Realized investment gains (losses):
Net realized investment gains (losses), excluding impairment losses	77.4	47.9	(8)
Other-than-temporary impairments:
Total other-than-temporary impairment losses	(21.9)	(35.9)	(42.9)
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3
Net impairment losses recognized	(22.8)	(32.3)	(39.9)
Gain (loss) on dissolution of variable interest entities	(4.3)	(7.3)	11.3
Total realized gains (losses)	50.3	8.3	(36.6)
Fee revenue and other income	48.3	50.5	58.9
Total revenues	4,297.2	3,985.1	3,811.9
Benefits and expenses:
Insurance policy benefits	2,602.7	2,390.5	2,308.3
Loss on reinsurance transaction and transition expenses	0	75.4	9
Interest expense	123.7	116.4	94.9
Amortization	239.3	253.3	260
Loss on extinguishment of debt	0	0	32.8
Loss on extinguishment of borrowings related to variable interest entities	9.5	0	0
Other operating costs and expenses	841.5	796.3	739.2
Total benefits and expenses	3,816.7	3,631.9	3,444.2
Income before income taxes	480.5	353.2	367.7
Income tax expense (benefit):
Tax expense on period income	162.8	127.8	129.5
Valuation allowance for deferred tax assets and other tax items	142.1	(132.8)	(32.5)
Net income	$ 175.6	$ 358.2	$ 270.7
Basic:
Weighted average shares outstanding (in shares)	170,025	176,638	193,054
Net income (in dollars per share)	$ 1.03	$ 2.03	$ 1.40
Diluted:
Weighted average shares outstanding (in shares)	172,144	178,323	195,166
Net income (in dollars per share)	$ 1.02	$ 2.01	$ 1.39

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 175.6	$ 358.2	$ 270.7
Other comprehensive income, before tax:
Unrealized gains (losses) for the period	959.3	424.4	(1,337.6)
Amortization of present value of future profits and deferred acquisition costs	(29.7)	(27.9)	157.9
Amount related to premium deficiencies assuming the net unrealized gains (losses) had been realized	(310.5)	(46.9)	495.3
Reclassification adjustments:
For net realized investment (gains) losses included in net income	(40.2)	(18.6)	29.6
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains (losses) included in net income	1	0.7	(0.5)
Unrealized gains (losses) on investments	579.9	331.7	(655.3)
Change related to deferred compensation plan	0	8.6	(0.1)
Other comprehensive income (loss) before tax	579.9	340.3	(655.4)
Income tax (expense) benefit related to items of accumulated other comprehensive income	(195.6)	(120.7)	232.9
Other comprehensive income (loss), net of tax	384.3	219.6	(422.5)
Comprehensive income (loss)	$ 559.9	$ 577.8	$ (151.8)

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common stock and additional paid-in capital	Accumulated other comprehensive income	Retained earnings
Balance, beginning of period at Dec. 31, 2014	$ 4,688.2	$ 3,734.4	$ 825.3	$ 128.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	270.7			270.7
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit))	(420.4)		(420.4)
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit))	(2.1)		(2.1)
Cost of common stock repurchased	(365.2)	(365.2)
Dividends on common stock	(52.1)			(52.1)
Stock options, restricted stock and performance units	19.4	19.4
Balance, end of period at Dec. 31, 2015	4,138.5	3,388.6	402.8	347.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	358.2			358.2
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit))	221.1		221.1
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit))	(1.5)		(1.5)
Cost of common stock repurchased	(203)	(203)
Dividends on common stock	(54.6)			(54.6)
Stock options, restricted stock and performance units	28.2	28.2
Balance, end of period at Dec. 31, 2016	4,486.9	3,213.8	622.4	650.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting change	0.3	0.9		(0.6)
Net income	175.6			175.6
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit))	382.1		382.1
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit))	2.2		2.2
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	0		205.4	(205.4)
Cost of common stock repurchased	(167.1)	(167.1)
Dividends on common stock	(59.9)			(59.9)
Stock options, restricted stock and performance units	27.4	27.4
Balance, end of period at Dec. 31, 2017	$ 4,847.5	$ 3,075	$ 1,212.1	$ 560.4

CONSOLIDATED STATEMENT OF SHAR7

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Parentheticals) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Stockholders' Equity [Abstract]
Change in unrealized appreciation (depreciation) of investments, applicable income tax expense (benefit)	$ 194.4	$ 121.5	$ (231.7)
Change in noncredit component of impairment losses on fixed maturities, available for sale, applicable income tax expense (benefit)	$ 1.2	$ (0.8)	$ (1.2)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Insurance policy income	$ 2,483.2	$ 2,457	$ 2,423.4
Net investment income	1,229.6	1,201	1,205.9
Fee revenue and other income	48.3	50.5	58.9
Cash and cash equivalents received upon recapture of reinsurance	0	73.6	0
Insurance policy benefits	(1,973.1)	(1,916)	(1,879.4)
Interest expense	(120.5)	(106)	(90)
Deferrable policy acquisition costs	(236.1)	(242.7)	(246.4)
Other operating costs	(740.9)	(747.9)	(720.5)
Income taxes	(77.4)	(6.7)	(4.1)
Net cash from operating activities	613.1	762.8	747.8
Cash flows from investing activities:
Sales of investments	2,487.4	2,841.8	2,177.6
Maturities and redemptions of investments	3,324.6	2,507.2	1,853.4
Purchases of investments	(6,141)	(6,159.8)	(4,767.2)
Net sales (purchases) of trading securities	108.9	(84.2)	(12.3)
Change in cash and cash equivalents held by variable interest entities	10.4	175.1	(296.1)
Other	(29.9)	(22.5)	(25)
Net cash provided (used) by investing activities	(239.6)	(742.4)	(1,069.6)
Cash flows from financing activities:
Issuance of notes payable, net	0	0	910
Payments on notes payable	0	0	(797.1)
Expenses related to extinguishment of debt	0	0	(17.8)
Issuance of common stock	8.3	8.4	6.3
Payments to repurchase common stock	(168.3)	(210)	(365.4)
Common stock dividends paid	(59.6)	(54.8)	(52)
Amounts received for deposit products	1,445.9	1,386.7	1,241.9
Withdrawals from deposit products	(1,232.6)	(1,181.6)	(1,225)
Issuance of investment borrowings:
Federal Home Loan Bank	432	432.7	475
Related to variable interest entities	981.6	493.2	544.7
Payments on investment borrowings:
Federal Home Loan Bank	(432.7)	(333.5)	(425.7)
Related to variable interest entities and other	(1,248.6)	(514.9)	(132)
Investment borrowings - repurchase agreements, net	0	0	(20.4)
Net cash provided (used) by financing activities	(274)	26.2	142.5
Net increase (decrease) in cash and cash equivalents	99.5	46.6	(179.3)
Cash and cash equivalents, beginning of year	478.9	432.3	611.6
Cash and cash equivalents, end of year	$ 578.4	$ 478.9	$ 432.3

BUSINESS AND BASIS OF PRESENTAT

BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS AND BASIS OF PRESENTATION	BUSINESS AND BASIS OF PRESENTATION CNO Financial Group, Inc., a Delaware corporation ("CNO"), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products. The terms "CNO Financial Group, Inc.", "CNO", the "Company", "we", "us", and "our" as used in these financial statements refer to CNO and its subsidiaries. Such terms, when used to describe insurance business and products, refer to the insurance business and products of CNO's insurance subsidiaries. We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets. We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing. The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; long-term care in run off; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting as an additional business segment, the long-term care block recaptured from Beechwood Re Ltd. ("BRe"), as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance". The Company’s insurance segments are described below: • Bankers Life, which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life"). Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee. • Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National. • Colonial Penn , which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn"). • Long-term care in run-off consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC"). We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We have reclassified certain amounts from the prior periods to conform to the 2017 presentation. These reclassifications have no effect on net income or shareholders' equity. The accompanying financial statements include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates. When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods. For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals. If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Investments Fixed maturity securities include available for sale bonds and redeemable preferred stocks. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders’ equity. Equity securities include available for sale investments in common stock, exchange-traded funds and non-redeemable preferred stock. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders' equity. Mortgage loans held in our investment portfolio are carried at amortized unpaid balances, net of provisions for estimated losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received. Policy loans are stated at current unpaid principal balances. Policy loans are collateralized by the cash surrender value of the life insurance policy. Interest income is recorded as earned using the contractual interest rate. Trading securities include: (i) investments purchased with the intent of selling in the near team to generate income; (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products); and (iii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments and investments supporting insurance liabilities and reinsurance agreements is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in realized investment gains (losses). Investment income related to investments supporting certain insurance liabilities is substantially offset by the change in insurance policy benefits related to certain products. Other invested assets include: (i) call options purchased in an effort to offset or hedge the effects of certain policyholder benefits related to our fixed index annuity and life insurance products; (ii) Company-owned life insurance ("COLI"); and (iii) certain non-traditional investments. We carry the call options at estimated fair value as further described in the section of this note entitled "Accounting for Derivatives". We carry COLI at its cash surrender value which approximates its net realizable value. Non-traditional investments include investments in certain limited partnerships and hedge funds which are accounted for using the equity method; and promissory notes, which are accounted for using the cost method. In accounting for limited partnerships and hedge funds, we consistently use the most recently available financial information provided by the general partner or manager of each of these investments, which is one to three months prior to the end of our reporting period. Interest income on fixed maturity securities is recognized when earned using a constant effective yield method giving effect to amortization of premiums and accretion of discounts. Prepayment fees are recognized when earned. Dividends on equity securities are recognized when declared. When we sell a security (other than trading securities), we report the difference between the sale proceeds and amortized cost (determined based on specific identification) as a realized investment gain or loss. We regularly evaluate our investments for possible impairment as further described in the note to the consolidated financial statements entitled "Investments". When a security defaults (including mortgage loans) or securities are other-than-temporarily impaired, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full. Cash and Cash Equivalents Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value. Deferred Acquisition Costs Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For interest-sensitive life or annuity products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate. When we realize a gain or loss on investments backing our interest-sensitive life or annuity products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity. We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years. Present Value of Future Profits The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the "Effective Date", the effective date of the bankruptcy reorganization of Conseco, Inc., an Indiana corporation (our "Predecessor")). The discount rate we used to determine the present value of future profits was 12 percent . The balance of this account is amortized and evaluated for recovery in the same manner as described above for deferred acquisition costs. We also adjust the present value of future profits for the change in amortization that would have been recorded if the fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields, similar to the manner described above for deferred acquisition costs. We limit the total adjustment related to the impact of unrealized losses to the total present value of future profits plus interest. Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts For interest-sensitive life and annuity contracts that do not involve significant mortality or morbidity risk, the amounts collected from policyholders are considered deposits and are not included in revenue. Revenues for these contracts consist of charges for policy administration, cost of insurance charges and surrender charges assessed against policyholders' account balances. Such revenues are recognized when the service or coverage is provided, or when the policy is surrendered. We establish liabilities for annuity and interest-sensitive life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. In addition, policyholder account values for certain interest-sensitive life products are impacted by our assumptions related to changes of certain non-guaranteed elements that we are allowed to make under the terms of the policy, such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. Sales inducements provided to the policyholders of these products are recognized as liabilities over the period that the contract must remain in force to qualify for the inducement. The options attributed to the policyholder related to our fixed index annuity products are accounted for as embedded derivatives as described in the section of this note entitled "Accounting for Derivatives". Premiums from individual life products (other than interest-sensitive life contracts) and health products are recognized when due. When premiums are due over a significantly shorter period than the period over which benefits are provided, any gross premium in excess of the net premium (i.e., the portion of the gross premium required to provide for all expected future benefits and expenses) is deferred and recognized into revenue in a constant relationship to insurance in force. Benefits are recorded as an expense when they are incurred. We establish liabilities for traditional life, accident and health insurance, and life contingent payment annuity products using mortality tables in general use in the United States, which are modified to reflect the Company's actual experience when appropriate. We establish liabilities for accident and health insurance products using morbidity tables based on the Company's actual or expected experience. These reserves are computed at amounts that, with additions from estimated future premiums received and with interest on such reserves at estimated future rates, are expected to be sufficient to meet our obligations under the terms of the policy. Liabilities for future policy benefits are computed on a net-level premium method based upon assumptions as to future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses determined when the policies were issued (or with respect to policies inforce at August 31, 2003, the Company's best estimate of such assumptions on the Effective Date). We make an additional provision to allow for potential adverse deviation for some of our assumptions. Once established, assumptions on these products are generally not changed unless a premium deficiency exists. In that case, a premium deficiency reserve is recognized and the future pattern of reserve changes is modified to reflect the relationship of premiums to benefits based on the current best estimate of future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses, determined without an additional provision for potential adverse deviation. We establish claim reserves based on our estimate of the loss to be incurred on reported claims plus estimates of incurred but unreported claims based on our past experience. Accounting for Long-term Care Premium Rate Increases Many of our long-term care policies have been subject to premium rate increases. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the Effective Date. With respect to certain premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options: • Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists. • Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage. • Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established. Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit. Accounting for Certain Marketing Agreements Bankers Life has entered into various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute prescription drug and Medicare Advantage plans. These agreements allow Bankers Life to offer these products to current and potential future policyholders without investment in management and infrastructure. We receive fee income related to the plans sold through our distribution channels. We account for these distribution agreements as follows: • We recognize distribution income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract. • We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract. Reinsurance In the normal course of business, we seek to limit our loss exposure on any single insured or to certain groups of policies by ceding reinsurance to other insurance enterprises. We currently retain no more than $.8 million of mortality risk on any one policy. We diversify the risk of reinsurance loss by using a number of reinsurers that have strong claims-paying ratings. In each case, the ceding CNO subsidiary is directly liable for claims reinsured in the event the assuming company is unable to pay. The cost of reinsurance ceded totaled $105.0 million , $123.9 million and $133.6 million in 2017 , 2016 and 2015 , respectively. We deduct this cost from insurance policy income. Reinsurance recoveries netted against insurance policy benefits totaled $88.6 million , $130.1 million and $167.7 million in 2017 , 2016 and 2015 , respectively. From time to time, we assume insurance from other companies. Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs. Reinsurance premiums assumed totaled $30.4 million , $34.0 million and $38.5 million in 2017 , 2016 and 2015 , respectively. Insurance policy benefits related to reinsurance assumed totaled $44.7 million , $47.5 million and $48.0 million in 2017 , 2016 and 2015 , respectively. In December 2013, two of our insurance subsidiaries entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to BRe. Pursuant to the agreements, the insurance subsidiaries paid an additional premium of $96.9 million to BRe and an amount equal to the related net liabilities. The insurance subsidiaries' ceded reserve credits were secured by assets in market-value trusts subject to a 7% overcollateralization, investment guidelines and periodic true-up provisions. Future payments into the trusts to maintain collateral requirements were the responsibility of BRe. In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business. As a result of the recapture, we were required to value the assets and liabilities as of the date of recapture based on valuation methodologies that are consistent with the methodologies used by CNO to value its other investments and insurance liabilities. Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions): Market value of investments $ 504.7 Insurance liabilities (552.2 ) Write-off of reinsurance receivables (17.9 ) Estimated transaction expenses (10.0 ) Pre-tax loss (75.4 ) Tax benefit 26.4 Increase in valuation allowance for deferred tax assets (4.1 ) After-tax loss $ (53.1 ) Income Taxes Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and net operating loss carryforwards ("NOLs"). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted. A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire. At December 31, 2017 , our valuation allowance for our net deferred tax assets was $89.1 million , as we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax assets and assessing the effects of limitations and/or interpretations on the value of such component to be fully recognized in the future. Investments in Variable Interest Entities We have concluded that we are the primary beneficiary with respect to certain variable interest entities ("VIEs"), which are consolidated in our financial statements. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments. The assets held by the trusts are legally isolated and not available to the Company. The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company. The Company has no financial obligation to the VIEs beyond its investment in each VIE. The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade. Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information about VIEs. In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager. These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations. Our maximum exposure to loss on these securities is limited to our cost basis in the investment. We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses. At December 31, 2017 , we held investments in various limited partnerships, in which we are not the primary beneficiary, totaling $371.1 million (classified as other invested assets). At December 31, 2017 , we had unfunded commitments to these partnerships of $276.5 million . Our maximum exposure to loss on these investments is limited to the amount of our investment. Investment borrowings Three of the Company's insurance subsidiaries (Washington National, Bankers Life and Colonial Penn) are members of the Federal Home Loan Bank ("FHLB"). As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB. We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings. At December 31, 2017 , the carrying value of the FHLB common stock was $71.2 million . As of December 31, 2017 , collateralized borrowings from the FHLB totaled $1.6 billion and the proceeds were used to purchase fixed maturity securities. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet. The borrowings are collateralized by investments with an estimated fair value of $1.9 billion at December 31, 2017 , which are maintained in a custodial account for the benefit of the FHLB. Substantially all of such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet. The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions): Amount Maturity Interest rate at borrowed date December 31, 2017 $ 50.0 January 2019 Variable rate – 1.779% 50.0 February 2019 Variable rate – 1.509% 100.0 March 2019 Variable rate – 1.971% 21.8 July 2019 Variable rate – 2.001% 15.0 October 2019 Variable rate – 1.887% 50.0 May 2020 Variable rate – 1.997% 21.8 June 2020 Fixed rate – 1.960% 25.0 September 2020 Variable rate – 2.300% 100.0 September 2020 Variable rate – 2.212% 50.0 September 2020 Variable rate – 2.224% 75.0 September 2020 Variable rate – 1.813% 100.0 October 2020 Variable rate – 1.453% 50.0 December 2020 Variable rate – 2.072% 100.0 July 2021 Variable rate – 1.909% 100.0 July 2021 Variable rate – 1.879% 57.7 August 2021 Variable rate – 1.921% 28.2 August 2021 Fixed rate – 2.550% 125.0 August 2021 Variable rate – 2.032% 50.0 September 2021 Variable rate – 2.002% 22.0 May 2022 Variable rate – 1.829% 100.0 May 2022 Variable rate – 1.780% 10.0 June 2022 Variable rate – 2.150% 50.0 July 2022 Variable rate – 1.726% 50.0 July 2022 Variable rate – 1.745% 50.0 July 2022 Variable rate – 1.758% 50.0 August 2022 Variable rate – 1.782% 50.0 December 2022 Variable rate – 1.795% 50.0 December 2022 Variable rate – 1.795% 24.7 March 2023 Fixed rate – 2.160% 20.5 June 2025 Fixed rate – 2.940% $ 1,646.7 The variable rate borrowings are pre-payable on each interest reset date without penalty. The fixed rate borrowings are pre-payable subject to payment of a yield maintenance fee based on prevailing market interest rates. At December 31, 2017 , the aggregate yield maintenance fee to prepay all fixed rate borrowings was $2.1 million . Interest expense of $27.0 million , $17.5 million and $10.9 million in 2017 , 2016 and 2015 , respectively, was recognized related to total borrowings from the FHLB. Accounting for Derivatives Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period. Typically, on each policy anniversary date, a new index period begins. We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to contractual minimums. The Company accounts for the options attributed to the policyholder for the estimated life of the contract as embedded derivatives. These accounting requirements often create volatility in the earnings from these products. We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked. From time to time, we utilize United States Treasury interest rate futures primarily to hedge interest rate risk related to anticipated mortgage loan transactions. We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income. Multibucket Annuity Products The Company's multibucket annuity is an annuity product that credits interest based on the experience of a particular market strategy. Policyholders allocate their annuity premium payments to several different market strategies based on different asset classes within the Company's investment portfolio. Interest is credited to this product based on the market return of the given strategy, less management fees, and funds may be moved between different strategies. The Company guarantees a minimum return of premium plus approximately 3 percent per annum over the life of the contract. The investments backing the market strategies of these products are designated by the Company as trading securities. The change in the fair value of these securities is recognized as investment income (classified as income from policyholder and other special-purpose portfolios), which is substantially offset by the change in insurance policy benefits for these products. We hold insurance liabilities of $32.3 million and $32.8 million related to multibucket annuity products as of December 31, 2017 and 2016 , respectively. Sales Inducements Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract. Certain of our life insurance products offer persistency bonuses credited to the contract holder's balance after the policy has been outstanding for a specified period of time. These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP. Such amounts are deferred and amortized in the same manner as deferred acquisition costs. Sales inducements deferred totaled $2.0 million , $3.4 million and $3.8 million during 2017 , 2016 and 2015 , respectively. Amounts amortized totaled $8.9 million , $11.4 million and $13.8 million during 2017 , 2016 and 2015 , respectively. The unamortized balance of deferred sales inducements was $42.5 million and $49.4 million at December 31, 2017 and 2016 , respectively. The balance of insurance liabilities for persistency bonus benefits was $.3 million and $.5 million at December 31, 2017 and 2016 , respectively. Out-of-Period Adjustments In 2017 , we recorded the net effect of out-of-period adjustments which decreased insurance policy benefits by $4.2 million , increased other operating costs and expenses by $2.0 million , increased tax expense by $.8 million and increased our net income by $1.4 million (or 1 cent per diluted share). We evaluated these adjustments taking into account both qualitative and quantitative factors and considered the impact of these adjustments in relation to each period, as well as the periods in which they originated. The impact of recognizing these adjustments in prior years was not significant to any individual period. Management believes these adjustments are immaterial to the consolidated financial statements and all previously issued financial statements. Recently Issued Accounting Standards Pending Accounting Standards In May 2014, the Financial Accounting Standards Board (the "FASB") issued authoritative guidance for recognizing revenue from contracts with customers. Certain contracts with customers are specifically excluded from this guidance, including insurance contracts. The core principle of the new guidance is that an entity should recognize revenue when it transfers promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will be effective for the Company on January 1, 2018 and permits two methods of transition upon adoption; full retrospective and modified retrospective. Under the full retrospective method, prior periods would be restated under the new revenue standard, providing for comparability in all periods presented. Under the modified retrospective method, prior periods would not be restated. Instead, revenues and other disclosures for pre-2018 periods would be provided in the notes to the financial statements as previously reported under the current revenue standard. The new guidance will impact our accounting for various distribution and marketing agreements with other insurance companies pursuant to which Bankers Life's career agents distribute third party products including prescription drug and Medicare Advantage plans. The revenue associated with these distribution agreements has been less than 1 percent of our total revenue. Our annual fee income earned during a calendar year will not change, but the amount recognized during each quarterly period will vary based on the sales of such products in each period. Accordingly, the adoption of this guidance is not expected to have a material impact on our consolidated financial statements. The Company will adopt the new guidance using the modified retrospective method. In January 2016, the FASB issued authoritative guidance related to the recognition and measurement of financial assets and financial liabilities which made targeted improvements to GAAP as follows: (i) Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. (ii) Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value. (iii) Eliminate the requirement for public business entitie

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	INVESTMENTS At December 31, 2017 , the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Other-than-temporary impairments included in accumulated other comprehensive income Investment grade (a): Corporate securities $ 12,419.3 $ 1,670.7 $ (14.6 ) $ 14,075.4 $ — United States Treasury securities and obligations of United States government corporations and agencies 146.4 31.5 (.2 ) 177.7 — States and political subdivisions 1,819.9 234.8 (.4 ) 2,054.3 — Debt securities issued by foreign governments 79.5 3.8 (.2 ) 83.1 — Asset-backed securities 1,730.7 39.7 (3.2 ) 1,767.2 — Collateralized debt obligations 257.1 2.3 — 259.4 — Commercial mortgage-backed securities 1,304.1 33.2 (9.1 ) 1,328.2 — Mortgage pass-through securities 1.8 .2 — 2.0 — Collateralized mortgage obligations 293.9 16.4 (.2 ) 310.1 (.2 ) Total investment grade fixed maturities, available for sale 18,052.7 2,032.6 (27.9 ) 20,057.4 (.2 ) Below-investment grade (a) (b): Corporate securities 867.0 28.4 (12.4 ) 883.0 — States and political subdivisions 2.0 — — 2.0 — Asset-backed securities 1,355.2 132.9 (.9 ) 1,487.2 — Commercial mortgage-backed securities 49.9 .6 (1.2 ) 49.3 — Collateralized mortgage obligations 375.3 56.8 (.1 ) 432.0 (.8 ) Total below-investment grade fixed maturities, available for sale 2,649.4 218.7 (14.6 ) 2,853.5 (.8 ) Total fixed maturities, available for sale $ 20,702.1 $ 2,251.3 $ (42.5 ) $ 22,910.9 $ (1.0 ) Equity securities $ 491.1 $ 23.6 $ (3.0 ) $ 511.7 _______________ (a) Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC"). NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch). NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch). References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above. (b) Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations. The NAIC evaluates the fixed maturity investments of insurers for regulatory and capital assessment purposes and assigns securities to one of six credit quality categories called NAIC designations, which are used by insurers when preparing their annual statements based on statutory accounting principles. The NAIC designations are generally similar to the credit quality designations of the NRSROs for marketable fixed maturity securities, except for certain structured securities. However, certain structured securities rated below investment grade by the NRSROs can be assigned NAIC 1 or NAIC 2 designations depending on the cost basis of the holding relative to estimated recoverable amounts as determined by the NAIC. The following summarizes the NAIC designations and NRSRO equivalent ratings: NAIC Designation NRSRO Equivalent Rating 1 AAA/AA/A 2 BBB 3 BB 4 B 5 CCC and lower 6 In or near default A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of December 31, 2017 is as follows (dollars in millions): NAIC designation Amortized cost Estimated fair value Percentage of total estimated fair value 1 $ 9,923.7 $ 11,028.5 48.1 % 2 9,821.6 10,906.2 47.6 Total NAIC 1 and 2 (investment grade) 19,745.3 21,934.7 95.7 3 676.2 693.8 3.0 4 225.0 225.9 1.0 5 46.3 45.9 .2 6 9.3 10.6 .1 Total NAIC 3,4,5 and 6 (below-investment grade) 956.8 976.2 4.3 $ 20,702.1 $ 22,910.9 100.0 % At December 31, 2016 , the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Other-than-temporary impairments included in accumulated other comprehensive income Investment grade: Corporate securities $ 11,582.6 $ 1,073.9 $ (99.8 ) $ 12,556.7 $ — United States Treasury securities and obligations of United States government corporations and agencies 143.8 20.5 — 164.3 — States and political subdivisions 1,798.2 186.7 (7.9 ) 1,977.0 — Debt securities issued by foreign governments 37.1 .2 (.4 ) 36.9 — Asset-backed securities 1,169.6 29.2 (8.7 ) 1,190.1 — Collateralized debt obligations 227.5 1.0 (.3 ) 228.2 — Commercial mortgage-backed securities 1,467.2 32.9 (26.6 ) 1,473.5 — Mortgage pass-through securities 2.3 .2 — 2.5 — Collateralized mortgage obligations 304.8 14.6 (.2 ) 319.2 — Total investment grade fixed maturities, available for sale 16,733.1 1,359.2 (143.9 ) 17,948.4 — Below-investment grade: Corporate securities 967.3 26.1 (39.2 ) 954.2 (3.6 ) States and political subdivisions 13.6 — (1.7 ) 11.9 (3.0 ) Asset-backed securities 1,471.9 55.1 (6.8 ) 1,520.2 — Collateralized debt obligations 2.5 — — 2.5 — Commercial mortgage-backed securities 63.8 .2 (1.3 ) 62.7 — Collateralized mortgage obligations 550.9 46.8 (1.4 ) 596.3 (1.4 ) Total below-investment grade fixed maturities, available for sale 3,070.0 128.2 (50.4 ) 3,147.8 (8.0 ) Total fixed maturities, available for sale $ 19,803.1 $ 1,487.4 $ (194.3 ) $ 21,096.2 $ (8.0 ) Equity securities $ 580.7 $ 11.5 $ (8.0 ) $ 584.2 Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments. These amounts, included in shareholders' equity as of December 31, 2017 and 2016 , were as follows (dollars in millions): 2017 2016 Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized $ 2.6 $ (1.1 ) Net unrealized gains on all other investments 2,227.3 1,311.9 Adjustment to present value of future profits (a) (94.0 ) (106.2 ) Adjustment to deferred acquisition costs (292.6 ) (223.5 ) Adjustment to insurance liabilities (295.8 ) (13.5 ) Deferred income tax liabilities (335.4 ) (345.2 ) Accumulated other comprehensive income $ 1,212.1 $ 622.4 ________ (a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy. At December 31, 2017 , adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred tax assets included $(83.8) million , $(134.9) million , $(295.8) million and $111.1 million , respectively, for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields. At December 31, 2016 , adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred tax assets included $(94.1) million , $(96.4) million , $(13.5) million and $72.5 million , respectively, for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields. Below-Investment Grade Securities At December 31, 2017 , the amortized cost of the Company's below-investment grade fixed maturity securities was $2,649.4 million , or 13 percent of the Company's fixed maturity portfolio. The estimated fair value of the below-investment grade portfolio was $2,853.5 million , or 108 percent of the amortized cost. Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities. Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer. Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions. The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry. Contractual Maturity The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 328.1 $ 335.1 Due after one year through five years 1,947.3 2,052.3 Due after five years through ten years 1,508.7 1,601.3 Due after ten years 11,550.0 13,286.8 Subtotal 15,334.1 17,275.5 Structured securities 5,368.0 5,635.4 Total fixed maturities, available for sale $ 20,702.1 $ 22,910.9 Net Investment Income Net investment income consisted of the following (dollars in millions): 2017 2016 2015 General account assets: Fixed maturities $ 1,133.8 $ 1,081.4 $ 1,090.1 Equity securities 25.3 21.5 18.3 Mortgage loans 91.5 91.0 91.4 Policy loans 7.7 7.3 7.3 Other invested assets 44.4 24.3 17.4 Cash and cash equivalents 5.9 2.0 .8 Policyholder and other special-purpose portfolios: Trading securities (a) 12.8 12.2 10.7 Options related to fixed index products: Option income (loss) 110.3 (40.1 ) 36.5 Change in value of options 52.2 69.3 (72.7 ) Other special-purpose portfolios 90.6 79.7 55.5 Gross investment income 1,574.5 1,348.6 1,255.3 Less investment expenses 23.2 23.4 21.7 Net investment income $ 1,551.3 $ 1,325.2 $ 1,233.6 _________________ (a) Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were $3.8 million , $(.2) million and $.4 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. At December 31, 2017 , the carrying value of fixed maturities and mortgage loans that were non-income producing during 2017 totaled $2.8 million and $10.6 million , respectively. Net Realized Investment Gains (Losses) The following table sets forth the net realized investment gains (losses) for the periods indicated (dollars in millions): 2017 2016 2015 Fixed maturity securities, available for sale: Gross realized gains on sale $ 68.0 $ 137.7 $ 95.7 Gross realized losses on sale (24.2 ) (95.2 ) (88.4 ) Impairments: Total other-than-temporary impairment losses (12.5 ) (15.2 ) (17.9 ) Other-than-temporary impairment losses recognized in accumulated other comprehensive income (.9 ) 3.6 3.0 Net impairment losses recognized (13.4 ) (11.6 ) (14.9 ) Net realized investment gains (losses) from fixed maturities 30.4 30.9 (7.6 ) Equity securities 11.6 20.9 3.7 Mortgage loans 1.1 — (2.3 ) Impairments on preferred stock and other investments (9.4 ) (20.7 ) (25.0 ) Gain (loss) on dissolution of variable interest entities (4.3 ) (7.3 ) 11.3 Other (a) 20.9 (15.5 ) (16.7 ) Net realized investment gains (losses) $ 50.3 $ 8.3 $ (36.6 ) _________________ (a) Changes in the estimated fair value of trading securities that we have elected the fair value option (and are still held as of the end of the respective years) were $12.8 million , $(.5) million and $(9.2) million for the years ended December 31, 2017 , 2016 and 2015 , respectively. During 2017 , we recognized net realized investment gains of $50.3 million , which were comprised of: (i) $63.1 million of net gains from the sales of investments; (ii) $4.3 million of losses on the dissolution of VIEs; (iii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $11.5 million ; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $2.8 million ; and (v) $22.8 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2017 , 2016 and 2015 , VIEs that were required to be consolidated were dissolved. We recognized losses of $4.3 million and $7.3 million during 2017 and 2016 , respectively, and a gain of $11.3 million during 2015 , representing the difference between the borrowings of such VIEs and the contractual distributions required following the liquidation of the underlying assets. During 2016 , we recognized net realized investment gains of $8.3 million , which were comprised of: (i) $47.5 million of net gains from the sales of investments; (ii) a $7.3 million loss on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.4 million ; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $.8 million ; and (v) $32.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income ( $35.9 million , prior to the $3.6 million of impairment losses recognized through accumulated other comprehensive income). During 2015 , we recognized net realized investment losses of $36.6 million , which were comprised of: (i) $8.2 million of net gains from the sales of investments; (ii) an $11.3 million gain on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $9.2 million ; (iv) the decrease in fair value of embedded derivatives related to a modified coinsurance agreement of $7.0 million ; and (v) $39.9 million of writedowns of investments for other than temporary declines in fair value recognized through net income ( $42.9 million , prior to the $3.0 million of impairment losses recognized through accumulated other comprehensive income). At December 31, 2017 , there was one fixed maturity investment in default with an amortized cost and carrying value of $.5 million and $.4 million , respectively. During 2017 , the $24.2 million of realized losses on sales of $427.6 million of fixed maturity securities, available for sale, included: (i) $16.8 million related to various corporate securities; (ii) $3.6 million related to commercial mortgage-backed securities; and (iii) $3.8 million related to various other investments. Securities are generally sold at a loss following unforeseen issuer-specific events or conditions or shifts in perceived relative values. These reasons include but are not limited to: (i) changes in the investment environment; (ii) expectation that the market value could deteriorate; (iii) our desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) changes in expected portfolio cash flows. During 2017 , we recognized $22.8 million of impairment losses recorded in earnings which included: (i) $6.7 million of writedowns on fixed maturities in the energy sector; (ii) $5.2 million of writedowns related to a mortgage loan; and (iii) $10.9 million of writedowns on other investments. Factors considered in determining the writedowns of investments in 2017 included changes in the estimated recoverable value of the assets related to each investment and the timing of and complexities related to the recovery process. During 2016 , the $95.2 million of realized losses on sales of $790.2 million of fixed maturity securities, available for sale included: (i) $79.2 million related to various corporate securities (including $63.5 million related to sales of investments in the energy sector); (ii) $5.8 million related to commercial mortgage-backed securities; (iii) $5.7 million related to asset-backed securities; and (iv) $4.5 million related to various other investments. During 2016 , we recognized $32.3 million of impairment losses recorded in earnings which included: (i) $9.3 million of writedowns on fixed maturities in the energy sector; (ii) $3.7 million of writedowns on a direct loan due to borrower specific events; (iii) $12.7 million of writedowns on a privately placed preferred stock of an entity formed to construct and operate a chemical plant; (iv) $1.2 million of writedowns of investments held by VIEs due to other-than-temporary declines in value; and (v) $5.4 million of writedowns on other investments. Factors considered in determining the writedowns of investments in 2016 included the subordination status of each investment, the impact of recent downgrades and issuer specific events, including the impact of low oil prices on issuers in the energy sector. During 2015 , the $88.4 million of realized losses on sales of $724.4 million of fixed maturity securities, available for sale, primarily related to various corporate securities (including $59.7 million related to sales of investments in the energy sector). During 2015 , we recognized $39.9 million of impairment losses recorded in earnings which included: (i) $10.2 million of writedowns on fixed maturities in the energy sector; (ii) $16.4 million of writedowns on commercial bank loans held by VIEs; (iii) a $7.9 million writedown of a legacy investment in a private company that was liquidated; and (iv) $5.4 million of losses on other investments (primarily fixed maturities). We no longer have any exposure to legacy private companies related to investments acquired by our Predecessor. Our fixed maturity investments are generally purchased in the context of various long-term strategies, including funding insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities. In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities. The following summarizes the investments sold at a loss during 2017 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions): At date of sale Number Amortized cost Fair value Less than 6 months prior to sale 4 $ 17.8 $ 13.0 Greater than or equal to 6 months and less than 12 months prior to sale 1 2.7 1.9 Greater than 12 months prior to sale 1 .7 .5 6 $ 21.2 $ 15.4 We regularly evaluate all of our investments with unrealized losses for possible impairment. Our assessment of whether unrealized losses are "other than temporary" requires significant judgment. Factors considered include: (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment's rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors. Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio. Significant losses could have a material adverse effect on our consolidated financial statements in future periods. Impairment losses on equity securities are recognized in net income. The manner in which impairment losses on fixed maturity securities, available for sale, are recognized in the financial statements is dependent on the facts and circumstances related to the specific security. If we intend to sell a security or it is more likely than not that we would be required to sell a security before the recovery of its amortized cost, the security is other-than-temporarily impaired and the full amount of the impairment is recognized as a loss through earnings. If we do not expect to recover the amortized cost basis, we do not plan to sell the security, and if it is not more likely than not that we would be required to sell a security before the recovery of its amortized cost, less any current period credit loss, the recognition of the other-than-temporary impairment is bifurcated. We recognize the credit loss portion in net income and the noncredit loss portion in accumulated other comprehensive income. We estimate the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the effective interest rate implicit to the security at the date of purchase or the current yield to accrete an asset-backed or floating-rate security. The methodology and assumptions for establishing the best estimate of future cash flows vary depending on the type of security. For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees. For corporate bonds, cash flow estimates are derived from scenario-based outcomes of expected corporate restructurings or the disposition of assets using bond-specific facts and circumstances. The previous amortized cost basis less the impairment recognized in net income becomes the security's new cost basis. We accrete the new cost basis to the estimated future cash flows over the expected remaining life of the security, except when the security is in default or considered nonperforming. The remaining noncredit impairment, which is recorded in accumulated other comprehensive income, is the difference between the security's estimated fair value and our best estimate of future cash flows discounted at the effective interest rate prior to impairment. The remaining noncredit impairment typically represents changes in the market interest rates, current market liquidity and risk premiums. As of December 31, 2017 , other-than-temporary impairments included in accumulated other comprehensive income totaled $1.0 million (before taxes and related amortization). Mortgage loans are impaired when it is probable that we will not collect the contractual principal and interest on the loan. We measure impairment based upon the difference between the carrying value of the loan and the estimated fair value of the collateral securing the loan less cost to sell. The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the years ended December 31, 2017 , 2016 and 2015 (dollars in millions): Year ended December 31, 2017 2016 2015 Credit losses on fixed maturity securities, available for sale, beginning of period $ (5.5 ) $ (2.6 ) $ (1.0 ) Add: credit losses on other-than-temporary impairments not previously recognized — (3.0 ) (2.0 ) Less: credit losses on securities sold 4.7 .1 .4 Less: credit losses on securities impaired due to intent to sell (a) — — — Add: credit losses on previously impaired securities (2.0 ) — — Less: increases in cash flows expected on previously impaired securities — — — Credit losses on fixed maturity securities, available for sale, end of period $ (2.8 ) $ (5.5 ) $ (2.6 ) __________ (a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis. Investments with Unrealized Losses The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 26.9 $ 26.9 Due after one year through five years 195.4 193.3 Due after five years through ten years 108.9 105.2 Due after ten years 602.0 580.0 Subtotal 933.2 905.4 Structured securities 1,268.3 1,253.6 Total $ 2,201.5 $ 2,159.0 The following summarizes the investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis for the period indicated as of December 31, 2017 (dollars in millions): Number Cost Unrealized Estimated Less than 6 months 1 $ 9.2 $ (1.9 ) $ 7.3 $ 9.2 $ (1.9 ) $ 7.3 The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2017 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair value Unrealized losses Fair value Unrealized losses Fair value Unrealized losses United States Treasury securities and obligations of United States government corporations and agencies $ 28.2 $ (.2 ) $ .7 $ — $ 28.9 $ (.2 ) States and political subdivisions 18.3 (.1 ) 14.9 (.3 ) 33.2 (.4 ) Debt securities issued by foreign governments 7.7 (.1 ) 5.4 (.1 ) 13.1 (.2 ) Corporate securities 470.5 (6.8 ) 359.7 (20.2 ) 830.2 (27.0 ) Asset-backed securities 601.4 (2.0 ) 122.2 (2.1 ) 723.6 (4.1 ) Collateralized debt obligations 3.0 — — — 3.0 — Commercial mortgage-backed securities 276.8 (1.7 ) 218.2 (8.6 ) 495.0 (10.3 ) Collateralized mortgage obligations 20.5 (.2 ) 11.5 (.1 ) 32.0 (.3 ) Total fixed maturities, available for sale $ 1,426.4 $ (11.1 ) $ 732.6 $ (31.4 ) $ 2,159.0 $ (42.5 ) Equity securities $ 58.7 $ (1.7 ) $ 21.2 $ (1.3 ) $ 79.9 $ (3.0 ) The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2016 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair value Unrealized losses Fair value Unrealized losses Fair value Unrealized losses United States Treasury securities and obligations of United States government corporations and agencies $ 8.0 $ — $ — $ — $ 8.0 $ — States and political subdivisions 176.3 (7.8 ) 18.3 (1.8 ) 194.6 (9.6 ) Debt securities issued by foreign governments 18.9 (.4 ) — — 18.9 (.4 ) Corporate securities 1,907.6 (75.5 ) 559.6 (63.5 ) 2,467.2 (139.0 ) Asset-backed securities 692.9 (8.5 ) 262.5 (7.0 ) 955.4 (15.5 ) Collateralized debt obligations 38.3 (.1 ) 30.8 (.2 ) 69.1 (.3 ) Commercial mortgage-backed securities 525.2 (16.6 ) 154.0 (11.3 ) 679.2 (27.9 ) Collateralized mortgage obligations 73.6 (.6 ) 34.6 (1.0 ) 108.2 (1.6 ) Total fixed maturities, available for sale $ 3,440.8 $ (109.5 ) $ 1,059.8 $ (84.8 ) $ 4,500.6 $ (194.3 ) Equity securities $ 239.4 $ (8.0 ) $ — $ — $ 239.4 $ (8.0 ) Based on management's current assessment of investments with unrealized losses at December 31, 2017 , the Company believes the issuers of the securities will continue to meet their obligations (or with respect to equity-type securities, the investment value will recover to its cost basis). While we do not have the intent to sell securities with unrealized losses and it is not more likely than not that we will be required to sell securities with unrealized losses prior to their anticipated recovery, our intent on an individual security may change, based upon market or other unforeseen developments. In such instances, if a loss is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which we had the intent to sell the security before its anticipated recovery. Structured Securities At December 31, 2017 fixed maturity investments included structured securities with an estimated fair value of $5.6 billion (or 25 percent of all fixed maturity securities). The yield characteristics of structured securities generally differ in some respects from those of traditional corporate fixed-income securities or government securities. For example, interest and principal payments on structured securities may occur more frequently, often monthly. In many instances, we are subject to variability in the amount and timing of principal and interest payments. For example, in many cases, partial prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including: the relative sensitivity of prepayments on the underlying assets backing the security to changes in interest rates and asset values; the availability of alternative financing; a variety of economic, geographic and other factors; the timing, pace and proceeds of liquidations of defaulted collateral; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure). In addition, the total amount of payments for non-agency structured securities may be affected by changes to cumulative default rates or loss severities of the related collateral. Historically, the rate of prepayments on structured securities has tended to increase when prevailing interest rates have declined significantly in absolute terms and also relative to the interest rates on the underlying collateral. The yields recognized on structured securities purchased at a discount to par will generally inc

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price. We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives. We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs. The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value. Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value. Valuation Hierarchy There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable. • Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities. • Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs. • Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions. At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value. This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions. Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels are reported as having occurred at the beginning of the period. There were no transfers between Level 1 and Level 2 in both 2017 and 2016 . The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value. These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value. Our Level 2 assets are valued as follows: • Fixed maturities available for sale, equity securities and trading securities Corporate securities are generally priced using market and income approaches. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads. U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity. States and political subdivisions are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads. Asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations are generally priced using market and income approaches. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates, and issue specific information including, but not limited to, collateral type, seniority and vintage. Equity securities (primarily comprised of non-redeemable preferred stock) are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads. • Investments held by VIEs Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads. • Other invested assets - derivatives The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes; time value and volatility factors underlying options; market interest rates; and non-performance risk. Third party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate. The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below. As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes: (i) a review of the methodology used by third party pricing services; (ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties. As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions. In those instances, we may request additional pricing quotes or apply internally developed valuations. However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received. The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes. Such inputs typically include: benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data. The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments. For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes. These broker quotes are non-binding and represent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs. Approximately 29 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs. The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs. For these securities, we use internally developed valuations. Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market. For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate. The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity. In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity. For certain embedded derivatives, we use actuarial assumptions in the determination of fair value which we consider to be Level 3 inputs. The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2017 is as follows (dollars in millions): Quoted prices in active markets Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 14,728.0 $ 230.4 $ 14,958.4 United States Treasury securities and obligations of United States government corporations and agencies — 177.7 — 177.7 States and political subdivisions — 2,056.3 — 2,056.3 Debt securities issued by foreign governments — 79.2 3.9 83.1 Asset-backed securities — 3,230.2 24.2 3,254.4 Collateralized debt obligations — 259.4 — 259.4 Commercial mortgage-backed securities — 1,377.5 — 1,377.5 Mortgage pass-through securities — 2.0 — 2.0 Collateralized mortgage obligations — 742.1 — 742.1 Total fixed maturities, available for sale — 22,652.4 258.5 22,910.9 Equity securities - corporate securities 287.8 202.7 21.2 511.7 Trading securities: Corporate securities — 21.6 — 21.6 United States Treasury securities and obligations of United States government corporations and agencies — .5 — .5 Asset-backed securities — 95.8 — 95.8 Collateralized debt obligations — 2.7 — 2.7 Commercial mortgage-backed securities — 92.5 — 92.5 Collateralized mortgage obligations — 68.7 — 68.7 Equity securities 2.8 — — 2.8 Total trading securities 2.8 281.8 — 284.6 Investments held by variable interest entities - corporate securities — 1,522.0 4.9 1,526.9 Other invested assets - derivatives — 170.2 — 170.2 Assets held in separate accounts — 5.0 — 5.0 Total assets carried at fair value by category $ 290.6 $ 24,834.1 $ 284.6 $ 25,409.3 Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products $ — $ — $ 1,334.8 $ 1,334.8 The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2016 is as follows (dollars in millions): Quoted prices in active markets for identical assets or liabilities (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 13,252.4 $ 258.5 $ 13,510.9 United States Treasury securities and obligations of United States government corporations and agencies — 164.3 — 164.3 States and political subdivisions — 1,988.9 — 1,988.9 Debt securities issued by foreign governments — 33.0 3.9 36.9 Asset-backed securities — 2,649.9 60.4 2,710.3 Collateralized debt obligations — 225.3 5.4 230.7 Commercial mortgage-backed securities — 1,504.2 32.0 1,536.2 Mortgage pass-through securities — 2.5 — 2.5 Collateralized mortgage obligations — 915.5 — 915.5 Total fixed maturities, available for sale — 20,736.0 360.2 21,096.2 Equity securities - corporate securities 359.9 199.1 25.2 584.2 Trading securities: Corporate securities — 19.0 — 19.0 United States Treasury securities and obligations of United States government corporations and agencies — .5 — .5 Asset-backed securities — 94.3 — 94.3 Collateralized debt obligations — 2.4 — 2.4 Commercial mortgage-backed securities — 163.9 — 163.9 Collateralized mortgage obligations — 78.4 — 78.4 Equity securities 4.9 — — 4.9 Total trading securities 4.9 358.5 — 363.4 Investments held by variable interest entities - corporate securities — 1,724.3 — 1,724.3 Other invested assets - derivatives — 111.9 — 111.9 Assets held in separate accounts — 4.7 — 4.7 Total assets carried at fair value by category $ 364.8 $ 23,134.5 $ 385.4 $ 23,884.7 Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products $ — $ — $ 1,092.3 $ 1,092.3 For those financial instruments disclosed at fair value, we use the following methods and assumptions to determine the estimated fair values: Mortgage loans and policy loans. We discount future expected cash flows based on interest rates currently being offered for similar loans with similar risk characteristics. We aggregate loans with similar characteristics in our calculations. The fair value of policy loans approximates their carrying value. Company-owned life insurance is backed by a series of mutual funds and is carried at cash surrender value which approximates estimated fair value. Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value. Liabilities for policyholder account balances. The estimated fair value of insurance liabilities for policyholder account balances was approximately equal to its carrying value as interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year. Investment borrowings, notes payable and borrowings related to variable interest entities. For publicly traded debt, we use current fair values. For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements. The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions): December 31, 2017 Quoted prices in active markets for identical assets or liabilities (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,677.3 $ 1,677.3 $ 1,650.6 Policy loans — — 116.0 116.0 116.0 Other invested assets: Company-owned life insurance — 182.3 — 182.3 182.3 Cash and cash equivalents: Unrestricted 578.4 — — 578.4 578.4 Held by variable interest entities 178.9 — — 178.9 178.9 Liabilities: Policyholder account balances — — 11,220.7 11,220.7 11,220.7 Investment borrowings — 1,648.8 — 1,648.8 1,646.7 Borrowings related to variable interest entities — 1,432.9 — 1,432.9 1,410.7 Notes payable – direct corporate obligations — 962.3 — 962.3 914.6 December 31, 2016 Quoted prices in active markets for identical assets or liabilities (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,800.1 $ 1,800.1 $ 1,768.0 Policy loans — — 112.0 112.0 112.0 Other invested assets: Company-owned life insurance — 165.0 — 165.0 165.0 Cash and cash equivalents: Unrestricted 473.6 5.3 — 478.9 478.9 Held by variable interest entities 189.3 — — 189.3 189.3 Liabilities: Policyholder account balances — — 10,912.7 10,912.7 10,912.7 Investment borrowings — 1,650.0 — 1,650.0 1,647.4 Borrowings related to variable interest entities — 1,675.2 — 1,675.2 1,662.8 Notes payable – direct corporate obligations — 931.9 — 931.9 912.9 The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions): December 31, 2017 Beginning balance as of December 31, 2016 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of December 31, 2017 Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 258.5 $ (70.4 ) $ 5.8 $ 5.3 $ 31.2 $ — $ 230.4 $ (8.0 ) Debt securities issued by foreign governments 3.9 — — — — — 3.9 — Asset-backed securities 60.4 (4.3 ) — .7 — (32.6 ) 24.2 — Collateralized debt obligations 5.4 (2.5 ) — — — (2.9 ) — — Commercial mortgage-backed securities 32.0 (1.2 ) .1 (.1 ) — (30.8 ) — — Total fixed maturities, available for sale 360.2 (78.4 ) 5.9 5.9 31.2 (66.3 ) 258.5 (8.0 ) Equity securities - corporate securities 25.2 (8.5 ) 6.3 (1.8 ) — — 21.2 — Investments held by variable interest entities - corporate securities — 4.9 — — — — 4.9 — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (1,092.3 ) (267.5 ) 25.0 — — — (1,334.8 ) 25.0 _________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended December 31, 2017 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 76.6 $ (147.0 ) $ — $ — $ (70.4 ) Asset-backed securities — (4.3 ) — — (4.3 ) Collateralized debt obligations — (2.5 ) — — (2.5 ) Commercial mortgage-backed securities — (1.2 ) — — (1.2 ) Total fixed maturities, available for sale 76.6 (155.0 ) — — (78.4 ) Equity securities - corporate securities — (8.5 ) — — (8.5 ) Investments held by variable interest entities - corporate securities 8.9 (4.0 ) — — 4.9 Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (178.9 ) 5.4 (159.3 ) 65.3 (267.5 ) The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2016 (dollars in millions): December 31, 2016 Beginning balance as of December 31, 2015 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of December 31, 2016 Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 170.4 $ 76.5 $ (10.7 ) $ 9.1 $ 20.3 $ (7.1 ) $ 258.5 $ (10.9 ) Debt securities issued by foreign governments — 4.0 — (.1 ) — — 3.9 — Asset-backed securities 35.9 9.7 — 2.2 26.3 (13.7 ) 60.4 — Collateralized debt obligations — 5.4 — — — — 5.4 — Commercial mortgage-backed securities 1.1 16.9 — .1 13.9 — 32.0 — Mortgage pass-through securities .1 (.1 ) — — — — — — Total fixed maturities, available for sale 207.5 112.4 (10.7 ) 11.3 60.5 (20.8 ) 360.2 (10.9 ) Equity securities - corporate securities 32.0 5.5 (12.7 ) .4 — — 25.2 (12.7 ) Trading securities - commercial mortgage-backed securities 39.9 — — — — (39.9 ) — — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (1,057.1 ) (96.0 ) 60.8 — — — (1,092.3 ) 60.8 ____________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended December 31, 2016 (dollars in millions): Purchases Received in reinsurance recapture Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 18.5 $ 89.2 $ (31.2 ) $ — $ — $ 76.5 Debt securities issued by foreign governments 4.0 — — — — 4.0 Asset-backed securities 16.9 — (7.2 ) — — 9.7 Collateralized debt obligations 5.4 — — — — 5.4 Commercial mortgage-backed securities 17.0 — (.1 ) — — 16.9 Mortgage pass-through securities — — (.1 ) — — (.1 ) Total fixed maturities, available for sale 61.8 89.2 (38.6 ) — — 112.4 Equity securities - corporate securities 3.3 2.2 — — — 5.5 Trading securities - corporate securities .2 — (.2 ) — — — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (148.3 ) — 21.2 (28.9 ) 60.0 (96.0 ) At December 31, 2017 , 52 percent of our Level 3 fixed maturities, available for sale, were investment grade and 89 percent of our Level 3 fixed maturities, available for sale, consisted of corporate securities. Realized and unrealized investment gains and losses presented in the preceding tables represent gains and losses during the time the applicable financial instruments were classified as Level 3. Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders' equity based on the appropriate accounting treatment for the instrument. The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date. The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2017 (dollars in millions): Fair value at December 31, 2017 Valuation techniques Unobservable inputs Range (weighted average) Assets: Corporate securities (a) $ 149.2 Discounted cash flow analysis Discount margins 1.45% - 71.29% (6.96%) Corporate securities (b) 2.8 Recovery method Percent of recovery expected 0% - 21.73% (18.42%) Asset-backed securities (c) 24.2 Discounted cash flow analysis Discount margins 1.80% - 3.71% (2.67%) Equity securities (d) 21.2 Market comparables EBITDA multiples 1.1X - 8.9X (1.1X) Other assets categorized as Level 3 (e) 87.2 Unadjusted third-party price source Not applicable Not applicable Total 284.6 Liabilities: Future policy benefits (f) 1,334.8 Discounted projected embedded derivatives Projected portfolio yields 5.15% - 5.61% (5.60%) Discount rates 0.92 - 2.51% (2.00%) Surrender rates 1.20% - 46.40% (12.30%) ________________________________ (a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement. (c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements. (e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources. (f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative. The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2016 (dollars in millions): Fair value at December 31, 2016 Valuation techniques Unobservable inputs Range (weighted average) Assets: Corporate securities (a) $ 148.5 Discounted cash flow analysis Discount margins 1.35% - 27.71% (13.52%) Corporate securities (b) 14.8 Recovery method Percent of recovery expected 5% - 69% (55%) Asset-backed securities (c) 24.0 Discounted cash flow analysis Discount margins 2.06% - 3.64% (2.76%) Equity securities (d) 25.2 Market comparables EBITDA multiples 0.4X - 6.2X (5.9X) Other assets categorized as Level 3 (e) 172.9 Unadjusted third-party price source Not applicable Not applicable Total 385.4 Liabilities: Future policy benefits (f) 1,092.3 Discounted projected embedded derivatives Projected portfolio yields 5.15% - 5.61% (5.59%) Discount rates 0.18 - 3.06% (2.07%) Surrender rates 0.94% - 46.48% (13.52%) ________________________________ (a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement. (c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is EBITDA multiples

LIABILITIES FOR INSURANCE PRODU

LIABILITIES FOR INSURANCE PRODUCTS	12 Months Ended
	Dec. 31, 2017
Insurance [Abstract]
LIABILITIES FOR INSURANCE PRODUCTS	LIABILITIES FOR INSURANCE PRODUCTS Our future policy benefits are summarized as follows (dollars in millions): Withdrawal assumption Morbidity assumption Mortality assumption Interest rate assumption 2017 2016 Long-term care Company experience Company experience Company experience 6% $ 5,669.0 $ 5,346.1 Traditional life insurance contracts Company experience Company experience (a) 5% 2,401.2 2,322.1 Accident and health contracts Company experience Company experience Company experience 5% 2,812.0 2,695.6 Interest-sensitive life insurance contracts Company experience Company experience Company experience 5% 44.9 52.2 Annuities and supplemental contracts with life contingencies Company experience Company experience (b) 4% 594.2 537.3 Total $ 11,521.3 $ 10,953.3 ____________________ (a) Principally, modifications of: (i) the 1965 ‑ 70 and 1975 - 80 Basic Tables; and (ii) the 1941, 1958 and 1980 Commissioners' Standard Ordinary Tables; as well as Company experience. (b) Principally, modifications of: (i) the 1971 Individual Annuity Mortality Table; (ii) the 1983 Table "A"; and (iii) the Annuity 2000 Mortality Table; as well as Company experience. Our policyholder account balances are summarized as follows (dollars in millions): 2017 2016 Fixed index annuities $ 5,942.2 $ 5,324.5 Other annuities 4,183.8 4,541.8 Interest-sensitive life insurance contracts 1,094.7 1,046.4 Total $ 11,220.7 $ 10,912.7 The Company establishes reserves for insurance policy benefits based on assumptions as to investment yields, mortality, morbidity, withdrawals, lapses and maintenance expenses. These reserves include amounts for estimated future payment of claims based on actuarial assumptions. The balance includes provision for the Company's best estimate of the future policyholder benefits to be incurred on this business, given recent and expected future changes in experience. Changes in the unpaid claims reserve (included in claims payable) and disabled life reserves related to accident and health insurance (included in the liability for future policy benefits) were as follows (dollars in millions): 2017 2016 2015 Balance, beginning of year $ 1,777.6 $ 1,731.8 $ 1,679.5 Less reinsurance (receivables) payables 14.0 (130.0 ) (125.0 ) Net balance, beginning of year 1,791.6 1,601.8 1,554.5 Incurred claims related to: Current year 1,548.1 1,526.4 1,481.0 Prior years (a) (26.7 ) 96.6 (13.3 ) Total incurred 1,521.4 1,623.0 1,467.7 Interest on claim reserves 78.4 75.3 71.0 Paid claims related to: Current year 845.5 837.2 841.8 Prior years 702.6 671.3 649.6 Total paid 1,548.1 1,508.5 1,491.4 Net balance, end of year 1,843.3 1,791.6 1,601.8 Add reinsurance receivables (payables) (15.1 ) (14.0 ) 130.0 Balance, end of year $ 1,828.2 $ 1,777.6 $ 1,731.8 ___________ (a) The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. Such amounts will fluctuate based upon the estimation procedures used to determine the amount of unpaid losses. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The components of income tax expense (benefit) were as follows (dollars in millions): 2017 2016 2015 Current tax expense (benefit) $ 90.8 $ (45.2 ) $ 10.7 Deferred tax expense 72.0 173.0 118.6 Valuation allowance applicable to current year income (15.3 ) (14.0 ) — Income tax expense calculated based on annual effective tax rate 147.5 113.8 129.3 Income tax expense on discrete items: Change in valuation allowance (13.4 ) 40.7 (32.5 ) Impact of federal tax reform 310.6 — — Change in valuation allowance related to federal tax reform (138.1 ) — — IRS settlement — (170.4 ) — Other items (1.7 ) 10.9 .2 Total income tax expense (benefit) $ 304.9 $ (5.0 ) $ 97.0 The Tax Reform Act makes broad and complex changes to the Code including reducing the federal corporate income tax rate to 21% from 35% effective January 1, 2018. As a result of the reduction in the federal corporate income tax rate, we reduced the value of our net deferred tax assets by $172.5 million (net of the reduction in the valuation allowance for deferred tax assets) which was recorded as additional income tax expense for the year ended December 31, 2017. The $172.5 million adjustment to our net deferred tax assets is a provisional amount as defined in the SEC's Staff Accounting Bulletin No. 118 ("SAB 118"), issued in December 2017 to address complexities in completing the calculations resulting from the Tax Reform Act. Although we were able to make a reasonable estimate of the impact of the Tax Reform Act based on the information available, we have not analyzed the calculations in sufficient detail to complete the accounting process, including the analysis of the calculations of life insurance tax reserves and future taxable income used to estimate the deferred tax valuation allowance. SAB 118 provides guidance on accounting for the effects of the Tax Reform Act when our accounting process is incomplete but we are able to determine a reasonable estimate. A final determination is required to be made within a measurement period not to extend beyond one year from the enactment date of the Tax Reform Act. We will continue to analyze our estimate of the impact of the Tax Reform Act and expect the process to be completed in the fourth quarter of 2018. A reconciliation of the U.S. statutory corporate tax rate to the effective rate reflected in the consolidated statement of operations is as follows: 2017 2016 2015 U.S. statutory corporate rate 35.0 % 35.0 % 35.0 % Valuation allowance (6.0 ) 7.6 (8.8 ) Non-taxable income and nondeductible benefits, net (2.0 ) (1.1 ) (.2 ) State taxes .6 2.2 2.1 Impact of federal tax reform 64.7 — — Change in valuation allowance related to federal tax reform (28.8 ) — — Impact of IRS settlement — (48.2 ) — Other items — 3.1 (1.7 ) Effective tax rate 63.5 % (1.4 )% 26.4 % The components of the Company's income tax assets and liabilities are summarized below (dollars in millions): 2017 2016 Deferred tax assets: Net federal operating loss carryforwards $ 489.6 $ 882.9 Net state operating loss carryforwards 9.3 12.3 Investments 4.3 17.8 Insurance liabilities 415.8 668.4 Other 48.9 66.3 Gross deferred tax assets 967.9 1,647.7 Deferred tax liabilities: Present value of future profits and deferred acquisition costs (165.4 ) (277.8 ) Accumulated other comprehensive income (337.2 ) (344.1 ) Gross deferred tax liabilities (502.6 ) (621.9 ) Net deferred tax assets before valuation allowance 465.3 1,025.8 Valuation allowance (89.1 ) (240.2 ) Net deferred tax assets 376.2 785.6 Current income taxes prepaid (accrued) (9.3 ) 4.1 Income tax assets, net $ 366.9 $ 789.7 Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and NOLs. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted. A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire. Based on our assessment, it appears more likely than not that $376.2 million of our total deferred tax assets of $465.3 million will be realized through future taxable earnings. Accordingly, we have established a deferred tax valuation allowance of $89.1 million at December 31, 2017 ( $77.4 million of which relates to our net federal operating loss carryforwards and $11.7 million relates to state deferred tax assets). We will continue to assess the need for a valuation allowance in the future. If future results are less than projected, an increase to the valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded. We use a deferred tax valuation model to assess the need for a valuation allowance. Our model is adjusted to reflect changes in our projections of future taxable income including changes resulting from the Tax Reform Act, investment strategies, the impact of the sale or reinsurance of business and the recapture of business previously ceded. Our estimates of future taxable income are based on evidence we consider to be objective and verifiable. At December 31, 2017 , our projection of future taxable income for purposes of determining the valuation allowance is based on our adjusted average annual taxable income which is assumed to increase by 3 percent for the next five years, and level taxable income is assumed thereafter. In the projections used for our analysis, our adjusted average taxable income of approximately $345 million consisted of $85 million of non-life taxable income and $260 million of life taxable income. Based on our assessment, we recognized a decrease to the allowance for deferred tax assets of $151.1 million in 2017 , including the impacts of the Tax Reform Act. We have evaluated the recovery of our deferred tax assets and assessed the effect of limitations and/or interpretations on their value and have concluded that it is more likely than not that the value recognized will be fully realized in the future. Changes in our valuation allowance are summarized as follows (dollars in millions): Balance, December 31, 2014 $ 246.0 Decrease in 2015 (32.5 ) (a) Balance, December 31, 2015 213.5 Increase in 2016 26.7 (b) Balance, December 31, 2016 240.2 Decrease in 2017 (166.8 ) (c) Cumulative effect of accounting change 15.7 (d) Balance, December 31, 2017 $ 89.1 ___________________ (a) The 2015 reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income. (b) The 2016 increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the Internal Revenue Service (the "IRS"). (c) The 2017 decrease to the deferred tax valuation allowance includes: (i) $138.1 million related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii) $13.4 million of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii) $15.3 million of reductions in the deferred tax valuation allowance reflecting higher current year taxable income than previously reflected in our deferred tax valuation model. (d) Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of $15.7 million related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of $15.7 million was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance. Recovery of our deferred tax asset is dependent on achieving the level of future taxable income projected in our deferred tax valuation model and failure to do so could result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future. The Internal Revenue Code (the "Code") limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of: (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities). There is no similar limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities). This limitation is the primary reason a valuation allowance for NOLs is required. Section 382 of the Code imposes limitations on a corporation's ability to use its NOLs when the company undergoes a 50 percent ownership change over a three year period. Future transactions and the timing of such transactions could cause an ownership change for Section 382 income tax purposes. Such transactions may include, but are not limited to, additional repurchases under our securities repurchase program, issuances of common stock and acquisitions or sales of shares of CNO stock by certain holders of our shares, including persons who have held, currently hold or may accumulate in the future, five percent or more of our outstanding common stock for their own account. Many of these transactions are beyond our control. If an additional ownership change were to occur for purposes of Section 382, we would be required to calculate an annual restriction on the use of our NOLs to offset future taxable income. The annual restriction would be calculated based upon the value of CNO's equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate ( 1.96 percent at December 31, 2017 ), and the annual restriction could limit our ability to use a substantial portion of our NOLs to offset future taxable income. We regularly monitor ownership change (as calculated for purposes of Section 382) and, as of December 31, 2017 , we were below the 50 percent ownership change level that would trigger further impairment of our ability to utilize our NOLs. In 2009, the Company's Board of Directors adopted a Section 382 Rights Agreement designed to protect shareholder value by preserving the value of our tax assets primarily associated with tax NOLs under Section 382. The Section 382 Rights Agreement was adopted to reduce the likelihood of an ownership change occurring by deterring the acquisition of stock that would create " 5 percent shareholders" as defined in Section 382. The Section 382 Rights Agreement has been amended three times, most recently effective November 13, 2017 (the "Third Amended Section 382 Rights Agreement"). The Third Amended Section 382 Rights Agreement extended the expiration date of the Section 382 Rights Agreement to November 13, 2020, updated the purchase price of the rights described below and provided for a new series of preferred stock relating to the rights that is substantially identical to the prior series of preferred stock. The Company expects to submit the Third Amended Section 382 Rights Agreement to the Company’s stockholders for approval at the Company’s 2018 annual meeting. Under the Section 382 Rights Agreement, one right was distributed for each share of our common stock outstanding as of the close of business on January 30, 2009 and for each share issued after that date. Pursuant to the Third Amended Section 382 Rights Agreement, if any person or group (subject to certain exemptions) becomes an owner of more than 4.99 percent of the Company's outstanding common stock (or any other interest in the Company that would be treated as "stock" under applicable Section 382 regulations) without the approval of the Board of Directors, there would be a triggering event causing significant dilution in the voting power and economic ownership of that person or group. Shareholders who held more than 4.99 percent of the Company's outstanding common stock as of December 6, 2011 will trigger a dilutive event only if they acquire additional shares exceeding one percent of our outstanding shares without prior approval from the Board of Directors. In 2010, our shareholders approved an amendment to CNO's certificate of incorporation designed to prevent certain transfers of common stock which could otherwise adversely affect our ability to use our NOLs (the "Original Section 382 Charter Amendment"). Subject to the provisions set forth in the Original Section 382 Charter Amendment, transfers of our common stock would be void and of no effect if the effect of the purported transfer would be to: (i) increase the direct or indirect ownership of our common stock by any person or public group (as such term is defined in the regulations under Section 382) from less than 5% to 5% or more of our common stock; (ii) increase the percentage of our common stock owned directly or indirectly by a person or public group owning or deemed to own 5% or more of our common stock; or (iii) create a new public group. The Original Section 382 Charter Amendment was amended and extended in 2013 and in 2016 (the "2016 Section 382 Charter Amendment"). The expiration date for the 2016 Section 382 Charter Amendment is July 31, 2019. As of December 31, 2017 , we had $2.3 billion of federal NOLs (all of which were non-life NOLs). The following table summarizes the expiration dates of our loss carryforwards (dollars in millions): Net operating loss Year of expiration carryforwards 2023 $ 1,744.8 2025 85.2 2026 149.9 2027 10.8 2028 80.3 2029 213.2 2030 .3 2031 .2 2032 44.4 2033 .6 2034 .9 2035 .8 Total federal NOLs $ 2,331.4 We also had deferred tax assets related to NOLs for state income taxes of $9.3 million and $12.3 million at December 31, 2017 and 2016 , respectively. The related state NOLs are available to offset future state taxable income in certain states through 2025. There were no unrecognized tax benefits in 2017. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the year ended December 31, 2016 is as follows (dollars in millions): 2016 Balance at beginning of year $ 234.2 Increase based on tax positions taken in prior years 3.4 Decrease in unrecognized tax benefits related to settlements with taxing authorities (237.6 ) Balance at end of year $ — In the fourth quarter of 2016, we reached a settlement with the IRS related to two uncertain tax positions: (i) $280.7 million of life NOLs and $130.0 million of non-life NOLs related to the classification of the loss on our investment in Conseco Senior Health Insurance Company when it was transferred to an independent trust in 2008; and (ii) $66.7 million of non-life NOLs related to a bad debt deduction with respect to a stock purchase loan made by our Predecessor to a member of its board of directors. The settlement resulted in a reduction to tax expense of approximately $118.7 million in the fourth quarter of 2016 (the period in which these matters were settled and the fully executed documentation was received). The $118.7 million benefit includes: (i) a $98.2 million tax benefit related to additional life NOLs; (ii) a $17.1 million tax benefit related to additional non-life NOLs (net of an increase to the deferred tax valuation allowance of $51.7 million ); and (iii) a $3.4 million reduction in interest recognized in prior periods on alternative minimum tax that will no longer be required to be paid. The additional life NOLs related to the settlement offset our life taxable income in the third and fourth quarters of 2016 and the tax gain realized on the recapture of the ceded long-term care business from BRe. The settlement also reduced the amount of current income tax accrued at December 31, 2016 , as presented in the components of income tax assets and liabilities schedule provided in this note to consolidated financial statements by approximately $50 million . All of the life NOLs were utilized by December 31, 2016. Accordingly, we began making estimated federal tax payments equal to the prescribed federal tax rate applied to 65 percent of our life insurance company taxable income due to the limitations on the extent to which we can use non-life NOLs to offset life insurance company taxable income. Under current law, we will continue to pay tax on 65 percent of our life insurance company taxable income until all non-life NOLs are utilized or expire. The IRS is also conducting an examination of 2013 through 2014. In connection with this exam, we have agreed to extend the statute of limitations for 2013 through September 30, 2018. The Company’s various state income tax returns are generally open for tax years beginning in 2014, based on individual state statutes of limitation. Generally, for tax years which generate NOLs, capital losses or tax credit carryforwards, the statute remains open until the expiration of the statute of limitations for the tax year in which such carryforwards are utilized. The outcome of tax audits cannot be predicted with certainty. If the Company’s tax audits are not resolved in a manner consistent with management’s expectations, the Company may be required to adjust its provision for income taxes.

NOTES PAYABLE - DIRECT CORPORAT

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS	NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS The following notes payable were direct corporate obligations of the Company as of December 31, 2017 and 2016 (dollars in millions): 2017 2016 4.500% Senior Notes due May 2020 $ 325.0 $ 325.0 5.250% Senior Notes due May 2025 500.0 500.0 Revolving Credit Agreement (as defined below) 100.0 100.0 Unamortized debt issuance costs (10.4 ) (12.1 ) Direct corporate obligations $ 914.6 $ 912.9 Notes On May 19, 2015, the Company executed the Indenture, dated as of May 19, 2015 (the "Base Indenture") and the First Supplemental Indenture, dated as of May 19, 2015 (the "Supplemental Indenture" and, together with the Base Indenture, the "Indenture"), between the Company and Wilmington Trust, National Association, as trustee (the "Trustee") pursuant to which the Company issued $325.0 million aggregate principal amount of 4.500% Senior Notes due 2020 (the "2020 Notes") and $500.0 million aggregate principal amount of 5.250% Senior Notes due 2025 (the "2025 Notes" and, together with the 2020 Notes, the "Notes"). The Company used the proceeds of the offering of the Notes, together with borrowings under the Revolving Credit Agreement (as defined below): (i) to repay all amounts outstanding under our previous senior secured credit agreement; (ii) to redeem and satisfy and discharge all of the outstanding 6.375% Senior Secured Notes due October 2020 (the " 6.375% Notes"); and (iii) to pay fees and expenses related to the offering of the Notes and the foregoing transactions. The remaining proceeds of the Notes and the borrowings under the Revolving Credit Agreement were used for general corporate purposes, including share repurchases. The 2020 Notes mature on May 30, 2020, and the 2025 Notes mature on May 30, 2025. Interest on the 2020 Notes is payable at 4.500% per annum. Interest on the 2025 Notes is payable at 5.250% per annum. Interest on the Notes is payable semi-annually in cash in arrears on May 30 and November 30 of each year, commencing on November 30, 2015. The Notes are the Company's senior unsecured obligations and rank equally with the Company's other senior unsecured and unsubordinated debt from time to time outstanding, including obligations under the Revolving Credit Agreement (as defined below). The Notes are effectively subordinated to all of the Company's existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness. The Notes are structurally subordinated to all existing and future indebtedness and other liabilities of the Company's subsidiaries. The Company may redeem some or all of the 2020 Notes at any time or from time to time at a "make-whole" redemption price plus accrued and unpaid interest to, but not including, the redemption date. Prior to February 28, 2025, the Company may redeem some or all of the 2025 Notes at any time or from time to time at a "make-whole" redemption price plus accrued and unpaid interest to, but not including, the redemption date. On and after February 28, 2025, the Company may redeem some or all of the 2025 Notes at any time or from time to time at a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date. Upon the occurrence of a Change of Control Repurchase Event (as defined in the Indenture), the Company will be required to make an offer to repurchase the Notes at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase. The Indenture contains covenants that restrict the Company’s ability, with certain exceptions, to: • incur certain subsidiary indebtedness without also guaranteeing the Notes; • create liens; • enter into sale and leaseback transactions; • issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and • consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets. The Indenture provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants in the Indenture, failure to pay at maturity or acceleration of other indebtedness, a failure to pay certain judgments and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, the Trustee or holders of at least 25% in principal amount of the then outstanding Notes may declare the principal of and accrued but unpaid interest, including any additional interest, on all of the Notes to be due and payable. Revolving Credit Agreement On May 19, 2015, the Company entered into a $150.0 million four -year unsecured revolving credit agreement with KeyBank National Association, as administrative agent (the "Agent"), and the lenders from time to time party thereto. On May 19, 2015, the Company made an initial drawing of $100.0 million under the Revolving Credit Agreement, resulting in $50.0 million available for additional borrowings. On October 13, 2017, the Company entered into an amendment and restatement agreement (the "Amendment Agreement") with respect to its revolving credit agreement (as amended by the Amendment Agreement, the "Revolving Credit Agreement"). The Amendment Agreement, among other things, increased the total commitments available under the revolving credit facility from $150.0 million to $250.0 million , increased the aggregate amount of additional incremental loans the Company may incur from $50.0 million to $100.0 million and extended the maturity date of the revolving credit facility from May 19, 2019 to the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the 2020 Notes, which is November 30, 2019. The Revolving Credit Agreement includes an uncommitted subfacility for swingline loans of up to $5.0 million , and up to $5.0 million of the Revolving Credit Agreement is available for the issuance of letters of credit. The Company may incur additional incremental loans under the Revolving Credit Agreement in an aggregate principal amount of up to $100.0 million provided that there are no events of default and subject to certain other terms and conditions including the delivery of certain documentation. The interest rates with respect to loans under the Revolving Credit Agreement are based on, at the Company's option, a floating base rate (defined as a per annum rate equal to the highest of: (i) the federal funds rate plus 0.50% ; (ii) the "prime rate" of the Agent; and (iii) the eurodollar rate for a one-month interest period plus an applicable margin based on the Company's unsecured debt rating), or a eurodollar rate plus an applicable margin based on the Company's unsecured debt rating. The margins under the Revolving Credit Agreement range from 1.375% to 2.125% ( 1.75% to 2.25% prior to the Amendment Agreement), in the case of loans at the eurodollar rate, and 0.375% to 1.125% ( .75% to 1.25% prior to the Amendment Agreement), in the case of loans at the base rate. At December 31, 2017 , the interest rate on the amounts outstanding under the Revolving Credit Agreement was 3.44 percent . In addition, the daily average undrawn portion of the Revolving Credit Agreement will accrue a commitment fee payable quarterly in arrears. The applicable margin for, and the commitment fee applicable to, the Revolving Credit Agreement, will be adjusted from time to time pursuant to a ratings based pricing grid. In addition, a fronting fee, in an amount equal to 0.125% per annum on the aggregate face amount of the outstanding letters of credit, will be payable to the issuers of such letters of credit. The Revolving Credit Agreement contains certain financial, affirmative and negative covenants. The negative covenants in the Revolving Credit Agreement include restrictions that relate to, among other things and subject to customary baskets, exceptions and limitations for facilities of this type: • subsidiary debt; • liens; • restrictive agreements; • restricted payments during the continuance of an event of default; • disposition of assets and sale and leaseback transactions; • transactions with affiliates; • change in business; • fundamental changes; • modification of certain agreements; and • changes to fiscal year. The Revolving Credit Agreement requires the Company to maintain (each as calculated in accordance with the Revolving Credit Agreement): (i) a debt to total capitalization ratio of not more than 35.0 percent ( 30.0 percent prior to the Amendment Agreement) (such ratio was 20.3 percent at December 31, 2017 ); (ii) an aggregate ratio of total adjusted capital to company action level risk-based capital for the Company's insurance subsidiaries of not less than 250 percent (such ratio was estimated to be 446 percent at December 31, 2017 ); and (iii) a minimum consolidated net worth of not less than the sum of (x) $2,674 million plus (y) 50.0% of the net equity proceeds received by the Company from the issuance and sale of equity interests in the Company (the Company's consolidated net worth was $3,635.4 million at December 31, 2017 compared to the minimum requirement of $2,684.9 million ). The Revolving Credit Agreement provides for customary events of default (subject in certain cases to customary grace and cure periods), which include, without limitation, the following: • non-payment; • breach of representations, warranties or covenants; • cross-default and cross-acceleration; • bankruptcy and insolvency events; • judgment defaults; • actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement; • change of control; and • customary ERISA defaults. If an event of default under the Revolving Credit Agreement occurs and is continuing, the Agent may accelerate the amounts and terminate all commitments outstanding under the Revolving Credit Agreement. Loss on Extinguishment of Debt In 2015, we recognized a loss on extinguishment of debt totaling $32.8 million primarily related to: (i) the redemption premium related to the repayment of the 6.375% Notes; and (ii) the write-off of unamortized discount and issuance costs associated with the repayment of our previous senior secured credit agreement and the 6.375% Notes. Scheduled Repayment of our Direct Corporate Obligations The scheduled repayment of our direct corporate obligations was as follows at December 31, 2017 (dollars in millions): Year ending December 31, 2018 $ — 2019 100.0 (a) 2020 325.0 2021 — 2022 — Thereafter 500.0 $ 925.0 _________________________ (a) The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019.

LITIGATION AND OTHER LEGAL PROC

LITIGATION AND OTHER LEGAL PROCEEDINGS	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
LITIGATION AND OTHER LEGAL PROCEEDINGS	LITIGATION AND OTHER LEGAL PROCEEDINGS Legal Proceedings The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals. On September 29, 2016, Washington National and BCLIC commenced an arbitration proceeding seeking compensatory, consequential and punitive damages against BRe based upon BRe’s incurable material breaches of the long-term care reinsurance agreements, conversion, fraud, and breaches of fiduciary duties and the obligation to deal honestly and in good faith. BRe filed a counterclaim against Washington National and BCLIC in the arbitration alleging damages relating to the reinsurance agreements and their termination. In addition, on September 29, 2016, a complaint was filed by BCLIC and Washington National in the United States District Court for the Southern District of New York, Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Moshe M. Feuer, Scott Taylor and David Levy, Case No. 16-cv-7646, alleging, among other claims, fraud/fraudulent concealment, and violation of the Racketeer Influenced and Corrupt Organizations Act. These allegations relate to the long-term care reinsurance agreements between BRe and Washington National and BCLIC, respectively, and emanate from the undisclosed relationships between and among the defendants (who were the principal owners and officers of BRe) and Platinum Partners, LP and its affiliates. On April 27, 2017, an amended complaint was filed adding Beechwood Capital Group, LLC as a defendant. Feuer, Taylor and Levy have moved to compel arbitration of Washington National's and BCLIC's claims. Washington National and BCLIC intend to vigorously pursue their claims for damages and other remedies in the arbitration and the litigation described above. By public notice dated July 26, 2017, the Cayman Islands Monetary Authority advised that, effective July 25, 2017, two individuals (the "Controllers") had been appointed pursuant to Section 24(2)(h) of the Cayman Islands Insurance Law to assume control of the affairs of BRe. According to the public notice, effective with their appointment, the Controllers assumed immediate control of the affairs of BRe and have all the powers necessary to administer the affairs of BRe including power to terminate its insurance business. The Controllers are responsible for assessing the financial position of BRe and submitting a report to the Cayman Islands Monetary Authority by a date to be specified. We are in the process of assessing the potential impact of this action on the proceedings described in the foregoing paragraph. On July 20, 2007, a complaint was filed in the Hamilton County, Indiana Circuit Court, Signature Estates of Indiana, Inc. d/b/a Gordon Marketing, Stephens-Matthews Marketing, Inc., Shields Brokerage, Inc. and Edwin A. Hildebrand d/b/a Hildebrand Insurance Services v. Conseco Medical Insurance Company, Conseco Medical Insurance Company a/k/a Washington National Insurance Company and Washington National Insurance Company, Cause No. 29D02- 0707-PL-790. The Plaintiffs are independent insurance marketing organizations which previously marketed Conseco Medical Insurance Company ("CMIC") individual major medical products and which are claiming damages for allegedly fraudulent conduct by CMIC in withdrawing from this business in 2002. The Plaintiffs contend that they relied on CMIC’s alleged representations that its major medical business was profitable and that CMIC was committed to it. The Plaintiffs further allege that when CMIC exited the market, it caused agents that were previously writing business through their organizations to cease doing business with them, thereby causing irreparable damage. CMIC merged into Washington National, effective July 1, 2003. On December 16, 2016, following a jury trial, verdicts were entered in favor of the plaintiffs, and compensatory damages aggregating $4.7 million and punitive damages aggregating $6.0 million were awarded to the plaintiffs. Washington National filed post-trial motions requesting the court correct errors, grant a new trial, find that punitive damages were improper, and reduce both compensatory and punitive damages. Plaintiffs filed motions requesting pre-judgment interest and attorney fees. On June 19, 2017, the court reduced punitive damages by $1.5 million and denied plaintiffs' motions for pre-judgment interest and attorney fees. Each side appealed the decision and the case was subsequently settled. Regulatory Examinations and Fines Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows. In August 2011, we were notified of an examination to be done on behalf of a number of states for the purpose of determining compliance with unclaimed property laws by the Company and its subsidiaries. Such examination has included inquiries related to the use of data available on the U.S. Social Security Administration's Death Master File to identify instances where benefits under life insurance policies, annuities and retained asset accounts are payable. We are continuing to provide information to the examiners in response to their requests. A total of 38 states and the District of Columbia are currently participating in this examination. Guaranty Fund Assessments The balance sheet at December 31, 2017 , included: (i) accruals of $14.1 million , representing our estimate of all known assessments that will be levied against the Company's insurance subsidiaries by various state guaranty associations based on premiums written through December 31, 2017 ; and (ii) receivables of $20.0 million that we estimate will be recovered through a reduction in future premium taxes as a result of such assessments. At December 31, 2016 , such guaranty fund assessment accruals were $24.9 million and such receivables were $26.7 million . These estimates are subject to change when the associations determine more precisely the losses that have occurred and how such losses will be allocated among the insurance companies. We recognized expense for such assessments of $11.0 million , $2.8 million and $1.2 million in 2017 , 2016 and 2015 , respectively. Guarantees In accordance with the terms of the employment agreements of two of the Company's former chief executive officers, certain wholly-owned subsidiaries of the Company are the guarantors of the former executives' nonqualified supplemental retirement benefits. The liability for such benefits was $24.2 million and $25.0 million at December 31, 2017 and 2016 , respectively, and is included in the caption "Other liabilities" in the consolidated balance sheet. Leases and Certain Other Long-Term Commitments The Company rents office space, equipment and computer software under noncancellable operating lease agreements. In addition, the Company has entered into certain sponsorship agreements which require future payments. Total expense pursuant to these lease and sponsorship agreements was $61.4 million , $56.8 million and $48.8 million in 2017 , 2016 and 2015 , respectively. Future required minimum payments as of December 31, 2017 , were as follows (dollars in millions): 2018 $ 33.5 2019 18.2 2020 11.8 2021 8.0 2022 5.6 Thereafter 3.6 Total $ 80.7

AGENT DEFERRED COMPENSATION PLA

AGENT DEFERRED COMPENSATION PLAN	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
AGENT DEFERRED COMPENSATION PLAN	AGENT DEFERRED COMPENSATION PLAN For our agent deferred compensation plan, it is our policy to immediately recognize changes in the actuarial benefit obligation resulting from either actual experience being different than expected or from changes in actuarial assumptions. One of our insurance subsidiaries has a noncontributory, unfunded deferred compensation plan for qualifying members of its career agency force. Benefits are based on years of service and career earnings. In 2016, the agent deferred compensation plan was amended to: (i) freeze participation in the plan; (ii) freeze benefits accrued under the plan; and (iii) add a limited cashout feature. During the third quarter of 2016, we made lump sum settlement distributions to plan participants with account balances that were below a certain threshold consistent with the provision of the amended plan. We recognized a pre-tax gain of $6.1 million related to the settlement distributions in the third quarter of 2016. The actuarial measurement date of this deferred compensation plan is December 31. The liability recognized in the consolidated balance sheet for the agent deferred compensation plan was $168.2 million and $156.3 million at December 31, 2017 and 2016 , respectively. Expenses incurred on this plan were $18.8 million , $8.1 million and $2.2 million during 2017 , 2016 and 2015 , respectively (including the recognition of gains (losses) of $(12.2) million , $3.1 million and $15.2 million in 2017 , 2016 and 2015 , respectively, primarily resulting from: (i) changes in the discount rate assumption used to determine the deferred compensation plan liability to reflect current investment yields; (ii) changes in mortality table assumptions; and (iii) the aforementioned settlement distributions in 2016). We purchased COLI as an investment vehicle to fund the agent deferred compensation plan. The COLI assets are not assets of the agent deferred compensation plan, and as a result, are accounted for outside the plan and are recorded in the consolidated balance sheet as other invested assets. The carrying value of the COLI assets was $182.3 million and $165.0 million at December 31, 2017 and 2016 , respectively. Death benefits related to the COLI and changes in the cash surrender value (which approximates net realizable value) of the COLI assets are recorded as net investment income on special-purpose portfolios and totaled $24.6 million , $6.9 million and $.5 million in 2017 , 2016 and 2015 , respectively. We used the following assumptions for the deferred compensation plan to calculate: 2017 2016 Benefit obligations: Discount rate 3.75 % 4.25 % Net periodic cost: Discount rate 4.25 % 4.50 % The discount rate is based on the yield of a hypothetical portfolio of high quality debt instruments which could effectively settle plan benefits on a present value basis as of the measurement date. The benefits expected to be paid pursuant to our agent deferred compensation plan as of December 31, 2017 were as follows (dollars in millions): 2018 $ 7.4 2019 7.6 2020 7.9 2021 8.0 2022 8.3 2023 - 2027 45.2 One of our insurance subsidiaries has another unfunded nonqualified deferred compensation program for qualifying members of its career agency force. Such agents may defer a certain percentage of their net commissions into the program. In addition, annual Company contributions are made based on the agent's production and vest over a period of five to 10 years. The liability recognized in the consolidated balance sheet for this program was $22.9 million and $11.2 million at December 31, 2017 and 2016 , respectively. Company contribution expense totaled $6.6 million and $4.4 million in 2017 and 2016 , respectively. We purchased Trust-Owned Life Insurance ("TOLI") as an investment vehicle to fund the program. The TOLI assets are not assets of the program, and as a result, are accounted for outside the program and are recorded in the consolidated balance sheet as other invested assets. The carrying value of the TOLI assets was $18.0 million and $5.1 million at December 31, 2017 and 2016 , respectively. The Company has a qualified defined contribution plan for which substantially all employees are eligible. Company contributions, which match a portion of certain voluntary employee contributions to the plan, totaled $5.5 million , $5.3 million and $5.0 million in 2017 , 2016 and 2015 , respectively. Employer matching contributions are discretionary.

DERIVATIVES

DERIVATIVES	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	DERIVATIVES Our freestanding and embedded derivatives, which are not designated as hedging instruments, are held at fair value and are summarized as follows (dollars in millions): Fair value 2017 2016 Assets: Other invested assets: Fixed index call options $ 170.2 $ 111.9 Reinsurance receivables (1.4 ) (4.2 ) Total assets $ 168.8 $ 107.7 Liabilities: Future policy benefits: Fixed index products $ 1,334.8 $ 1,092.3 Total liabilities $ 1,334.8 $ 1,092.3 The activity associated with freestanding derivative instruments is measured as either the notional or the number of contracts. The activity associated with the fixed index annuity embedded derivatives are shown by the number of policies. The following table represents activity associated with derivative instruments as of the dates indicated: Measurement December 31, 2016 Additions Maturities/terminations December 31, 2017 Fixed index annuities - embedded derivative Policies 100,812 11,437 (7,560 ) 104,689 Fixed index call options Notional (a) $ 2,455.1 $ 3,021.8 $ (2,471.1 ) $ 3,005.8 _________________ (a) Dollars in millions. We are required to establish an embedded derivative related to a modified coinsurance agreement pursuant to which we assume the risks of a block of health insurance business. The embedded derivative represents the mark-to-market adjustment for approximately $126 million in underlying investments held by the ceding reinsurer. The following table provides the pre-tax gains (losses) recognized in net income for derivative instruments, which are not designated as hedges for the periods indicated (dollars in millions): 2017 2016 2015 Net investment income from policyholder and other special-purpose portfolios: Fixed index call options $ 162.5 $ 29.2 $ (36.2 ) Net realized gains (losses): Interest rate futures — (1.1 ) (2.7 ) Embedded derivative related to modified coinsurance agreement 2.8 .8 (7.0 ) Total 2.8 (.3 ) (9.7 ) Insurance policy benefits: Embedded derivative related to fixed index annuities 25.0 60.8 36.3 Total $ 190.3 $ 89.7 $ (9.6 ) Derivative Counterparty Risk If the counterparties to the call options fail to meet their obligations, we may recognize a loss. We limit our exposure to such a loss by diversifying among several counterparties believed to be strong and creditworthy. At December 31, 2017 , all of our counterparties were rated "A-" or higher by S&P. From time to time, we enter into exchange-traded interest rate future contracts. The contracts are marked to market and margined on a daily basis. The Company has minimal exposure to credit-related losses in the event of nonperformance. The Company and its subsidiaries are parties to master netting arrangements with its counterparties related to entering into various derivative contracts. Exchange-traded derivatives require margin accounts which we offset. The following table summarizes information related to derivatives with master netting arrangements or collateral as of December 31, 2017 and 2016 (dollars in millions): Gross amounts not offset in the balance sheet Gross amounts recognized Gross amounts offset in the balance sheet Net amounts of assets presented in the balance sheet Financial instruments Cash collateral received Net amount December 31, 2017: Fixed index call options $ 170.2 $ — $ 170.2 $ — $ — $ 170.2 December 31, 2016: Fixed index call options 111.9 — 111.9 — — 111.9

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHAREHOLDERS' EQUITY	SHAREHOLDERS' EQUITY Changes in the number of shares of common stock outstanding were as follows (shares in thousands): 2017 2016 2015 Balance, beginning of year 173,754 184,029 203,324 Treasury stock purchased and retired (7,808 ) (11,688 ) (20,582 ) Stock options exercised 725 978 769 Restricted and performance stock vested (a) 187 435 518 Balance, end of year 166,858 173,754 184,029 ____________________ (a) In 2017 , 2016 and 2015 , such amount was reduced by 103 thousand , 191 thousand and 237 thousand shares, respectively, which were tendered to the Company for the payment of required federal and state tax withholdings owed on the vesting of restricted and performance stock. In May 2011, the Company announced a securities repurchase program of up to $100.0 million . In February 2012, June 2012, December 2012, December 2013, November 2014, November 2015 and May 2017, the Company's Board of Directors approved, in aggregate, an additional $1,900.0 million to repurchase the Company's outstanding securities. In 2017 , 2016 and 2015 , we repurchased 7.8 million , 11.7 million and 20.6 million shares, respectively, for $167.1 million , $203.0 million and $365.2 million , respectively, under the securities repurchase program. The Company had remaining repurchase authority of $385.6 million as of December 31, 2017 . In 2017 , 2016 and 2015 , dividends declared and paid on common stock totaled $59.6 million ( $0.35 per common share), $54.8 million ( $0.31 per common share) and $52.0 million ( $0.27 per common share), respectively. In May 2017, the Company increased its quarterly common stock dividend to $0.09 per share from $0.08 per share. In May 2016, the Company increased its quarterly common stock dividend to $0.08 per share from $0.07 per share. In May 2015, the Company increased its quarterly common stock dividend to $0.07 per share from $0.06 per share. The Company has a long-term incentive plan which permits the grant of CNO incentive or non-qualified stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance shares or units and certain other equity-based awards to certain directors, officers and employees of the Company and certain other individuals who perform services for the Company. As of December 31, 2017 , 7.5 million shares remained available for issuance under the plan. Our stock option awards are generally granted with an exercise price equal to the market price of the Company's stock on the date of grant and a maximum term of ten years. Our stock option awards granted in 2007 through 2009 generally vested on a graded basis over a three year service term and expired five years from the date of grant. Our stock options granted in 2010 through 2014 generally vest on a graded basis over a three year service term and expire seven years from the date of grant. Our stock options granted in 2015, 2016 and 2017 generally vest on a graded basis over a three year service term and expire ten years from the date of grant. The vesting periods for our awards of restricted stock and restricted stock units (collectively "restricted stock") range from immediate vesting to a period of three years. A summary of the Company's stock option activity and related information for 2017 is presented below (shares in thousands; dollars in millions, except per share amounts): Shares Weighted average exercise price Weighted average remaining life (in years) Aggregate intrinsic value Outstanding at the beginning of the year 5,354 $ 14.73 Options granted 729 21.06 Exercised (237 ) (17.81 ) $ 5.2 Forfeited or terminated (725 ) (11.43 ) Outstanding at the end of the year 5,121 15.95 5.4 $ 37.2 Options exercisable at the end of the year 2,440 3.0 $ 19.2 Available for future grant 7,488 A summary of the Company's stock option activity and related information for 2016 is presented below (shares in thousands; dollars in millions, except per share amounts): Shares Weighted average exercise price Weighted average remaining life (in years) Aggregate intrinsic value Outstanding at the beginning of the year 5,199 $ 13.32 Options granted 1,706 17.45 Exercised (978 ) (8.70 ) $ 6.1 Forfeited or terminated (573 ) (20.41 ) Outstanding at the end of the year 5,354 14.73 5.9 $ 37.1 Options exercisable at the end of the year 2,187 2.7 $ 15.1 Available for future grant 4,620 A summary of the Company's stock option activity and related information for 2015 is presented below (shares in thousands; dollars in millions, except per share amounts): Shares Weighted average exercise price Weighted average remaining life (in years) Aggregate intrinsic value Outstanding at the beginning of the year 5,011 $ 12.04 Options granted 1,361 16.45 Exercised (769 ) (8.20 ) $ 4.8 Forfeited or terminated (404 ) (17.70 ) Outstanding at the end of the year 5,199 13.32 4.8 $ 38.4 Options exercisable at the end of the year 2,399 2.5 $ 15.3 Available for future grant 6,882 We recognized compensation expense related to stock options totaling $6.3 million ( $4.1 million after income taxes) in 2017 , $12.2 million ( $7.9 million after income taxes) in 2016 and $9.6 million ( $6.2 million after income taxes) in 2015 . Compensation expense related to stock options reduced both basic and diluted earnings per share by two cent s in 2017 , four cent s in 2016 and three cent s in 2015 . At December 31, 2017 , the unrecognized compensation expense for non-vested stock options totaled $4.2 million which is expected to be recognized over a weighted average period of 1.5 years. Cash received by the Company from the exercise of stock options was $8.3 million , $8.4 million and $6.3 million during 2017 , 2016 and 2015 , respectively. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions: 2017 2016 2015 Grants Grants Grants Weighted average risk-free interest rates 2.2 % 1.4 % 1.7 % Weighted average dividend yields 1.5 % 1.6 % 1.5 % Volatility factors 32 % 36 % 85 % Weighted average expected life (in years) 6.3 6.3 6.3 Weighted average fair value per share $ 6.20 $ 5.48 $ 10.83 The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on the Company's history and expectation of dividend payouts. Volatility factors are based on the weekly historical volatility of the Company's common stock equal to the expected life of the option. The expected life is based on the average of the graded vesting period and the contractual terms of the option. The exercise price was equal to the market price of our stock on the date of grant for all options granted in 2017 , 2016 and 2015 . The following table summarizes information about stock options outstanding at December 31, 2017 (shares in thousands): Options outstanding Options exercisable Range of exercise prices Number outstanding Remaining life (in years) Average exercise price Number exercisable Average exercise price $6.77 - $7.51 605 0.9 $ 7.47 605 $ 7.47 $10.88 - $16.22 683 2.3 11.12 670 11.02 $16.42 - $21.48 3,833 6.7 18.15 1,165 18.04 5,121 2,440 During 2017 , 2016 and 2015 , the Company granted restricted stock of .3 million , .4 million and .1 million , respectively, to certain directors, officers and employees of the Company at a weighted average fair value of $20.87 per share, $18.17 per share and $17.59 per share, respectively. The fair value of such grants totaled $6.9 million , $7.3 million and $1.7 million in 2017 , 2016 and 2015 , respectively. Such amounts are recognized as compensation expense over the vesting period of the restricted stock. A summary of the Company's non-vested restricted stock activity for 2017 is presented below (shares in thousands): Shares Weighted average grant date fair value Non-vested shares, beginning of year 369 $ 18.10 Granted 330 20.87 Vested (147 ) (18.38 ) Forfeited (17 ) (20.59 ) Non-vested shares, end of year 535 19.65 At December 31, 2017 , the unrecognized compensation expense for non-vested restricted stock totaled $5.5 million which is expected to be recognized over a weighted average period of 1.8 years. At December 31, 2016 , the unrecognized compensation expense for non-vested restricted stock totaled $5.0 million . We recognized compensation expense related to restricted stock awards totaling $6.1 million , $3.1 million and $2.2 million in 2017 , 2016 and 2015 , respectively. The fair value of restricted stock that vested during 2017 , 2016 and 2015 was $2.7 million , $2.1 million and $2.7 million , respectively. Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the accounting policy for forfeiture rate assumptions. Under the new guidance, we elected to account for forfeitures as they occur. The impact of adoption of this provision of the guidance increased additional paid-in capital by $.9 million , decreased retained earnings by $.6 million and increased income tax assets by $.3 million . Prior to 2017, authoritative guidance required us to estimate the amount of unvested stock-based awards that would be forfeited in future periods and reduce the amount of compensation expense recognized over the applicable service period to reflect such estimate. In 2017 , 2016 and 2015 the Company granted performance units totaling 452,900 , 507,976 and 516,660 , respectively, pursuant to its long-term incentive plan to certain officers of the Company. The criteria for payment for such awards are based on certain company-wide performance levels that must be achieved within a specified performance time (generally three years ), each as defined in the award. The performance units granted in 2017, 2016 and 2015 provide for a payout of up to 200 percent of the award if certain performance thresholds are achieved, and the performance units granted prior to 2015 provide for a payout of up to 150 percent of the award if certain performance thresholds are achieved. Unless antidilutive, the diluted weighted average shares outstanding would reflect the number of performance units expected to be issued, using the treasury stock method. A summary of the Company's performance units is presented below (shares in thousands): Total shareholder return awards Operating return on equity awards Pre-tax operating income awards Awards outstanding at December 31, 2014 519 343 176 Granted in 2015 258 258 — Additional shares issued pursuant to achieving certain performance criteria (a) 85 — 85 Shares vested in 2015 (260 ) — (260 ) Forfeited (53 ) (52 ) (1 ) Awards outstanding at December 31, 2015 549 549 — Granted in 2016 254 254 — Additional shares issued pursuant to achieving certain performance criteria (a) 87 65 — Shares vested in 2016 (261 ) (239 ) — Forfeited (59 ) (59 ) — Awards outstanding at December 31, 2016 570 570 — Granted in 2017 226 226 — Additional shares issued pursuant to achieving certain performance criteria (a) — 30 — Shares vested in 2017 — (144 ) — Forfeited (167 ) (53 ) — Awards outstanding at December 31, 2017 629 629 — _________________________ (a) The performance units that vested in these years provided for a payout of up to 150 percent of the award if certain performance levels were achieved. The grant date fair value of the performance units awarded was $11.2 million and $10.3 million in 2017 and 2016 , respectively. We recognized compensation expense of $9.0 million , $7.7 million and $5.3 million in 2017 , 2016 and 2015 , respectively, related to the performance units. As further discussed in the footnote to the consolidated financial statements entitled "Income Taxes", the Company's Board of Directors adopted the Section 382 Rights Agreement in 2009 and has amended and extended the Section 382 Rights Agreement on three occasions. The Section 382 Rights Agreement, as amended, is designed to protect shareholder value by preserving the value of our tax assets primarily associated with NOLs. At the time the Section 382 Rights Agreement was adopted, the Company declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of common stock. The dividend was payable on January 30, 2009, to the shareholders of record as of the close of business on that date and a Right is also attached to each share of CNO common stock issued after that date. Pursuant to the Section 382 Rights Agreement, as amended, each Right entitles the shareholder to purchase from the Company one one-thousandth of a share of Series D Junior Participating Preferred Stock, par value $.01 per share (the "Junior Preferred Stock") of the Company at a price of $90.00 per one one-thousandth of a share of Junior Preferred Stock. The description and terms of the Rights are set forth in the Section 382 Rights Agreement, as amended. The Rights would become exercisable in the event any person or group (subject to certain exemptions) becomes an owner of more than 4.99 percent of the outstanding stock of CNO (a "Threshold Holder") without the approval of the Board of Directors or an existing shareholder who is currently a Threshold Holder acquires additional shares exceeding one percent of our outstanding shares without prior approval from the Board of Directors. A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands): 2017 2016 2015 Net income for diluted earnings per share $ 175.6 $ 358.2 $ 270.7 Shares: Weighted average shares outstanding for basic earnings per share 170,025 176,638 193,054 Effect of dilutive securities on weighted average shares: Stock options, restricted stock and performance units 2,119 1,685 2,112 Weighted average shares outstanding for diluted earnings per share 172,144 178,323 195,166 Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Restricted shares (including our performance units) are not included in basic earnings per share until vested. Diluted earnings per share reflect the potential dilution that could occur if outstanding stock options were exercised and restricted stock was vested. The dilution from options and restricted shares is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the average market price during the period, reducing the dilutive effect of the exercise of the options (or the vesting of the restricted stock and performance units).

OTHER OPERATING STATEMENT DATA

OTHER OPERATING STATEMENT DATA	12 Months Ended
	Dec. 31, 2017
Insurance [Abstract]
OTHER OPERATING STATEMENT DATA	OTHER OPERATING STATEMENT DATA Insurance policy income consisted of the following (dollars in millions): 2017 2016 2015 Direct premiums collected $ 4,013.4 $ 3,942.7 $ 3,769.6 Reinsurance assumed 30.2 33.8 38.4 Reinsurance ceded (114.4 ) (132.9 ) (142.8 ) Premiums collected, net of reinsurance 3,929.2 3,843.6 3,665.2 Change in unearned premiums 19.0 6.2 5.9 Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities (1,445.9 ) (1,386.7 ) (1,241.9 ) Premiums on traditional products with mortality or morbidity risk 2,502.3 2,463.1 2,429.2 Fees and surrender charges on interest-sensitive products 145.0 138.0 126.8 Insurance policy income $ 2,647.3 $ 2,601.1 $ 2,556.0 The four states with the largest shares of 2017 collected premiums were Florida ( 10 percent ), Pennsylvania ( 6 percent ), Texas ( 6 percent ) and California ( 5 percent ). No other state accounted for more than five percent of total collected premiums. Other operating costs and expenses were as follows (dollars in millions): 2017 2016 2015 Commission expense $ 115.6 $ 110.5 $ 103.8 Salaries and wages 237.3 231.0 205.2 Other 488.6 454.8 430.2 Total other operating costs and expenses $ 841.5 $ 796.3 $ 739.2 Changes in the present value of future profits were as follows (dollars in millions): 2017 2016 2015 Balance, beginning of year $ 401.8 $ 449.0 $ 489.4 Amortization (54.4 ) (62.2 ) (69.1 ) Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale 12.2 15.0 28.7 Balance, end of year $ 359.6 $ 401.8 $ 449.0 Based on current conditions and assumptions as to future events on all policies inforce, the Company expects to amortize approximately 11 percent of the December 31, 2017 balance of the present value of future profits in 2018 , 10 percent in 2019 , 9 percent in 2020 , 7 percent in 2021 and 7 percent in 2022 . The discount rate used to determine the amortization of the present value of future profits averaged approximately 5 percent in the years ended December 31, 2017 , 2016 and 2015 . In accordance with authoritative guidance, we are required to amortize the present value of future profits in relation to estimated gross profits for interest-sensitive life products and annuity products. Such guidance also requires that estimates of expected gross profits used as a basis for amortization be evaluated regularly, and that the total amortization recorded to date be adjusted by a charge or credit to the statement of operations, if actual experience or other evidence suggests that earlier estimates should be revised. Changes in deferred acquisition costs were as follows (dollars in millions): 2017 2016 2015 Balance, beginning of year $ 1,044.7 $ 1,083.3 $ 770.6 Additions 236.1 242.7 246.4 Amortization (184.9 ) (191.1 ) (190.9 ) Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale (69.1 ) (90.2 ) 257.2 Balance, end of year $ 1,026.8 $ 1,044.7 $ 1,083.3

CONSOLIDATED STATEMENT CASH FLO

CONSOLIDATED STATEMENT CASH FLOWS	12 Months Ended
	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
CONSOLIDATED STATEMENT OF CASH FLOWS	CONSOLIDATED STATEMENT OF CASH FLOWS The following disclosures supplement our consolidated statement of cash flows. The following reconciles net income to net cash provided by operating activities (dollars in millions): 2017 2016 2015 Cash flows from operating activities: Net income $ 175.6 $ 358.2 $ 270.7 Adjustments to reconcile net income to net cash from operating activities: Amortization and depreciation 265.4 275.0 283.4 Income taxes 227.5 (11.7 ) 92.9 Insurance liabilities 464.7 332.8 297.4 Accrual and amortization of investment income (321.6 ) (124.2 ) (27.6 ) Deferral of policy acquisition costs (236.1 ) (242.7 ) (246.4 ) Net realized investment (gains) losses (50.3 ) (8.3 ) 36.6 Loss on reinsurance transactions and transition expenses — 75.4 9.0 Cash and cash equivalents received upon recapture of reinsurance — 73.6 — Loss on extinguishment of borrowings related to variable interest entities 9.5 — — Loss on extinguishment of debt — — 32.8 Other 78.4 34.7 (1.0 ) Net cash from operating activities $ 613.1 $ 762.8 $ 747.8 Other non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions): 2017 2016 2015 Stock options, restricted stock and performance units $ 21.4 $ 23.0 $ 17.1 Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe — 431.1 —

STATUTORY INFORMATION (BASED ON

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES)	12 Months Ended
	Dec. 31, 2017
Insurance [Abstract]
STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES)	STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES) Statutory accounting practices prescribed or permitted by regulatory authorities for the Company's insurance subsidiaries differ from GAAP. The Company's insurance subsidiaries reported the following amounts to regulatory agencies, after appropriate elimination of intercompany accounts among such subsidiaries (dollars in millions): 2017 2016 Statutory capital and surplus $ 1,904.4 $ 1,956.8 Asset valuation reserve 246.8 253.3 Interest maintenance reserve 487.0 486.9 Total $ 2,638.2 $ 2,697.0 Statutory capital and surplus included investments in upstream affiliates of $42.6 million at both December 31, 2017 and 2016 , which were eliminated in the consolidated financial statements prepared in accordance with GAAP. Statutory earnings build the capital required by ratings agencies and regulators. Statutory earnings, fees and interest paid by the insurance companies to the parent company create the "cash flow capacity" the parent company needs to meet its obligations, including debt service. The consolidated statutory net income (a non-GAAP measure) of our insurance subsidiaries was $352.3 million , $256.6 million (including approximately $110 million loss on the recapture of long-term care business) and $332.6 million in 2017 , 2016 and 2015 , respectively. Included in such net income were net realized capital losses, net of income taxes, of $9.9 million , $29.7 million and $18.0 million in 2017 , 2016 and 2015 , respectively. In addition, such net income included pre-tax amounts for fees and interest paid to CNO or its non-life subsidiaries totaling $158.3 million , $153.9 million and $154.2 million in 2017 , 2016 and 2015 , respectively. Insurance regulators may prohibit the payment of dividends or other payments by our insurance subsidiaries to parent companies if they determine that such payment could be adverse to our policyholders or contract holders. Otherwise, the ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations. Insurance regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in some states, the lesser of): (i) statutory net gain from operations or statutory net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. However, as each of the immediate insurance subsidiaries of CDOC, Inc. ("CDOC", our wholly owned subsidiary and the immediate parent of Washington National and Conseco Life Insurance Company of Texas) has negative earned surplus, any dividend payments from the insurance subsidiaries to CNO requires the prior approval of the director or commissioner of the applicable state insurance department. During 2017 , our insurance subsidiaries paid dividends of $357.7 million to CDOC. The payment of interest on surplus debentures requires either prior written notice or approval of the director or commissioner of the applicable state insurance department. Dividends and other payments from our non-insurance subsidiaries to CNO or CDOC do not require approval by any regulatory authority or other third party. In accordance with an order from the Florida Office of Insurance Regulation, Washington National may not distribute funds to any affiliate or shareholder, except pursuant to agreements that have been approved, without prior notice to the Florida Office of Insurance Regulation. In addition, the risk-based capital ("RBC") and other capital requirements described below can also limit, in certain circumstances, the ability of our insurance subsidiaries to pay dividends. RBC requirements provide a tool for insurance regulators to determine the levels of statutory capital and surplus an insurer must maintain in relation to its insurance and investment risks and the need for possible regulatory attention. The RBC requirements provide four levels of regulatory attention, varying with the ratio of the insurance company's total adjusted capital (defined as the total of its statutory capital and surplus, asset valuation reserve and certain other adjustments) to its RBC (as measured on December 31 of each year) as follows: (i) if a company's total adjusted capital is less than 100 percent but greater than or equal to 75 percent of its RBC, the company must submit a comprehensive plan to the regulatory authority proposing corrective actions aimed at improving its capital position (the "Company Action Level"); (ii) if a company's total adjusted capital is less than 75 percent but greater than or equal to 50 percent of its RBC, the regulatory authority will perform a special examination of the company and issue an order specifying the corrective actions that must be taken; (iii) if a company's total adjusted capital is less than 50 percent but greater than or equal to 35 percent of its RBC, the regulatory authority may take any action it deems necessary, including placing the company under regulatory control; and (iv) if a company's total adjusted capital is less than 35 percent of its RBC, the regulatory authority must place the company under its control. In addition, the RBC requirements provide for a trend test if a company's total adjusted capital is between 100 percent and 150 percent of its RBC at the end of the year. The trend test calculates the greater of the decrease in the margin of total adjusted capital over RBC: (i) between the current year and the prior year; and (ii) for the average of the last 3 years. It assumes that such decrease could occur again in the coming year. Any company whose trended total adjusted capital is less than 95 percent of its RBC would trigger a requirement to submit a comprehensive plan as described above for the Company Action Level. The 2017 statutory annual statements of each of our insurance subsidiaries reflect total adjusted capital in excess of the levels subjecting the subsidiaries to any regulatory action. In addition, although we are under no obligation to do so, we may elect to contribute additional capital or retain greater amounts of capital to strengthen the surplus of certain insurance subsidiaries. Any election to contribute or retain additional capital could impact the amounts our insurance subsidiaries pay as dividends to the holding company. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher ratings and by the capital levels that we target for our insurance subsidiaries. At December 31, 2017 , the consolidated RBC ratio of our insurance subsidiaries exceeded the minimum RBC requirement included in our Revolving Credit Agreement. See the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for further discussion of various financial ratios and balances we are required to maintain. We calculate the consolidated RBC ratio by assuming all of the assets, liabilities, capital and surplus and other aspects of the business of our insurance subsidiaries are combined together in one insurance subsidiary, with appropriate intercompany eliminations.

BUSINESS SEGMENTS

BUSINESS SEGMENTS	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
BUSINESS SEGMENTS	BUSINESS SEGMENTS The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting the long-term care block recaptured from BRe effective September 30, 2016, as an additional business segment. We measure segment performance by excluding the loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment in the agent deferred compensation plan, loss on extinguishment of debt, income taxes and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs ("pre-tax operating earnings") because we believe that this performance measure is a better indicator of the ongoing business and trends in our business. Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of net realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business. The loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment in the agent deferred compensation plan, loss on extinguishment of debt and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs depend on market conditions or represent unusual items that do not necessarily relate to the underlying business of our segments. Net realized investment gains (losses) and fair value changes in embedded derivative liabilities (net of related amortization) may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business. Operating information by segment was as follows (dollars in millions): 2017 2016 2015 Revenues: Bankers Life: Insurance policy income: Annuities $ 20.3 $ 22.0 $ 22.4 Health 1,231.1 1,244.1 1,251.0 Life 415.2 393.0 375.3 Net investment income (a) 1,107.3 936.8 884.7 Fee revenue and other income (a) 44.1 34.4 27.7 Total Bankers Life revenues 2,818.0 2,630.3 2,561.1 Washington National: Insurance policy income: Annuities 2.1 2.9 3.0 Health 642.9 627.9 615.4 Life 26.4 25.0 25.4 Net investment income (a) 270.2 259.3 253.6 Fee revenue and other income (a) 1.0 1.3 1.3 Total Washington National revenues 942.6 916.4 898.7 Colonial Penn: Insurance policy income: Health 2.1 2.6 3.0 Life 289.7 278.8 260.5 Net investment income (a) 44.4 44.2 43.0 Fee revenue and other income (a) 1.3 1.1 1.0 Total Colonial Penn revenues 337.5 326.7 307.5 Long-term care in run-off: Insurance policy income - health 17.5 4.8 — Net investment income (a) 34.6 9.4 — Total Long-term care in run-off revenues 52.1 14.2 — Corporate operations: Net investment income 35.5 16.6 11.3 Fee revenue and other income 8.5 10.0 8.6 Total corporate revenues 44.0 26.6 19.9 Total revenues $ 4,194.2 $ 3,914.2 $ 3,787.2 (continued on next page) (continued from previous page) 2017 2016 2015 Expenses: Bankers Life: Insurance policy benefits $ 1,771.8 $ 1,620.6 $ 1,588.4 Amortization 163.6 176.5 187.1 Interest expense on investment borrowings 19.8 13.2 8.8 Other operating costs and expenses 443.9 422.1 407.2 Total Bankers Life expenses 2,399.1 2,232.4 2,191.5 Washington National: Insurance policy benefits 581.1 561.7 546.6 Amortization 58.8 59.1 55.2 Interest expense on investment borrowings 6.3 3.7 2.0 Other operating costs and expenses 198.1 189.0 183.4 Total Washington National expenses 844.3 813.5 787.2 Colonial Penn: Insurance policy benefits 199.6 201.9 189.0 Amortization 16.3 15.3 14.4 Interest expense on investment borrowings .9 .6 .1 Other operating costs and expenses 98.1 107.2 98.4 Total Colonial Penn expenses 314.9 325.0 301.9 Long-term care in run-off: Insurance policy benefits 47.3 17.6 — Other operating costs and expenses 3.1 .5 — Total Long-term care in run-off expenses 50.4 18.1 — Corporate operations: Interest expense on corporate debt 46.5 45.8 45.0 Interest expense on investment borrowings — — .2 Other operating costs and expenses 84.3 69.1 38.6 Total corporate expenses 130.8 114.9 83.8 Total expenses 3,739.5 3,503.9 3,364.4 Pre-tax operating earnings by segment: Bankers Life 418.9 397.9 369.6 Washington National 98.3 102.9 111.5 Colonial Penn 22.6 1.7 5.6 Long-term care in run-off 1.7 (3.9 ) — Corporate operations (86.8 ) (88.3 ) (63.9 ) Pre-tax operating earnings $ 454.7 $ 410.3 $ 422.8 ___________________ (a) It is not practicable to provide additional components of revenue by product or services. A reconciliation of segment revenues and expenses to consolidated revenues and expenses and net income is as follows (dollars in millions): 2017 2016 2015 Total segment revenues $ 4,194.2 $ 3,914.2 $ 3,787.2 Net realized investment gains (losses) 50.3 8.3 (36.6 ) Revenues related to certain non-strategic investments and earnings attributable to VIEs 52.7 52.6 36.3 Fee revenue related to transition and support services agreements — 10.0 25.0 Consolidated revenues 4,297.2 3,985.1 3,811.9 Total segment expenses 3,739.5 3,503.9 3,364.4 Insurance policy benefits - fair value changes in embedded derivative liabilities 2.9 (11.3 ) (15.7 ) Amortization related to fair value changes in embedded derivative liabilities (.4 ) 1.7 3.8 Amortization related to net realized investment gains (losses) 1.0 .7 (.5 ) Expenses related to certain non-strategic investments and expenses attributable to VIEs 61.5 54.6 43.0 Fair value changes and amendment related to agent deferred compensation plan 12.2 (3.1 ) (15.1 ) Loss on extinguishment of debt — — 32.8 Loss on reinsurance transaction and transition expenses — 75.4 9.0 Expenses related to transition and support services agreements — 10.0 22.5 Consolidated expenses 3,816.7 3,631.9 3,444.2 Income before tax 480.5 353.2 367.7 Income tax expense: Tax expense on period income 162.8 127.8 129.5 Valuation allowance for deferred tax assets and other tax items 142.1 (132.8 ) (32.5 ) Net income $ 175.6 $ 358.2 $ 270.7 Segment balance sheet information was as follows (dollars in millions): 2017 2016 Assets: Bankers Life $ 21,134.9 $ 19,876.4 Washington National 7,674.3 7,555.7 Colonial Penn 1,059.3 1,022.9 Long-term care in run-off 692.9 656.2 Corporate operations 2,548.9 2,864.0 Total assets $ 33,110.3 $ 31,975.2 Liabilities: Bankers Life $ 18,031.6 $ 17,144.9 Washington National 6,101.5 6,096.9 Colonial Penn 921.0 898.5 Long-term care in run-off 580.4 562.2 Corporate operations 2,628.3 2,785.8 Total liabilities $ 28,262.8 $ 27,488.3 The following table presents selected financial information of our segments (dollars in millions): Segment Present value of future profits Deferred acquisition costs Insurance liabilities 2017 Bankers Life $ 81.1 $ 606.5 $ 16,541.2 Washington National 243.7 310.8 5,590.7 Colonial Penn 34.8 109.5 834.4 Long-term care in run-off — — 572.7 Total $ 359.6 $ 1,026.8 $ 23,539.0 2016 Bankers Life $ 95.5 $ 646.2 $ 15,702.8 Washington National 266.8 299.9 5,586.7 Colonial Penn 39.5 98.6 809.6 Long-term care in run-off — — 554.7 Total $ 401.8 $ 1,044.7 $ 22,653.8

QUARTERLY FINANCIAL DATA (UNAU

QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Data [Abstract]
QUARTERLY FINANCIAL DATA (UNAUDITED)	QUARTERLY FINANCIAL DATA (UNAUDITED) We compute earnings per common share for each quarter independently of earnings per share for the year. The sum of the quarterly earnings per share may not equal the earnings per share for the year because of: (i) transactions affecting the weighted average number of shares outstanding in each quarter; and (ii) the uneven distribution of earnings during the year. Quarterly financial data (unaudited) were as follows (dollars in millions, except per share data): 2017 1st Qtr. 2nd Qtr. 3rd Qtr. 4th Qtr. (a) Revenues $ 1,070.7 $ 1,057.1 $ 1,079.3 $ 1,090.1 Income before income taxes $ 96.7 $ 128.5 $ 129.9 $ 125.4 Income tax expense 34.4 45.1 29.1 196.3 Net income (loss) $ 62.3 $ 83.4 $ 100.8 $ (70.9 ) Earnings per common share: Basic: Net income (loss) $ .36 $ .49 $ .60 $ (.42 ) Diluted: Net income (loss) $ .36 $ .48 $ .59 $ (.42 ) 2016 1st Qtr. 2nd Qtr. 3rd Qtr. 4th Qtr. Revenues $ 960.4 $ 1,003.9 $ 1,015.9 $ 1,004.9 Income before income taxes $ 40.5 $ 82.7 $ 49.3 $ 180.7 Income tax expense (benefit) (5.0 ) 22.8 30.7 (53.5 ) Net income $ 45.5 $ 59.9 $ 18.6 $ 234.2 Earnings per common share: Basic: Net income $ .25 $ .34 $ .11 $ 1.35 Diluted: Net income $ .25 $ .33 $ .11 $ 1.34 ___________________ (a) In the fourth quarter of 2017, our net loss reflected the unfavorable impact of $172.5 million related to the Tax Reform Act which was enacted in December 2017.

INVESTMENTS IN VARIABLE INTERES

INVESTMENTS IN VARIABLE INTEREST ENTITIES	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
INVESTMENTS IN VARIABLE INTEREST ENTITIES	INVESTMENTS IN VARIABLE INTEREST ENTITIES We have concluded that we are the primary beneficiary with respect to certain VIEs, which are consolidated in our financial statements. In consolidating the VIEs, we consistently use the financial information most recently distributed to investors in the VIE. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments. The assets held by the trusts are legally isolated and not available to the Company. The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company. During the three years ended December 31, 2017 , VIEs that were required to be consolidated were dissolved. We recognized losses of $4.3 million and $7.3 million during 2017 and 2016 , respectively, and a gain of $11.3 million during 2015 , representing the difference between the borrowings of such VIEs and the contractual distributions required following the liquidation of the underlying assets. The scheduled repayment of the remaining principal balance of the borrowings related to the VIEs are as follows: $3.0 million in 2018; $3.6 million in 2019; $2.1 million in 2020; $1.3 million in 2021; $539.9 million in 2028; and $878.0 million in 2030. The Company has no financial obligation to the VIEs beyond its investment in each VIE. Certain of our insurance subsidiaries are noteholders of the VIEs. Another subsidiary of the Company is the investment manager for the VIEs. As such, it has the power to direct the most significant activities of the VIEs which materially impacts the economic performance of the VIEs. The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated (dollars in millions): December 31, 2017 VIEs Eliminations Net effect on consolidated balance sheet Assets: Investments held by variable interest entities $ 1,526.9 $ — $ 1,526.9 Notes receivable of VIEs held by insurance subsidiaries — (155.5 ) (155.5 ) Cash and cash equivalents held by variable interest entities 178.9 — 178.9 Accrued investment income 2.6 (.1 ) 2.5 Income tax assets, net .7 — .7 Other assets 10.0 (1.5 ) 8.5 Total assets $ 1,719.1 $ (157.1 ) $ 1,562.0 Liabilities: Other liabilities $ 158.3 $ (4.4 ) $ 153.9 Borrowings related to variable interest entities 1,410.7 — 1,410.7 Notes payable of VIEs held by insurance subsidiaries 167.6 (167.6 ) — Total liabilities $ 1,736.6 $ (172.0 ) $ 1,564.6 December 31, 2016 VIEs Eliminations Net effect on consolidated balance sheet Assets: Investments held by variable interest entities $ 1,724.3 $ — $ 1,724.3 Notes receivable of VIEs held by insurance subsidiaries — (204.2 ) (204.2 ) Cash and cash equivalents held by variable interest entities 189.3 — 189.3 Accrued investment income 3.0 (.1 ) 2.9 Income tax assets, net 6.4 (1.3 ) 5.1 Other assets 13.1 (1.8 ) 11.3 Total assets $ 1,936.1 $ (207.4 ) $ 1,728.7 Liabilities: Other liabilities $ 81.8 $ (6.4 ) $ 75.4 Borrowings related to variable interest entities 1,662.8 — 1,662.8 Notes payable of VIEs held by insurance subsidiaries 203.3 (203.3 ) — Total liabilities $ 1,947.9 $ (209.7 ) $ 1,738.2 The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions): 2017 2016 2015 Revenues: Net investment income – policyholder and other special-purpose portfolios $ 69.8 $ 78.9 $ 62.1 Fee revenue and other income 5.9 6.4 1.6 Total revenues 75.7 85.3 63.7 Expenses: Interest expense 50.2 53.1 38.8 Other operating expenses 1.8 1.5 2.0 Total expenses 52.0 54.6 40.8 Income before net realized investment losses and income taxes 23.7 30.7 22.9 Net realized investment losses (5.6 ) (20.4 ) (6.4 ) Loss on extinguishment of borrowings (9.5 ) — — Income before income taxes $ 8.6 $ 10.3 $ 16.5 The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade. At December 31, 2017 , such loans had an amortized cost of $1,524.9 million ; gross unrealized gains of $8.6 million ; gross unrealized losses of $6.6 million ; and an estimated fair value of $1,526.9 million . The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 11.2 $ 11.2 Due after one year through five years 541.8 542.0 Due after five years through ten years 971.9 973.7 Total $ 1,524.9 $ 1,526.9 The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 2.4 $ 2.4 Due after one year through five years 178.2 174.3 Due after five years through ten years 299.8 297.1 Total $ 480.4 $ 473.8 During 2017 , the VIEs recognized net realized investment losses of $5.6 million , which were comprised of: (i) $1.2 million of net gains from the sales of fixed maturities; (ii) $4.3 million of losses on the dissolution of VIEs; and (iii) $2.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2016 , the VIEs recognized net realized investment losses of $20.4 million which were comprised of: (i) $11.9 million of net losses from the sales of fixed maturities; (ii) a $7.3 million loss on the dissolution of a VIE; and (iii) $1.2 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2015 , the VIEs recognized net realized investment losses of $6.4 million which were comprised of: (i) $1.3 million of net losses from the sales of fixed maturities; (ii) an $11.3 million gain on the dissolution of a VIE; and (iii) $16.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income. At December 31, 2017 , there were no investments held by the VIEs that were in default. During 2017 , $109.6 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $3.0 million . During 2016 , $192.2 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $20.3 million . During 2015 , $46.1 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $1.8 million . At December 31, 2017 , the VIEs held: (i) investments with a fair value of $445.4 million and gross unrealized losses of $4.9 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $28.4 million and gross unrealized losses of $1.7 million that had been in an unrealized loss position for greater than twelve months. At December 31, 2016 , the VIEs held: (i) investments with a fair value of $93.8 million and gross unrealized losses of $.9 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $143.9 million and gross unrealized losses of $2.9 million that had been in an unrealized loss position for greater than twelve months. The investments held by the VIEs are evaluated for other-than-temporary declines in fair value in a manner that is consistent with the Company's fixed maturities, available for sale.

SCHEDULE II

SCHEDULE II	12 Months Ended
	Dec. 31, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Financial Information of Registrant (Parent Company)	SCHEDULE II Condensed Financial Information of Registrant (Parent Company) Balance Sheet as of December 31, 2017 and 2016 (Dollars in millions) ASSETS 2017 2016 Cash and cash equivalents - unrestricted $ 161.1 $ 106.1 Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5) 243.6 167.9 Investment in wholly-owned subsidiaries (eliminated in consolidation) 5,440.7 5,220.3 Income tax assets, net 129.6 99.5 Receivable from subsidiaries (eliminated in consolidation) 6.3 2.0 Other assets 12.7 1.8 Total assets $ 5,994.0 $ 5,597.6 LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities: Notes payable $ 914.6 $ 912.9 Payable to subsidiaries (eliminated in consolidation) 143.0 128.4 Other liabilities 88.9 69.4 Total liabilities 1,146.5 1,110.7 Commitments and Contingencies Shareholders' equity: Common stock and additional paid-in capital ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614) 3,075.0 3,213.8 Accumulated other comprehensive income 1,212.1 622.4 Retained earnings 560.4 650.7 Total shareholders' equity 4,847.5 4,486.9 Total liabilities and shareholders' equity $ 5,994.0 $ 5,597.6 The accompanying notes are an integral part of the condensed financial statements. CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES SCHEDULE II Condensed Financial Information of Registrant (Parent Company) Statement of Operations for the years ended December 31, 2017 , 2016 and 2015 (Dollars in millions) 2017 2016 2015 Revenues: Net investment income $ 14.2 $ 15.6 $ 16.9 Net realized investment gains 2.4 17.7 3.5 Intercompany losses (eliminated in consolidation) — — (1.5 ) Total revenues 16.6 33.3 18.9 Expenses: Interest expense 46.5 45.8 45.2 Intercompany expenses (eliminated in consolidation) 1.7 .9 .4 Operating costs and expenses 75.4 48.2 21.0 Loss on extinguishment of debt — — 32.8 Total expenses 123.6 94.9 99.4 Loss before income taxes and equity in undistributed earnings of subsidiaries (107.0 ) (61.6 ) (80.5 ) Income tax expense (benefit) 27.4 (54.6 ) (37.9 ) Loss before equity in undistributed earnings of subsidiaries (134.4 ) (7.0 ) (42.6 ) Equity in undistributed earnings of subsidiaries (eliminated in consolidation) 310.0 365.2 313.3 Net income $ 175.6 $ 358.2 $ 270.7 The accompanying notes are an integral part of the condensed financial statements. CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES SCHEDULE II Condensed Financial Information of Registrant (Parent Company) Statement of Cash Flows for the years ended December 31, 2017 , 2016 and 2015 (Dollars in millions) 2017 2016 2015 Cash flows from operating activities $ (181.8 ) $ (110.7 ) $ (51.2 ) Cash flows from investing activities: Sales of investments 54.9 305.0 66.5 Sales of investments - affiliated* — — 16.0 Maturities and redemptions of investments - affiliated* — — 8.3 Purchases of investments (123.6 ) (198.4 ) (68.6 ) Purchases of investments - affiliated* — — (3.4 ) Net sales of trading securities 9.1 12.0 11.8 Dividends received from consolidated subsidiary, net of capital contributions of nil in 2017, $200.0 in 2016 and nil in 2015* 363.5 92.5 269.7 Net cash provided by investing activities 303.9 211.1 300.3 Cash flows from financing activities: Issuance of notes payable, net — — 910.0 Payments on notes payable — — (797.1 ) Expenses related to extinguishment of debt — — (17.8 ) Issuance of common stock 8.3 8.4 6.3 Payments to repurchase common stock (168.3 ) (210.0 ) (365.4 ) Common stock dividends paid (59.6 ) (54.8 ) (52.0 ) Investment borrowings - repurchase agreements, net — — (20.4 ) Issuance of notes payable to affiliates* 310.8 217.1 234.4 Payments on notes payable to affiliates* (158.3 ) (83.9 ) (104.8 ) Net cash used by financing activities (67.1 ) (123.2 ) (206.8 ) Net increase (decrease) in cash and cash equivalents 55.0 (22.8 ) 42.3 Cash and cash equivalents, beginning of the year 106.1 128.9 86.6 Cash and cash equivalents, end of the year $ 161.1 $ 106.1 $ 128.9 * Eliminated in consolidation The accompanying notes are an integral part of the condensed financial statements. CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES SCHEDULE II Notes to Condensed Financial Information 1. Basis of Presentation The condensed financial information should be read in conjunction with the consolidated financial statements of CNO Financial Group, Inc. The condensed financial information includes the accounts and activity of the parent company.

SCHEDULE IV

SCHEDULE IV	12 Months Ended
	Dec. 31, 2017
Supplemental Schedule of Reinsurance Premiums for Insurance Companies [Abstract]
Reinsurance	SCHEDULE IV Reinsurance for the years ended December 31, 2017 , 2016 and 2015 (Dollars in millions) 2017 2016 2015 Life insurance inforce: Direct $ 27,154.3 $ 27,048.1 $ 25,807.0 Assumed 120.5 128.7 137.4 Ceded (3,452.6 ) (3,604.0 ) (3,780.8 ) Net insurance inforce $ 23,822.2 $ 23,572.8 $ 22,163.6 Percentage of assumed to net .5 % .5 % .6 % 2017 2016 2015 Insurance policy income: Direct $ 2,576.9 $ 2,553.0 $ 2,524.3 Assumed 30.4 34.0 38.5 Ceded (105.0 ) (123.9 ) (133.6 ) Net premiums $ 2,502.3 $ 2,463.1 $ 2,429.2 Percentage of assumed to net 1.2 % 1.4 % 1.6 %

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Segments	The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; long-term care in run off; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting as an additional business segment, the long-term care block recaptured from Beechwood Re Ltd. ("BRe"), as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance". The Company’s insurance segments are described below: • Bankers Life, which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life"). Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee. • Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National. • Colonial Penn , which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn"). • Long-term care in run-off consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC")
Basis of Accounting	We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We have reclassified certain amounts from the prior periods to conform to the 2017 presentation. These reclassifications have no effect on net income or shareholders' equity.
Consolidation	The accompanying financial statements include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates.
Use of Estimates	When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods. For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals. If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.
Investments	Investments Fixed maturity securities include available for sale bonds and redeemable preferred stocks. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders’ equity. Equity securities include available for sale investments in common stock, exchange-traded funds and non-redeemable preferred stock. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders' equity. Mortgage loans held in our investment portfolio are carried at amortized unpaid balances, net of provisions for estimated losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received. Policy loans are stated at current unpaid principal balances. Policy loans are collateralized by the cash surrender value of the life insurance policy. Interest income is recorded as earned using the contractual interest rate. Trading securities include: (i) investments purchased with the intent of selling in the near team to generate income; (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products); and (iii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments and investments supporting insurance liabilities and reinsurance agreements is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in realized investment gains (losses). Investment income related to investments supporting certain insurance liabilities is substantially offset by the change in insurance policy benefits related to certain products. Other invested assets include: (i) call options purchased in an effort to offset or hedge the effects of certain policyholder benefits related to our fixed index annuity and life insurance products; (ii) Company-owned life insurance ("COLI"); and (iii) certain non-traditional investments. We carry the call options at estimated fair value as further described in the section of this note entitled "Accounting for Derivatives". We carry COLI at its cash surrender value which approximates its net realizable value. Non-traditional investments include investments in certain limited partnerships and hedge funds which are accounted for using the equity method; and promissory notes, which are accounted for using the cost method. In accounting for limited partnerships and hedge funds, we consistently use the most recently available financial information provided by the general partner or manager of each of these investments, which is one to three months prior to the end of our reporting period. Interest income on fixed maturity securities is recognized when earned using a constant effective yield method giving effect to amortization of premiums and accretion of discounts. Prepayment fees are recognized when earned. Dividends on equity securities are recognized when declared. When we sell a security (other than trading securities), we report the difference between the sale proceeds and amortized cost (determined based on specific identification) as a realized investment gain or loss. We regularly evaluate our investments for possible impairment as further described in the note to the consolidated financial statements entitled "Investments". When a security defaults (including mortgage loans) or securities are other-than-temporarily impaired, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.
Deferred Acquisition Costs	Deferred Acquisition Costs Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For interest-sensitive life or annuity products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate. When we realize a gain or loss on investments backing our interest-sensitive life or annuity products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity. We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.
Present Value of Future Profits	Present Value of Future Profits The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the "Effective Date", the effective date of the bankruptcy reorganization of Conseco, Inc., an Indiana corporation (our "Predecessor")). The discount rate we used to determine the present value of future profits was 12 percent . The balance of this account is amortized and evaluated for recovery in the same manner as described above for deferred acquisition costs. We also adjust the present value of future profits for the change in amortization that would have been recorded if the fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields, similar to the manner described above for deferred acquisition costs. We limit the total adjustment related to the impact of unrealized losses to the total present value of future profits plus interest.
Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts	Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts For interest-sensitive life and annuity contracts that do not involve significant mortality or morbidity risk, the amounts collected from policyholders are considered deposits and are not included in revenue. Revenues for these contracts consist of charges for policy administration, cost of insurance charges and surrender charges assessed against policyholders' account balances. Such revenues are recognized when the service or coverage is provided, or when the policy is surrendered. We establish liabilities for annuity and interest-sensitive life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. In addition, policyholder account values for certain interest-sensitive life products are impacted by our assumptions related to changes of certain non-guaranteed elements that we are allowed to make under the terms of the policy, such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. Sales inducements provided to the policyholders of these products are recognized as liabilities over the period that the contract must remain in force to qualify for the inducement. The options attributed to the policyholder related to our fixed index annuity products are accounted for as embedded derivatives as described in the section of this note entitled "Accounting for Derivatives". Premiums from individual life products (other than interest-sensitive life contracts) and health products are recognized when due. When premiums are due over a significantly shorter period than the period over which benefits are provided, any gross premium in excess of the net premium (i.e., the portion of the gross premium required to provide for all expected future benefits and expenses) is deferred and recognized into revenue in a constant relationship to insurance in force. Benefits are recorded as an expense when they are incurred. We establish liabilities for traditional life, accident and health insurance, and life contingent payment annuity products using mortality tables in general use in the United States, which are modified to reflect the Company's actual experience when appropriate. We establish liabilities for accident and health insurance products using morbidity tables based on the Company's actual or expected experience. These reserves are computed at amounts that, with additions from estimated future premiums received and with interest on such reserves at estimated future rates, are expected to be sufficient to meet our obligations under the terms of the policy. Liabilities for future policy benefits are computed on a net-level premium method based upon assumptions as to future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses determined when the policies were issued (or with respect to policies inforce at August 31, 2003, the Company's best estimate of such assumptions on the Effective Date). We make an additional provision to allow for potential adverse deviation for some of our assumptions. Once established, assumptions on these products are generally not changed unless a premium deficiency exists. In that case, a premium deficiency reserve is recognized and the future pattern of reserve changes is modified to reflect the relationship of premiums to benefits based on the current best estimate of future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses, determined without an additional provision for potential adverse deviation. We establish claim reserves based on our estimate of the loss to be incurred on reported claims plus estimates of incurred but unreported claims based on our past experience.
Accounting for Long-term Care Premium Rate Increases	Accounting for Long-term Care Premium Rate Increases Many of our long-term care policies have been subject to premium rate increases. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the Effective Date. With respect to certain premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options: • Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists. • Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage. • Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established. Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.
Accounting for Certain Marketing and Reinsurance Agreements	Accounting for Certain Marketing Agreements Bankers Life has entered into various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute prescription drug and Medicare Advantage plans. These agreements allow Bankers Life to offer these products to current and potential future policyholders without investment in management and infrastructure. We receive fee income related to the plans sold through our distribution channels. We account for these distribution agreements as follows: • We recognize distribution income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract. • We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract. Reinsurance In the normal course of business, we seek to limit our loss exposure on any single insured or to certain groups of policies by ceding reinsurance to other insurance enterprises. We currently retain no more than $.8 million of mortality risk on any one policy. We diversify the risk of reinsurance loss by using a number of reinsurers that have strong claims-paying ratings. In each case, the ceding CNO subsidiary is directly liable for claims reinsured in the event the assuming company is unable to pay. The cost of reinsurance ceded totaled $105.0 million , $123.9 million and $133.6 million in 2017 , 2016 and 2015 , respectively. We deduct this cost from insurance policy income. Reinsurance recoveries netted against insurance policy benefits totaled $88.6 million , $130.1 million and $167.7 million in 2017 , 2016 and 2015 , respectively. From time to time, we assume insurance from other companies. Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs. Reinsurance premiums assumed totaled $30.4 million , $34.0 million and $38.5 million in 2017 , 2016 and 2015 , respectively. Insurance policy benefits related to reinsurance assumed totaled $44.7 million , $47.5 million and $48.0 million in 2017 , 2016 and 2015 , respectively. In December 2013, two of our insurance subsidiaries entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to BRe. Pursuant to the agreements, the insurance subsidiaries paid an additional premium of $96.9 million to BRe and an amount equal to the related net liabilities. The insurance subsidiaries' ceded reserve credits were secured by assets in market-value trusts subject to a 7% overcollateralization, investment guidelines and periodic true-up provisions. Future payments into the trusts to maintain collateral requirements were the responsibility of BRe. In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business. As a result of the recapture, we were required to value the assets and liabilities as of the date of recapture based on valuation methodologies that are consistent with the methodologies used by CNO to value its other investments and insurance liabilities. Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions): Market value of investments $ 504.7 Insurance liabilities (552.2 ) Write-off of reinsurance receivables (17.9 ) Estimated transaction expenses (10.0 ) Pre-tax loss (75.4 ) Tax benefit 26.4 Increase in valuation allowance for deferred tax assets (4.1 ) After-tax loss $ (53.1 )
Income Taxes	Income Taxes Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and net operating loss carryforwards ("NOLs"). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted. A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire. At December 31, 2017 , our valuation allowance for our net deferred tax assets was $89.1 million , as we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax assets and assessing the effects of limitations and/or interpretations on the value of such component to be fully recognized in the future.
Investments in Variable Interest Entities	Investments in Variable Interest Entities We have concluded that we are the primary beneficiary with respect to certain variable interest entities ("VIEs"), which are consolidated in our financial statements. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments. The assets held by the trusts are legally isolated and not available to the Company. The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company. The Company has no financial obligation to the VIEs beyond its investment in each VIE. The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade. Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information about VIEs. In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager. These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations. Our maximum exposure to loss on these securities is limited to our cost basis in the investment. We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses.
Investment borrowings	Substantially all of such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet.
Accounting for Derivatives	Accounting for Derivatives Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period. Typically, on each policy anniversary date, a new index period begins. We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to contractual minimums. The Company accounts for the options attributed to the policyholder for the estimated life of the contract as embedded derivatives. These accounting requirements often create volatility in the earnings from these products. We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked. From time to time, we utilize United States Treasury interest rate futures primarily to hedge interest rate risk related to anticipated mortgage loan transactions. We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income.
Multibucket Annuity Products	Multibucket Annuity Products The Company's multibucket annuity is an annuity product that credits interest based on the experience of a particular market strategy. Policyholders allocate their annuity premium payments to several different market strategies based on different asset classes within the Company's investment portfolio. Interest is credited to this product based on the market return of the given strategy, less management fees, and funds may be moved between different strategies. The Company guarantees a minimum return of premium plus approximately 3 percent per annum over the life of the contract. The investments backing the market strategies of these products are designated by the Company as trading securities. The change in the fair value of these securities is recognized as investment income (classified as income from policyholder and other special-purpose portfolios), which is substantially offset by the change in insurance policy benefits for these products.
Sales Inducements	Sales Inducements Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract. Certain of our life insurance products offer persistency bonuses credited to the contract holder's balance after the policy has been outstanding for a specified period of time. These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP. Such amounts are deferred and amortized in the same manner as deferred acquisition costs.
Out-of-Period Adjustments	Out-of-Period Adjustments In 2017 , we recorded the net effect of out-of-period adjustments which decreased insurance policy benefits by $4.2 million , increased other operating costs and expenses by $2.0 million , increased tax expense by $.8 million and increased our net income by $1.4 million (or 1 cent per diluted share). We evaluated these adjustments taking into account both qualitative and quantitative factors and considered the impact of these adjustments in relation to each period, as well as the periods in which they originated. The impact of recognizing these adjustments in prior years was not significant to any individual period. Management believes these adjustments are immaterial to the consolidated financial statements and all previously issued financial statements.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Pending Accounting Standards In May 2014, the Financial Accounting Standards Board (the "FASB") issued authoritative guidance for recognizing revenue from contracts with customers. Certain contracts with customers are specifically excluded from this guidance, including insurance contracts. The core principle of the new guidance is that an entity should recognize revenue when it transfers promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will be effective for the Company on January 1, 2018 and permits two methods of transition upon adoption; full retrospective and modified retrospective. Under the full retrospective method, prior periods would be restated under the new revenue standard, providing for comparability in all periods presented. Under the modified retrospective method, prior periods would not be restated. Instead, revenues and other disclosures for pre-2018 periods would be provided in the notes to the financial statements as previously reported under the current revenue standard. The new guidance will impact our accounting for various distribution and marketing agreements with other insurance companies pursuant to which Bankers Life's career agents distribute third party products including prescription drug and Medicare Advantage plans. The revenue associated with these distribution agreements has been less than 1 percent of our total revenue. Our annual fee income earned during a calendar year will not change, but the amount recognized during each quarterly period will vary based on the sales of such products in each period. Accordingly, the adoption of this guidance is not expected to have a material impact on our consolidated financial statements. The Company will adopt the new guidance using the modified retrospective method. In January 2016, the FASB issued authoritative guidance related to the recognition and measurement of financial assets and financial liabilities which made targeted improvements to GAAP as follows: (i) Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. (ii) Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value. (iii) Eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet. (iv) Require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes. (v) Require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. (vi) Require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements. (vii) Clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. An entity should apply this guidance by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of the guidance. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company currently holds equity securities classified as available for sale securities that are measured at fair value with changes in fair value recognized through accumulated other comprehensive income. Upon adoption of this guidance, changes in fair value of such equity securities will be recognized through net income. Based upon the equity securities held at December 31, 2017, the estimated impact of the new guidance, assuming it was adopted on January 1, 2018, would be a cumulative effect adjustment that would increase retained earnings by approximately $17 million with a corresponding decrease to accumulated other comprehensive income of approximately $17 million . The Company may experience an increase in volatility in the income statement due to the requirement to measure equity investments at fair value with changes in fair value recognized in income. In addition, the Company will be required to modify certain disclosures upon adoption. In February 2016, the FASB issued authoritative guidance related to accounting for leases, requiring lessees to report most leases on their balance sheets, regardless of whether the lease is classified as a finance lease or an operating lease. For lessees, the initial lease liability is equal to the present value of future lease payments, and a corresponding asset, adjusted for certain items, is also recorded. Expense recognition for lessees will remain similar to current accounting requirements for capital and operating leases. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows. In June 2016, the FASB issued authoritative guidance related to the measurement of credit losses on financial instruments. The new guidance replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The guidance will be effective for the Company for fiscal years beginning in 2020, including interim periods within the fiscal year. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows. In August 2016, the FASB issued authoritative guidance related to how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, and others. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this guidance will result in reclassifications to certain cash receipts and payments within our consolidated statement of cash flows, but will have no impact on our consolidated financial position, results of operations or cash flows. In November 2016, the FASB issued authoritative guidance to address the diversity in practice that currently exists regarding the classification and presentation of changes in restricted cash on the statement of cash flows. The new guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Entities will also be required to disclose information about the nature of their restricted cash and restricted cash equivalents. Additionally, if cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item in the statement of financial position, entities will be required to present a reconciliation, either on the face of the statement of cash flows or disclosed in the notes, of the totals in the statement of cash flows to the related line item captions in the statement of financial position. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The adoption of this guidance will impact the presentation of our consolidated statement of cash flows and related cash flow disclosures, but will have no impact on our consolidated financial position, results of operations or cash flows. In January 2017, the FASB issued authoritative guidance that removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reported unit's fair value. Upon adoption, the guidance is to be applied prospectively. The guidance will be effective for the Company on January 1, 2020, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows. In March 2017, the FASB issued authoritative guidance related to the premium amortization on purchased callable debt securities. The guidance shortens the amortization period for certain callable debt securities held at a premium. Specifically, the new guidance requires the premium to be amortized to the earliest call date. The guidance does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance will be effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the guidance in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has not yet determined the expected impact of adoption of this guidance on our consolidated financial position, results of operations or cash flows. In May 2017, the FASB issued authoritative guidance related to which changes to the terms or conditions of a share-based award require an entity to apply modification accounting. The guidance will be effective for the Company in 2018. The guidance is to be applied prospectively to an award modified on or after the adoption date. The adoption of this guidance is not expected to have a material impact to the Company's consolidated financial position, results of operations or cash flows. In August 2017, the FASB issued authoritative guidance related to derivatives and hedging. The new guidance expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instruments and the hedged item in the financial statements. The new guidance also includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows. Adopted Accounting Standards In March 2016, the FASB issued authoritative guidance that clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under this guidance is required to assess the embedded call (put) options solely in accordance with a four-step decision sequence. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no effect on our consolidated financial statements. In March 2016, the FASB issued authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting policy for forfeiture rate assumptions, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new guidance requires all income tax effects of stock-based compensation awards to be recognized in the income statement when the awards vest or are settled. The new guidance also allows an employer to withhold shares upon settlement of an award to satisfy the employer's tax withholding requirements up to the highest marginal tax rate applicable to employees, without resulting in liability classification of the award. Current guidance strictly limits the withholding to the employer's minimum statutory tax withholding requirement. The guidance was effective for the Company on January 1, 2017. The impact of adoption was as follows (dollars in millions): January 1, 2017 Effect of Adoption of Authoritative Guidance Amounts prior to effect of adoption of authoritative guidance Election to account for forfeitures as they occur Recognition of excess tax benefits As adjusted Income tax assets $ 1,029.9 $ .3 $ 15.7 $ 1,045.9 Valuation allowance for deferred income tax assets (240.2 ) — (15.7 ) (255.9 ) Income tax assets, net 789.7 .3 — 790.0 Total assets 31,975.2 .3 — 31,975.5 Additional paid-in capital 3,212.1 .9 — 3,213.0 Retained earnings 650.7 (.6 ) — 650.1 Total shareholders' equity 4,486.9 .3 — 4,487.2 Total liabilities and shareholders' equity 31,975.2 .3 — 31,975.5 December 31, 2016 Amounts prior to effect of adoption of authoritative guidance Effect of adoption of authoritative guidance As adjusted Cash flows from operating activities: Other operating costs $ (751.2 ) $ 3.3 $ (747.9 ) Net cash flow from operating activities 759.5 3.3 762.8 Cash flows from financing activities: Payments to repurchase common stock (206.7 ) (3.3 ) (210.0 ) Net cash provided by financing activities 29.5 (3.3 ) 26.2 Net increase in cash and cash equivalents 46.6 — 46.6 December 31, 2015 Amounts prior to effect of adoption of authoritative guidance Effect of adoption of authoritative guidance As adjusted Cash flows from operating activities: Other operating costs $ (724.4 ) $ 3.9 $ (720.5 ) Net cash flow from operating activities 743.9 3.9 747.8 Cash flows from financing activities: Payments to repurchase common stock (361.5 ) (3.9 ) (365.4 ) Net cash provided by financing activities 146.4 (3.9 ) 142.5 Net decrease in cash and cash equivalents (179.3 ) — (179.3 ) In October 2016, the FASB issued authoritative guidance to amend the consolidation guidance on how a reporting entity that is the single decision maker of a VIE should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no impact on our consolidated financial statements. In February 2018, the FASB issued authoritative guidance that allows a reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects resulting from the Tax Cuts and Jobs Act (the "Tax Reform Act") enacted by the U.S. federal government on December 22, 2017. Such guidance only relates to the reclassification of the income tax effects of the Tax Reform Act. The Company early adopted this guidance and elected to reclassify the income tax effects of the Tax Reform Act from accumulated other comprehensive income as of December 31, 2017. As a result of such reclassification, retained earnings decreased by $205.4 million and accumulated other comprehensive income increased by $205.4 million . Such amount represents the decrease in the income tax rate from 35 percent to 21 percent on the net unrealized gains of our fixed maturity securities, available for sale, equity securities and certain other invested assets, net of related adjustments, included in accumulated other comprehensive income. Refer to the note to the consolidated financial statements entitled "Income Taxes" for additional information related to the Tax Reform Act.
Fair Value Measurements	For those financial instruments disclosed at fair value, we use the following methods and assumptions to determine the estimated fair values: Mortgage loans and policy loans. We discount future expected cash flows based on interest rates currently being offered for similar loans with similar risk characteristics. We aggregate loans with similar characteristics in our calculations. The fair value of policy loans approximates their carrying value. Company-owned life insurance is backed by a series of mutual funds and is carried at cash surrender value which approximates estimated fair value. Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value. Liabilities for policyholder account balances. The estimated fair value of insurance liabilities for policyholder account balances was approximately equal to its carrying value as interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year. Investment borrowings, notes payable and borrowings related to variable interest entities. For publicly traded debt, we use current fair values. For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price. We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives. We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs. The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value. Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value. Valuation Hierarchy There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable. • Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities. • Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs. • Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions. At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value. This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions. Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels are reported as having occurred at the beginning of the period. There were no transfers between Level 1 and Level 2 in both 2017 and 2016 . The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value. These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value. Our Level 2 assets are valued as follows: • Fixed maturities available for sale, equity securities and trading securities Corporate securities are generally priced using market and income approaches. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads. U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity. States and political subdivisions are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads. Asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations are generally priced using market and income approaches. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates, and issue specific information including, but not limited to, collateral type, seniority and vintage. Equity securities (primarily comprised of non-redeemable preferred stock) are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads. • Investments held by VIEs Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads. • Other invested assets - derivatives The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes; time value and volatility factors underlying options; market interest rates; and non-performance risk. Third party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate. The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below. As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes: (i) a review of the methodology used by third party pricing services; (ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties. As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions. In those instances, we may request additional pricing quotes or apply internally developed valuations. However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received. The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes. Such inputs typically include: benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data. The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments. For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes. These broker quotes are non-binding and represent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs. Approximately 29 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs. The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs. For these securities, we use internally developed valuations. Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market. For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate. The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity. In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity. For certain embedded derivatives, we use actuarial assumptions in the determination of fair value which we consider to be Level 3 inputs. Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders' equity based on the appropriate accounting treatment for the instrument. The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date.

SUMMARY OF SIGNIFICANT ACCOUN29

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of loss recapture of long-term care business	Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions): Market value of investments $ 504.7 Insurance liabilities (552.2 ) Write-off of reinsurance receivables (17.9 ) Estimated transaction expenses (10.0 ) Pre-tax loss (75.4 ) Tax benefit 26.4 Increase in valuation allowance for deferred tax assets (4.1 ) After-tax loss $ (53.1 )
Schedule of terms of federal home loan bank borrowing	The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions): Amount Maturity Interest rate at borrowed date December 31, 2017 $ 50.0 January 2019 Variable rate – 1.779% 50.0 February 2019 Variable rate – 1.509% 100.0 March 2019 Variable rate – 1.971% 21.8 July 2019 Variable rate – 2.001% 15.0 October 2019 Variable rate – 1.887% 50.0 May 2020 Variable rate – 1.997% 21.8 June 2020 Fixed rate – 1.960% 25.0 September 2020 Variable rate – 2.300% 100.0 September 2020 Variable rate – 2.212% 50.0 September 2020 Variable rate – 2.224% 75.0 September 2020 Variable rate – 1.813% 100.0 October 2020 Variable rate – 1.453% 50.0 December 2020 Variable rate – 2.072% 100.0 July 2021 Variable rate – 1.909% 100.0 July 2021 Variable rate – 1.879% 57.7 August 2021 Variable rate – 1.921% 28.2 August 2021 Fixed rate – 2.550% 125.0 August 2021 Variable rate – 2.032% 50.0 September 2021 Variable rate – 2.002% 22.0 May 2022 Variable rate – 1.829% 100.0 May 2022 Variable rate – 1.780% 10.0 June 2022 Variable rate – 2.150% 50.0 July 2022 Variable rate – 1.726% 50.0 July 2022 Variable rate – 1.745% 50.0 July 2022 Variable rate – 1.758% 50.0 August 2022 Variable rate – 1.782% 50.0 December 2022 Variable rate – 1.795% 50.0 December 2022 Variable rate – 1.795% 24.7 March 2023 Fixed rate – 2.160% 20.5 June 2025 Fixed rate – 2.940% $ 1,646.7
Summary of Impacts of Adoption of Recent Accounting Pronouncements	The impact of adoption was as follows (dollars in millions): January 1, 2017 Effect of Adoption of Authoritative Guidance Amounts prior to effect of adoption of authoritative guidance Election to account for forfeitures as they occur Recognition of excess tax benefits As adjusted Income tax assets $ 1,029.9 $ .3 $ 15.7 $ 1,045.9 Valuation allowance for deferred income tax assets (240.2 ) — (15.7 ) (255.9 ) Income tax assets, net 789.7 .3 — 790.0 Total assets 31,975.2 .3 — 31,975.5 Additional paid-in capital 3,212.1 .9 — 3,213.0 Retained earnings 650.7 (.6 ) — 650.1 Total shareholders' equity 4,486.9 .3 — 4,487.2 Total liabilities and shareholders' equity 31,975.2 .3 — 31,975.5 December 31, 2016 Amounts prior to effect of adoption of authoritative guidance Effect of adoption of authoritative guidance As adjusted Cash flows from operating activities: Other operating costs $ (751.2 ) $ 3.3 $ (747.9 ) Net cash flow from operating activities 759.5 3.3 762.8 Cash flows from financing activities: Payments to repurchase common stock (206.7 ) (3.3 ) (210.0 ) Net cash provided by financing activities 29.5 (3.3 ) 26.2 Net increase in cash and cash equivalents 46.6 — 46.6 December 31, 2015 Amounts prior to effect of adoption of authoritative guidance Effect of adoption of authoritative guidance As adjusted Cash flows from operating activities: Other operating costs $ (724.4 ) $ 3.9 $ (720.5 ) Net cash flow from operating activities 743.9 3.9 747.8 Cash flows from financing activities: Payments to repurchase common stock (361.5 ) (3.9 ) (365.4 ) Net cash provided by financing activities 146.4 (3.9 ) 142.5 Net decrease in cash and cash equivalents (179.3 ) — (179.3 )

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Schedule of fixed maturities for available for sale and equity securities	At December 31, 2017 , the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Other-than-temporary impairments included in accumulated other comprehensive income Investment grade (a): Corporate securities $ 12,419.3 $ 1,670.7 $ (14.6 ) $ 14,075.4 $ — United States Treasury securities and obligations of United States government corporations and agencies 146.4 31.5 (.2 ) 177.7 — States and political subdivisions 1,819.9 234.8 (.4 ) 2,054.3 — Debt securities issued by foreign governments 79.5 3.8 (.2 ) 83.1 — Asset-backed securities 1,730.7 39.7 (3.2 ) 1,767.2 — Collateralized debt obligations 257.1 2.3 — 259.4 — Commercial mortgage-backed securities 1,304.1 33.2 (9.1 ) 1,328.2 — Mortgage pass-through securities 1.8 .2 — 2.0 — Collateralized mortgage obligations 293.9 16.4 (.2 ) 310.1 (.2 ) Total investment grade fixed maturities, available for sale 18,052.7 2,032.6 (27.9 ) 20,057.4 (.2 ) Below-investment grade (a) (b): Corporate securities 867.0 28.4 (12.4 ) 883.0 — States and political subdivisions 2.0 — — 2.0 — Asset-backed securities 1,355.2 132.9 (.9 ) 1,487.2 — Commercial mortgage-backed securities 49.9 .6 (1.2 ) 49.3 — Collateralized mortgage obligations 375.3 56.8 (.1 ) 432.0 (.8 ) Total below-investment grade fixed maturities, available for sale 2,649.4 218.7 (14.6 ) 2,853.5 (.8 ) Total fixed maturities, available for sale $ 20,702.1 $ 2,251.3 $ (42.5 ) $ 22,910.9 $ (1.0 ) Equity securities $ 491.1 $ 23.6 $ (3.0 ) $ 511.7 _______________ (a) Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC"). NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch). NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch). References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above. (b) Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.
Schedule of NAIC designations and NRSRO equivalent ratings	The following summarizes the NAIC designations and NRSRO equivalent ratings: NAIC Designation NRSRO Equivalent Rating 1 AAA/AA/A 2 BBB 3 BB 4 B 5 CCC and lower 6 In or near default
Summary of fixed maturity securities available for sale	A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of December 31, 2017 is as follows (dollars in millions): NAIC designation Amortized cost Estimated fair value Percentage of total estimated fair value 1 $ 9,923.7 $ 11,028.5 48.1 % 2 9,821.6 10,906.2 47.6 Total NAIC 1 and 2 (investment grade) 19,745.3 21,934.7 95.7 3 676.2 693.8 3.0 4 225.0 225.9 1.0 5 46.3 45.9 .2 6 9.3 10.6 .1 Total NAIC 3,4,5 and 6 (below-investment grade) 956.8 976.2 4.3 $ 20,702.1 $ 22,910.9 100.0 %
Schedule of fixed maturities for available for sale and equity securities	At December 31, 2016 , the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Other-than-temporary impairments included in accumulated other comprehensive income Investment grade: Corporate securities $ 11,582.6 $ 1,073.9 $ (99.8 ) $ 12,556.7 $ — United States Treasury securities and obligations of United States government corporations and agencies 143.8 20.5 — 164.3 — States and political subdivisions 1,798.2 186.7 (7.9 ) 1,977.0 — Debt securities issued by foreign governments 37.1 .2 (.4 ) 36.9 — Asset-backed securities 1,169.6 29.2 (8.7 ) 1,190.1 — Collateralized debt obligations 227.5 1.0 (.3 ) 228.2 — Commercial mortgage-backed securities 1,467.2 32.9 (26.6 ) 1,473.5 — Mortgage pass-through securities 2.3 .2 — 2.5 — Collateralized mortgage obligations 304.8 14.6 (.2 ) 319.2 — Total investment grade fixed maturities, available for sale 16,733.1 1,359.2 (143.9 ) 17,948.4 — Below-investment grade: Corporate securities 967.3 26.1 (39.2 ) 954.2 (3.6 ) States and political subdivisions 13.6 — (1.7 ) 11.9 (3.0 ) Asset-backed securities 1,471.9 55.1 (6.8 ) 1,520.2 — Collateralized debt obligations 2.5 — — 2.5 — Commercial mortgage-backed securities 63.8 .2 (1.3 ) 62.7 — Collateralized mortgage obligations 550.9 46.8 (1.4 ) 596.3 (1.4 ) Total below-investment grade fixed maturities, available for sale 3,070.0 128.2 (50.4 ) 3,147.8 (8.0 ) Total fixed maturities, available for sale $ 19,803.1 $ 1,487.4 $ (194.3 ) $ 21,096.2 $ (8.0 ) Equity securities $ 580.7 $ 11.5 $ (8.0 ) $ 584.2
Schedule of accumulated other comprehensive income (loss)	Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments. These amounts, included in shareholders' equity as of December 31, 2017 and 2016 , were as follows (dollars in millions): 2017 2016 Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized $ 2.6 $ (1.1 ) Net unrealized gains on all other investments 2,227.3 1,311.9 Adjustment to present value of future profits (a) (94.0 ) (106.2 ) Adjustment to deferred acquisition costs (292.6 ) (223.5 ) Adjustment to insurance liabilities (295.8 ) (13.5 ) Deferred income tax liabilities (335.4 ) (345.2 ) Accumulated other comprehensive income $ 1,212.1 $ 622.4 ________ (a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy.
Schedule of investments classified by contractual maturity date	The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 328.1 $ 335.1 Due after one year through five years 1,947.3 2,052.3 Due after five years through ten years 1,508.7 1,601.3 Due after ten years 11,550.0 13,286.8 Subtotal 15,334.1 17,275.5 Structured securities 5,368.0 5,635.4 Total fixed maturities, available for sale $ 20,702.1 $ 22,910.9
Schedule of investment income	Net investment income consisted of the following (dollars in millions): 2017 2016 2015 General account assets: Fixed maturities $ 1,133.8 $ 1,081.4 $ 1,090.1 Equity securities 25.3 21.5 18.3 Mortgage loans 91.5 91.0 91.4 Policy loans 7.7 7.3 7.3 Other invested assets 44.4 24.3 17.4 Cash and cash equivalents 5.9 2.0 .8 Policyholder and other special-purpose portfolios: Trading securities (a) 12.8 12.2 10.7 Options related to fixed index products: Option income (loss) 110.3 (40.1 ) 36.5 Change in value of options 52.2 69.3 (72.7 ) Other special-purpose portfolios 90.6 79.7 55.5 Gross investment income 1,574.5 1,348.6 1,255.3 Less investment expenses 23.2 23.4 21.7 Net investment income $ 1,551.3 $ 1,325.2 $ 1,233.6 _________________ (a) Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were $3.8 million , $(.2) million and $.4 million for the years ended December 31, 2017 , 2016 and 2015 , respectively.
Schedule of realized gain (loss) on investments	The following table sets forth the net realized investment gains (losses) for the periods indicated (dollars in millions): 2017 2016 2015 Fixed maturity securities, available for sale: Gross realized gains on sale $ 68.0 $ 137.7 $ 95.7 Gross realized losses on sale (24.2 ) (95.2 ) (88.4 ) Impairments: Total other-than-temporary impairment losses (12.5 ) (15.2 ) (17.9 ) Other-than-temporary impairment losses recognized in accumulated other comprehensive income (.9 ) 3.6 3.0 Net impairment losses recognized (13.4 ) (11.6 ) (14.9 ) Net realized investment gains (losses) from fixed maturities 30.4 30.9 (7.6 ) Equity securities 11.6 20.9 3.7 Mortgage loans 1.1 — (2.3 ) Impairments on preferred stock and other investments (9.4 ) (20.7 ) (25.0 ) Gain (loss) on dissolution of variable interest entities (4.3 ) (7.3 ) 11.3 Other (a) 20.9 (15.5 ) (16.7 ) Net realized investment gains (losses) $ 50.3 $ 8.3 $ (36.6 ) _________________ (a) Changes in the estimated fair value of trading securities that we have elected the fair value option (and are still held as of the end of the respective years) were $12.8 million , $(.5) million and $(9.2) million for the years ended December 31, 2017 , 2016 and 2015 , respectively.
Schedule of credit losses recognized in earnings	The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the years ended December 31, 2017 , 2016 and 2015 (dollars in millions): Year ended December 31, 2017 2016 2015 Credit losses on fixed maturity securities, available for sale, beginning of period $ (5.5 ) $ (2.6 ) $ (1.0 ) Add: credit losses on other-than-temporary impairments not previously recognized — (3.0 ) (2.0 ) Less: credit losses on securities sold 4.7 .1 .4 Less: credit losses on securities impaired due to intent to sell (a) — — — Add: credit losses on previously impaired securities (2.0 ) — — Less: increases in cash flows expected on previously impaired securities — — — Credit losses on fixed maturity securities, available for sale, end of period $ (2.8 ) $ (5.5 ) $ (2.6 ) __________ (a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.
Schedule of investments with unrealized losses classified by contractual maturity date	The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 26.9 $ 26.9 Due after one year through five years 195.4 193.3 Due after five years through ten years 108.9 105.2 Due after ten years 602.0 580.0 Subtotal 933.2 905.4 Structured securities 1,268.3 1,253.6 Total $ 2,201.5 $ 2,159.0
Schedule of investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position	The following summarizes the investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis for the period indicated as of December 31, 2017 (dollars in millions): Number Cost Unrealized Estimated Less than 6 months 1 $ 9.2 $ (1.9 ) $ 7.3 $ 9.2 $ (1.9 ) $ 7.3 The following summarizes the investments sold at a loss during 2017 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions): At date of sale Number Amortized cost Fair value Less than 6 months prior to sale 4 $ 17.8 $ 13.0 Greater than or equal to 6 months and less than 12 months prior to sale 1 2.7 1.9 Greater than 12 months prior to sale 1 .7 .5 6 $ 21.2 $ 15.4
Schedule of unrealized loss on investments	The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2017 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair value Unrealized losses Fair value Unrealized losses Fair value Unrealized losses United States Treasury securities and obligations of United States government corporations and agencies $ 28.2 $ (.2 ) $ .7 $ — $ 28.9 $ (.2 ) States and political subdivisions 18.3 (.1 ) 14.9 (.3 ) 33.2 (.4 ) Debt securities issued by foreign governments 7.7 (.1 ) 5.4 (.1 ) 13.1 (.2 ) Corporate securities 470.5 (6.8 ) 359.7 (20.2 ) 830.2 (27.0 ) Asset-backed securities 601.4 (2.0 ) 122.2 (2.1 ) 723.6 (4.1 ) Collateralized debt obligations 3.0 — — — 3.0 — Commercial mortgage-backed securities 276.8 (1.7 ) 218.2 (8.6 ) 495.0 (10.3 ) Collateralized mortgage obligations 20.5 (.2 ) 11.5 (.1 ) 32.0 (.3 ) Total fixed maturities, available for sale $ 1,426.4 $ (11.1 ) $ 732.6 $ (31.4 ) $ 2,159.0 $ (42.5 ) Equity securities $ 58.7 $ (1.7 ) $ 21.2 $ (1.3 ) $ 79.9 $ (3.0 ) The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2016 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair value Unrealized losses Fair value Unrealized losses Fair value Unrealized losses United States Treasury securities and obligations of United States government corporations and agencies $ 8.0 $ — $ — $ — $ 8.0 $ — States and political subdivisions 176.3 (7.8 ) 18.3 (1.8 ) 194.6 (9.6 ) Debt securities issued by foreign governments 18.9 (.4 ) — — 18.9 (.4 ) Corporate securities 1,907.6 (75.5 ) 559.6 (63.5 ) 2,467.2 (139.0 ) Asset-backed securities 692.9 (8.5 ) 262.5 (7.0 ) 955.4 (15.5 ) Collateralized debt obligations 38.3 (.1 ) 30.8 (.2 ) 69.1 (.3 ) Commercial mortgage-backed securities 525.2 (16.6 ) 154.0 (11.3 ) 679.2 (27.9 ) Collateralized mortgage obligations 73.6 (.6 ) 34.6 (1.0 ) 108.2 (1.6 ) Total fixed maturities, available for sale $ 3,440.8 $ (109.5 ) $ 1,059.8 $ (84.8 ) $ 4,500.6 $ (194.3 ) Equity securities $ 239.4 $ (8.0 ) $ — $ — $ 239.4 $ (8.0 )
Schedule of structured securities	The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral, at December 31, 2017 (dollars in millions): Par value Amortized cost Estimated fair value Below 4 percent $ 2,101.7 $ 1,944.8 $ 2,014.9 4 percent – 5 percent 1,656.3 1,516.0 1,596.5 5 percent – 6 percent 1,407.1 1,271.8 1,362.6 6 percent – 7 percent 286.6 260.6 276.8 7 percent – 8 percent 83.0 83.7 92.5 8 percent and above 291.3 291.1 292.1 Total structured securities $ 5,826.0 $ 5,368.0 $ 5,635.4 The amortized cost and estimated fair value of structured securities at December 31, 2017 , summarized by type of security, were as follows (dollars in millions): Estimated fair value Type Amortized cost Amount Percent of fixed maturities Pass-throughs, sequential and equivalent securities $ 557.7 $ 617.2 2.7 % Planned amortization classes, target amortization classes and accretion-directed bonds 95.3 108.5 .5 Commercial mortgage-backed securities 1,354.0 1,377.5 6.0 Asset-backed securities 3,085.9 3,254.4 14.2 Collateralized debt obligations 257.1 259.4 1.1 Other 18.0 18.4 .1 Total structured securities $ 5,368.0 $ 5,635.4 24.6 %
Summary of weighted average loan-to-value ratio for outstanding mortgage loans	The following table provides the carrying value and estimated fair value of our outstanding commercial mortgage loans and the underlying collateral as of December 31, 2017 (dollars in millions): Estimated fair value Loan-to-value ratio (a) Carrying value Mortgage loans Collateral Less than 60% $ 944.7 $ 960.8 $ 2,330.6 60% to 70% 439.5 440.2 671.3 Greater than 70% to 80% 138.4 145.9 188.4 Greater than 80% to 90% 52.3 52.9 60.1 Greater than 90% 38.6 40.2 41.7 Total $ 1,613.5 $ 1,640.0 $ 3,292.1 ________________ (a) Loan-to-value ratios are calculated as the ratio of: (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair value measurements of financial instruments measured on a recurring basis	The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2017 is as follows (dollars in millions): Quoted prices in active markets Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 14,728.0 $ 230.4 $ 14,958.4 United States Treasury securities and obligations of United States government corporations and agencies — 177.7 — 177.7 States and political subdivisions — 2,056.3 — 2,056.3 Debt securities issued by foreign governments — 79.2 3.9 83.1 Asset-backed securities — 3,230.2 24.2 3,254.4 Collateralized debt obligations — 259.4 — 259.4 Commercial mortgage-backed securities — 1,377.5 — 1,377.5 Mortgage pass-through securities — 2.0 — 2.0 Collateralized mortgage obligations — 742.1 — 742.1 Total fixed maturities, available for sale — 22,652.4 258.5 22,910.9 Equity securities - corporate securities 287.8 202.7 21.2 511.7 Trading securities: Corporate securities — 21.6 — 21.6 United States Treasury securities and obligations of United States government corporations and agencies — .5 — .5 Asset-backed securities — 95.8 — 95.8 Collateralized debt obligations — 2.7 — 2.7 Commercial mortgage-backed securities — 92.5 — 92.5 Collateralized mortgage obligations — 68.7 — 68.7 Equity securities 2.8 — — 2.8 Total trading securities 2.8 281.8 — 284.6 Investments held by variable interest entities - corporate securities — 1,522.0 4.9 1,526.9 Other invested assets - derivatives — 170.2 — 170.2 Assets held in separate accounts — 5.0 — 5.0 Total assets carried at fair value by category $ 290.6 $ 24,834.1 $ 284.6 $ 25,409.3 Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products $ — $ — $ 1,334.8 $ 1,334.8 The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2016 is as follows (dollars in millions): Quoted prices in active markets for identical assets or liabilities (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 13,252.4 $ 258.5 $ 13,510.9 United States Treasury securities and obligations of United States government corporations and agencies — 164.3 — 164.3 States and political subdivisions — 1,988.9 — 1,988.9 Debt securities issued by foreign governments — 33.0 3.9 36.9 Asset-backed securities — 2,649.9 60.4 2,710.3 Collateralized debt obligations — 225.3 5.4 230.7 Commercial mortgage-backed securities — 1,504.2 32.0 1,536.2 Mortgage pass-through securities — 2.5 — 2.5 Collateralized mortgage obligations — 915.5 — 915.5 Total fixed maturities, available for sale — 20,736.0 360.2 21,096.2 Equity securities - corporate securities 359.9 199.1 25.2 584.2 Trading securities: Corporate securities — 19.0 — 19.0 United States Treasury securities and obligations of United States government corporations and agencies — .5 — .5 Asset-backed securities — 94.3 — 94.3 Collateralized debt obligations — 2.4 — 2.4 Commercial mortgage-backed securities — 163.9 — 163.9 Collateralized mortgage obligations — 78.4 — 78.4 Equity securities 4.9 — — 4.9 Total trading securities 4.9 358.5 — 363.4 Investments held by variable interest entities - corporate securities — 1,724.3 — 1,724.3 Other invested assets - derivatives — 111.9 — 111.9 Assets held in separate accounts — 4.7 — 4.7 Total assets carried at fair value by category $ 364.8 $ 23,134.5 $ 385.4 $ 23,884.7 Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products $ — $ — $ 1,092.3 $ 1,092.3 The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions): December 31, 2017 Quoted prices in active markets for identical assets or liabilities (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,677.3 $ 1,677.3 $ 1,650.6 Policy loans — — 116.0 116.0 116.0 Other invested assets: Company-owned life insurance — 182.3 — 182.3 182.3 Cash and cash equivalents: Unrestricted 578.4 — — 578.4 578.4 Held by variable interest entities 178.9 — — 178.9 178.9 Liabilities: Policyholder account balances — — 11,220.7 11,220.7 11,220.7 Investment borrowings — 1,648.8 — 1,648.8 1,646.7 Borrowings related to variable interest entities — 1,432.9 — 1,432.9 1,410.7 Notes payable – direct corporate obligations — 962.3 — 962.3 914.6 December 31, 2016 Quoted prices in active markets for identical assets or liabilities (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,800.1 $ 1,800.1 $ 1,768.0 Policy loans — — 112.0 112.0 112.0 Other invested assets: Company-owned life insurance — 165.0 — 165.0 165.0 Cash and cash equivalents: Unrestricted 473.6 5.3 — 478.9 478.9 Held by variable interest entities 189.3 — — 189.3 189.3 Liabilities: Policyholder account balances — — 10,912.7 10,912.7 10,912.7 Investment borrowings — 1,650.0 — 1,650.0 1,647.4 Borrowings related to variable interest entities — 1,675.2 — 1,675.2 1,662.8 Notes payable – direct corporate obligations — 931.9 — 931.9 912.9
Fair value, assets measured on recurring basis, unobservable input reconciliation	The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions): December 31, 2017 Beginning balance as of December 31, 2016 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of December 31, 2017 Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 258.5 $ (70.4 ) $ 5.8 $ 5.3 $ 31.2 $ — $ 230.4 $ (8.0 ) Debt securities issued by foreign governments 3.9 — — — — — 3.9 — Asset-backed securities 60.4 (4.3 ) — .7 — (32.6 ) 24.2 — Collateralized debt obligations 5.4 (2.5 ) — — — (2.9 ) — — Commercial mortgage-backed securities 32.0 (1.2 ) .1 (.1 ) — (30.8 ) — — Total fixed maturities, available for sale 360.2 (78.4 ) 5.9 5.9 31.2 (66.3 ) 258.5 (8.0 ) Equity securities - corporate securities 25.2 (8.5 ) 6.3 (1.8 ) — — 21.2 — Investments held by variable interest entities - corporate securities — 4.9 — — — — 4.9 — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (1,092.3 ) (267.5 ) 25.0 — — — (1,334.8 ) 25.0 _________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended December 31, 2017 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 76.6 $ (147.0 ) $ — $ — $ (70.4 ) Asset-backed securities — (4.3 ) — — (4.3 ) Collateralized debt obligations — (2.5 ) — — (2.5 ) Commercial mortgage-backed securities — (1.2 ) — — (1.2 ) Total fixed maturities, available for sale 76.6 (155.0 ) — — (78.4 ) Equity securities - corporate securities — (8.5 ) — — (8.5 ) Investments held by variable interest entities - corporate securities 8.9 (4.0 ) — — 4.9 Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (178.9 ) 5.4 (159.3 ) 65.3 (267.5 ) The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2016 (dollars in millions): December 31, 2016 Beginning balance as of December 31, 2015 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of December 31, 2016 Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 170.4 $ 76.5 $ (10.7 ) $ 9.1 $ 20.3 $ (7.1 ) $ 258.5 $ (10.9 ) Debt securities issued by foreign governments — 4.0 — (.1 ) — — 3.9 — Asset-backed securities 35.9 9.7 — 2.2 26.3 (13.7 ) 60.4 — Collateralized debt obligations — 5.4 — — — — 5.4 — Commercial mortgage-backed securities 1.1 16.9 — .1 13.9 — 32.0 — Mortgage pass-through securities .1 (.1 ) — — — — — — Total fixed maturities, available for sale 207.5 112.4 (10.7 ) 11.3 60.5 (20.8 ) 360.2 (10.9 ) Equity securities - corporate securities 32.0 5.5 (12.7 ) .4 — — 25.2 (12.7 ) Trading securities - commercial mortgage-backed securities 39.9 — — — — (39.9 ) — — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (1,057.1 ) (96.0 ) 60.8 — — — (1,092.3 ) 60.8 ____________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended December 31, 2016 (dollars in millions): Purchases Received in reinsurance recapture Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 18.5 $ 89.2 $ (31.2 ) $ — $ — $ 76.5 Debt securities issued by foreign governments 4.0 — — — — 4.0 Asset-backed securities 16.9 — (7.2 ) — — 9.7 Collateralized debt obligations 5.4 — — — — 5.4 Commercial mortgage-backed securities 17.0 — (.1 ) — — 16.9 Mortgage pass-through securities — — (.1 ) — — (.1 ) Total fixed maturities, available for sale 61.8 89.2 (38.6 ) — — 112.4 Equity securities - corporate securities 3.3 2.2 — — — 5.5 Trading securities - corporate securities .2 — (.2 ) — — — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (148.3 ) — 21.2 (28.9 ) 60.0 (96.0 )
Fair value, liabilities measured on recurring basis, unobservable input reconciliation	The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions): December 31, 2017 Beginning balance as of December 31, 2016 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of December 31, 2017 Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 258.5 $ (70.4 ) $ 5.8 $ 5.3 $ 31.2 $ — $ 230.4 $ (8.0 ) Debt securities issued by foreign governments 3.9 — — — — — 3.9 — Asset-backed securities 60.4 (4.3 ) — .7 — (32.6 ) 24.2 — Collateralized debt obligations 5.4 (2.5 ) — — — (2.9 ) — — Commercial mortgage-backed securities 32.0 (1.2 ) .1 (.1 ) — (30.8 ) — — Total fixed maturities, available for sale 360.2 (78.4 ) 5.9 5.9 31.2 (66.3 ) 258.5 (8.0 ) Equity securities - corporate securities 25.2 (8.5 ) 6.3 (1.8 ) — — 21.2 — Investments held by variable interest entities - corporate securities — 4.9 — — — — 4.9 — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (1,092.3 ) (267.5 ) 25.0 — — — (1,334.8 ) 25.0 _________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended December 31, 2017 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 76.6 $ (147.0 ) $ — $ — $ (70.4 ) Asset-backed securities — (4.3 ) — — (4.3 ) Collateralized debt obligations — (2.5 ) — — (2.5 ) Commercial mortgage-backed securities — (1.2 ) — — (1.2 ) Total fixed maturities, available for sale 76.6 (155.0 ) — — (78.4 ) Equity securities - corporate securities — (8.5 ) — — (8.5 ) Investments held by variable interest entities - corporate securities 8.9 (4.0 ) — — 4.9 Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (178.9 ) 5.4 (159.3 ) 65.3 (267.5 ) The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2016 (dollars in millions): December 31, 2016 Beginning balance as of December 31, 2015 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of December 31, 2016 Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 170.4 $ 76.5 $ (10.7 ) $ 9.1 $ 20.3 $ (7.1 ) $ 258.5 $ (10.9 ) Debt securities issued by foreign governments — 4.0 — (.1 ) — — 3.9 — Asset-backed securities 35.9 9.7 — 2.2 26.3 (13.7 ) 60.4 — Collateralized debt obligations — 5.4 — — — — 5.4 — Commercial mortgage-backed securities 1.1 16.9 — .1 13.9 — 32.0 — Mortgage pass-through securities .1 (.1 ) — — — — — — Total fixed maturities, available for sale 207.5 112.4 (10.7 ) 11.3 60.5 (20.8 ) 360.2 (10.9 ) Equity securities - corporate securities 32.0 5.5 (12.7 ) .4 — — 25.2 (12.7 ) Trading securities - commercial mortgage-backed securities 39.9 — — — — (39.9 ) — — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (1,057.1 ) (96.0 ) 60.8 — — — (1,092.3 ) 60.8 ____________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended December 31, 2016 (dollars in millions): Purchases Received in reinsurance recapture Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 18.5 $ 89.2 $ (31.2 ) $ — $ — $ 76.5 Debt securities issued by foreign governments 4.0 — — — — 4.0 Asset-backed securities 16.9 — (7.2 ) — — 9.7 Collateralized debt obligations 5.4 — — — — 5.4 Commercial mortgage-backed securities 17.0 — (.1 ) — — 16.9 Mortgage pass-through securities — — (.1 ) — — (.1 ) Total fixed maturities, available for sale 61.8 89.2 (38.6 ) — — 112.4 Equity securities - corporate securities 3.3 2.2 — — — 5.5 Trading securities - corporate securities .2 — (.2 ) — — — Liabilities: Future policy benefits - embedded derivatives associated with fixed index annuity products (148.3 ) — 21.2 (28.9 ) 60.0 (96.0 )
Fair value inputs	The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2017 (dollars in millions): Fair value at December 31, 2017 Valuation techniques Unobservable inputs Range (weighted average) Assets: Corporate securities (a) $ 149.2 Discounted cash flow analysis Discount margins 1.45% - 71.29% (6.96%) Corporate securities (b) 2.8 Recovery method Percent of recovery expected 0% - 21.73% (18.42%) Asset-backed securities (c) 24.2 Discounted cash flow analysis Discount margins 1.80% - 3.71% (2.67%) Equity securities (d) 21.2 Market comparables EBITDA multiples 1.1X - 8.9X (1.1X) Other assets categorized as Level 3 (e) 87.2 Unadjusted third-party price source Not applicable Not applicable Total 284.6 Liabilities: Future policy benefits (f) 1,334.8 Discounted projected embedded derivatives Projected portfolio yields 5.15% - 5.61% (5.60%) Discount rates 0.92 - 2.51% (2.00%) Surrender rates 1.20% - 46.40% (12.30%) ________________________________ (a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement. (c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements. (e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources. (f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative. The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2016 (dollars in millions): Fair value at December 31, 2016 Valuation techniques Unobservable inputs Range (weighted average) Assets: Corporate securities (a) $ 148.5 Discounted cash flow analysis Discount margins 1.35% - 27.71% (13.52%) Corporate securities (b) 14.8 Recovery method Percent of recovery expected 5% - 69% (55%) Asset-backed securities (c) 24.0 Discounted cash flow analysis Discount margins 2.06% - 3.64% (2.76%) Equity securities (d) 25.2 Market comparables EBITDA multiples 0.4X - 6.2X (5.9X) Other assets categorized as Level 3 (e) 172.9 Unadjusted third-party price source Not applicable Not applicable Total 385.4 Liabilities: Future policy benefits (f) 1,092.3 Discounted projected embedded derivatives Projected portfolio yields 5.15% - 5.61% (5.59%) Discount rates 0.18 - 3.06% (2.07%) Surrender rates 0.94% - 46.48% (13.52%) ________________________________ (a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement. (c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. (d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is EBITDA multiples. Generally, increases (decreases) in EBITDA multiples would result in higher (lower) fair value measurements. (e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources. (f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

LIABILITIES FOR INSURANCE PRO32

LIABILITIES FOR INSURANCE PRODUCTS (Tables)	12 Months Ended
	Dec. 31, 2017
Insurance [Abstract]
Schedule of insurance liabilities by product segment	Our future policy benefits are summarized as follows (dollars in millions): Withdrawal assumption Morbidity assumption Mortality assumption Interest rate assumption 2017 2016 Long-term care Company experience Company experience Company experience 6% $ 5,669.0 $ 5,346.1 Traditional life insurance contracts Company experience Company experience (a) 5% 2,401.2 2,322.1 Accident and health contracts Company experience Company experience Company experience 5% 2,812.0 2,695.6 Interest-sensitive life insurance contracts Company experience Company experience Company experience 5% 44.9 52.2 Annuities and supplemental contracts with life contingencies Company experience Company experience (b) 4% 594.2 537.3 Total $ 11,521.3 $ 10,953.3 ____________________ (a) Principally, modifications of: (i) the 1965 ‑ 70 and 1975 - 80 Basic Tables; and (ii) the 1941, 1958 and 1980 Commissioners' Standard Ordinary Tables; as well as Company experience. (b) Principally, modifications of: (i) the 1971 Individual Annuity Mortality Table; (ii) the 1983 Table "A"; and (iii) the Annuity 2000 Mortality Table; as well as Company experience. Our policyholder account balances are summarized as follows (dollars in millions): 2017 2016 Fixed index annuities $ 5,942.2 $ 5,324.5 Other annuities 4,183.8 4,541.8 Interest-sensitive life insurance contracts 1,094.7 1,046.4 Total $ 11,220.7 $ 10,912.7
Summary of liabilities for unpaid claims adjustment expense	Changes in the unpaid claims reserve (included in claims payable) and disabled life reserves related to accident and health insurance (included in the liability for future policy benefits) were as follows (dollars in millions): 2017 2016 2015 Balance, beginning of year $ 1,777.6 $ 1,731.8 $ 1,679.5 Less reinsurance (receivables) payables 14.0 (130.0 ) (125.0 ) Net balance, beginning of year 1,791.6 1,601.8 1,554.5 Incurred claims related to: Current year 1,548.1 1,526.4 1,481.0 Prior years (a) (26.7 ) 96.6 (13.3 ) Total incurred 1,521.4 1,623.0 1,467.7 Interest on claim reserves 78.4 75.3 71.0 Paid claims related to: Current year 845.5 837.2 841.8 Prior years 702.6 671.3 649.6 Total paid 1,548.1 1,508.5 1,491.4 Net balance, end of year 1,843.3 1,791.6 1,601.8 Add reinsurance receivables (payables) (15.1 ) (14.0 ) 130.0 Balance, end of year $ 1,828.2 $ 1,777.6 $ 1,731.8 ___________ (a) The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. Such amounts will fluctuate based upon the estimation procedures used to determine the amount of unpaid losses. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense	The components of income tax expense (benefit) were as follows (dollars in millions): 2017 2016 2015 Current tax expense (benefit) $ 90.8 $ (45.2 ) $ 10.7 Deferred tax expense 72.0 173.0 118.6 Valuation allowance applicable to current year income (15.3 ) (14.0 ) — Income tax expense calculated based on annual effective tax rate 147.5 113.8 129.3 Income tax expense on discrete items: Change in valuation allowance (13.4 ) 40.7 (32.5 ) Impact of federal tax reform 310.6 — — Change in valuation allowance related to federal tax reform (138.1 ) — — IRS settlement — (170.4 ) — Other items (1.7 ) 10.9 .2 Total income tax expense (benefit) $ 304.9 $ (5.0 ) $ 97.0
Schedule of effective income tax rate reconciliation	A reconciliation of the U.S. statutory corporate tax rate to the effective rate reflected in the consolidated statement of operations is as follows: 2017 2016 2015 U.S. statutory corporate rate 35.0 % 35.0 % 35.0 % Valuation allowance (6.0 ) 7.6 (8.8 ) Non-taxable income and nondeductible benefits, net (2.0 ) (1.1 ) (.2 ) State taxes .6 2.2 2.1 Impact of federal tax reform 64.7 — — Change in valuation allowance related to federal tax reform (28.8 ) — — Impact of IRS settlement — (48.2 ) — Other items — 3.1 (1.7 ) Effective tax rate 63.5 % (1.4 )% 26.4 %
Schedule of deferred tax assets and liabilities	The components of the Company's income tax assets and liabilities are summarized below (dollars in millions): 2017 2016 Deferred tax assets: Net federal operating loss carryforwards $ 489.6 $ 882.9 Net state operating loss carryforwards 9.3 12.3 Investments 4.3 17.8 Insurance liabilities 415.8 668.4 Other 48.9 66.3 Gross deferred tax assets 967.9 1,647.7 Deferred tax liabilities: Present value of future profits and deferred acquisition costs (165.4 ) (277.8 ) Accumulated other comprehensive income (337.2 ) (344.1 ) Gross deferred tax liabilities (502.6 ) (621.9 ) Net deferred tax assets before valuation allowance 465.3 1,025.8 Valuation allowance (89.1 ) (240.2 ) Net deferred tax assets 376.2 785.6 Current income taxes prepaid (accrued) (9.3 ) 4.1 Income tax assets, net $ 366.9 $ 789.7
Summary of valuation allowance	Changes in our valuation allowance are summarized as follows (dollars in millions): Balance, December 31, 2014 $ 246.0 Decrease in 2015 (32.5 ) (a) Balance, December 31, 2015 213.5 Increase in 2016 26.7 (b) Balance, December 31, 2016 240.2 Decrease in 2017 (166.8 ) (c) Cumulative effect of accounting change 15.7 (d) Balance, December 31, 2017 $ 89.1 ___________________ (a) The 2015 reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income. (b) The 2016 increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the Internal Revenue Service (the "IRS"). (c) The 2017 decrease to the deferred tax valuation allowance includes: (i) $138.1 million related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii) $13.4 million of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii) $15.3 million of reductions in the deferred tax valuation allowance reflecting higher current year taxable income than previously reflected in our deferred tax valuation model. (d) Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of $15.7 million related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of $15.7 million was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance.
Summary of operating loss carryforwards	As of December 31, 2017 , we had $2.3 billion of federal NOLs (all of which were non-life NOLs). The following table summarizes the expiration dates of our loss carryforwards (dollars in millions): Net operating loss Year of expiration carryforwards 2023 $ 1,744.8 2025 85.2 2026 149.9 2027 10.8 2028 80.3 2029 213.2 2030 .3 2031 .2 2032 44.4 2033 .6 2034 .9 2035 .8 Total federal NOLs $ 2,331.4
Reconciliation of unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits for the year ended December 31, 2016 is as follows (dollars in millions): 2016 Balance at beginning of year $ 234.2 Increase based on tax positions taken in prior years 3.4 Decrease in unrecognized tax benefits related to settlements with taxing authorities (237.6 ) Balance at end of year $ —

NOTES PAYABLE - DIRECT CORPOR34

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	The following notes payable were direct corporate obligations of the Company as of December 31, 2017 and 2016 (dollars in millions): 2017 2016 4.500% Senior Notes due May 2020 $ 325.0 $ 325.0 5.250% Senior Notes due May 2025 500.0 500.0 Revolving Credit Agreement (as defined below) 100.0 100.0 Unamortized debt issuance costs (10.4 ) (12.1 ) Direct corporate obligations $ 914.6 $ 912.9
Schedule of maturities of long-term debt	The scheduled repayment of our direct corporate obligations was as follows at December 31, 2017 (dollars in millions): Year ending December 31, 2018 $ — 2019 100.0 (a) 2020 325.0 2021 — 2022 — Thereafter 500.0 $ 925.0 _________________________ (a) The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019.

LITIGATION AND OTHER LEGAL PR35

LITIGATION AND OTHER LEGAL PROCEEDINGS (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum rental payments for operating leases	Future required minimum payments as of December 31, 2017 , were as follows (dollars in millions): 2018 $ 33.5 2019 18.2 2020 11.8 2021 8.0 2022 5.6 Thereafter 3.6 Total $ 80.7

AGENT DEFERRED COMPENSATION P36

AGENT DEFERRED COMPENSATION PLAN (Tables)	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Schedule of assumptions used	We used the following assumptions for the deferred compensation plan to calculate: 2017 2016 Benefit obligations: Discount rate 3.75 % 4.25 % Net periodic cost: Discount rate 4.25 % 4.50 %
Schedule of expected benefit payments	The benefits expected to be paid pursuant to our agent deferred compensation plan as of December 31, 2017 were as follows (dollars in millions): 2018 $ 7.4 2019 7.6 2020 7.9 2021 8.0 2022 8.3 2023 - 2027 45.2

DERIVATIVES (Tables)

DERIVATIVES (Tables)	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair value by balance sheet location	Our freestanding and embedded derivatives, which are not designated as hedging instruments, are held at fair value and are summarized as follows (dollars in millions): Fair value 2017 2016 Assets: Other invested assets: Fixed index call options $ 170.2 $ 111.9 Reinsurance receivables (1.4 ) (4.2 ) Total assets $ 168.8 $ 107.7 Liabilities: Future policy benefits: Fixed index products $ 1,334.8 $ 1,092.3 Total liabilities $ 1,334.8 $ 1,092.3
Schedule of derivative instruments	The following table represents activity associated with derivative instruments as of the dates indicated: Measurement December 31, 2016 Additions Maturities/terminations December 31, 2017 Fixed index annuities - embedded derivative Policies 100,812 11,437 (7,560 ) 104,689 Fixed index call options Notional (a) $ 2,455.1 $ 3,021.8 $ (2,471.1 ) $ 3,005.8 _________________ (a) Dollars in millions.
Schedule pre-tax gains (losses) recognized in net income for derivative instruments	The following table provides the pre-tax gains (losses) recognized in net income for derivative instruments, which are not designated as hedges for the periods indicated (dollars in millions): 2017 2016 2015 Net investment income from policyholder and other special-purpose portfolios: Fixed index call options $ 162.5 $ 29.2 $ (36.2 ) Net realized gains (losses): Interest rate futures — (1.1 ) (2.7 ) Embedded derivative related to modified coinsurance agreement 2.8 .8 (7.0 ) Total 2.8 (.3 ) (9.7 ) Insurance policy benefits: Embedded derivative related to fixed index annuities 25.0 60.8 36.3 Total $ 190.3 $ 89.7 $ (9.6 )
Derivatives with master netting arrangements	The following table summarizes information related to derivatives with master netting arrangements or collateral as of December 31, 2017 and 2016 (dollars in millions): Gross amounts not offset in the balance sheet Gross amounts recognized Gross amounts offset in the balance sheet Net amounts of assets presented in the balance sheet Financial instruments Cash collateral received Net amount December 31, 2017: Fixed index call options $ 170.2 $ — $ 170.2 $ — $ — $ 170.2 December 31, 2016: Fixed index call options 111.9 — 111.9 — — 111.9

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of common stock outstanding	Changes in the number of shares of common stock outstanding were as follows (shares in thousands): 2017 2016 2015 Balance, beginning of year 173,754 184,029 203,324 Treasury stock purchased and retired (7,808 ) (11,688 ) (20,582 ) Stock options exercised 725 978 769 Restricted and performance stock vested (a) 187 435 518 Balance, end of year 166,858 173,754 184,029 ____________________ (a) In 2017 , 2016 and 2015 , such amount was reduced by 103 thousand , 191 thousand and 237 thousand shares, respectively, which were tendered to the Company for the payment of required federal and state tax withholdings owed on the vesting of restricted and performance stock.
Schedule of share-based compensation	A summary of the Company's stock option activity and related information for 2017 is presented below (shares in thousands; dollars in millions, except per share amounts): Shares Weighted average exercise price Weighted average remaining life (in years) Aggregate intrinsic value Outstanding at the beginning of the year 5,354 $ 14.73 Options granted 729 21.06 Exercised (237 ) (17.81 ) $ 5.2 Forfeited or terminated (725 ) (11.43 ) Outstanding at the end of the year 5,121 15.95 5.4 $ 37.2 Options exercisable at the end of the year 2,440 3.0 $ 19.2 Available for future grant 7,488 A summary of the Company's stock option activity and related information for 2016 is presented below (shares in thousands; dollars in millions, except per share amounts): Shares Weighted average exercise price Weighted average remaining life (in years) Aggregate intrinsic value Outstanding at the beginning of the year 5,199 $ 13.32 Options granted 1,706 17.45 Exercised (978 ) (8.70 ) $ 6.1 Forfeited or terminated (573 ) (20.41 ) Outstanding at the end of the year 5,354 14.73 5.9 $ 37.1 Options exercisable at the end of the year 2,187 2.7 $ 15.1 Available for future grant 4,620 A summary of the Company's stock option activity and related information for 2015 is presented below (shares in thousands; dollars in millions, except per share amounts): Shares Weighted average exercise price Weighted average remaining life (in years) Aggregate intrinsic value Outstanding at the beginning of the year 5,011 $ 12.04 Options granted 1,361 16.45 Exercised (769 ) (8.20 ) $ 4.8 Forfeited or terminated (404 ) (17.70 ) Outstanding at the end of the year 5,199 13.32 4.8 $ 38.4 Options exercisable at the end of the year 2,399 2.5 $ 15.3 Available for future grant 6,882
Schedule of valuation assumptions on payment awards	The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions: 2017 2016 2015 Grants Grants Grants Weighted average risk-free interest rates 2.2 % 1.4 % 1.7 % Weighted average dividend yields 1.5 % 1.6 % 1.5 % Volatility factors 32 % 36 % 85 % Weighted average expected life (in years) 6.3 6.3 6.3 Weighted average fair value per share $ 6.20 $ 5.48 $ 10.83
Schedule of share-based compensation by exercise price range	The following table summarizes information about stock options outstanding at December 31, 2017 (shares in thousands): Options outstanding Options exercisable Range of exercise prices Number outstanding Remaining life (in years) Average exercise price Number exercisable Average exercise price $6.77 - $7.51 605 0.9 $ 7.47 605 $ 7.47 $10.88 - $16.22 683 2.3 11.12 670 11.02 $16.42 - $21.48 3,833 6.7 18.15 1,165 18.04 5,121 2,440
Schedule of nonvested share activity	A summary of the Company's non-vested restricted stock activity for 2017 is presented below (shares in thousands): Shares Weighted average grant date fair value Non-vested shares, beginning of year 369 $ 18.10 Granted 330 20.87 Vested (147 ) (18.38 ) Forfeited (17 ) (20.59 ) Non-vested shares, end of year 535 19.65
Schedule of performance share-based compensation	A summary of the Company's performance units is presented below (shares in thousands): Total shareholder return awards Operating return on equity awards Pre-tax operating income awards Awards outstanding at December 31, 2014 519 343 176 Granted in 2015 258 258 — Additional shares issued pursuant to achieving certain performance criteria (a) 85 — 85 Shares vested in 2015 (260 ) — (260 ) Forfeited (53 ) (52 ) (1 ) Awards outstanding at December 31, 2015 549 549 — Granted in 2016 254 254 — Additional shares issued pursuant to achieving certain performance criteria (a) 87 65 — Shares vested in 2016 (261 ) (239 ) — Forfeited (59 ) (59 ) — Awards outstanding at December 31, 2016 570 570 — Granted in 2017 226 226 — Additional shares issued pursuant to achieving certain performance criteria (a) — 30 — Shares vested in 2017 — (144 ) — Forfeited (167 ) (53 ) — Awards outstanding at December 31, 2017 629 629 — _________________________ (a) The performance units that vested in these years provided for a payout of up to 150 percent of the award if certain performance levels were achieved.
Schedule of earnings per share reconciliation	A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands): 2017 2016 2015 Net income for diluted earnings per share $ 175.6 $ 358.2 $ 270.7 Shares: Weighted average shares outstanding for basic earnings per share 170,025 176,638 193,054 Effect of dilutive securities on weighted average shares: Stock options, restricted stock and performance units 2,119 1,685 2,112 Weighted average shares outstanding for diluted earnings per share 172,144 178,323 195,166

OTHER OPERATING STATEMENT DATA

OTHER OPERATING STATEMENT DATA (Tables)	12 Months Ended
	Dec. 31, 2017
Insurance [Abstract]
Schedule of insurance policy income	Insurance policy income consisted of the following (dollars in millions): 2017 2016 2015 Direct premiums collected $ 4,013.4 $ 3,942.7 $ 3,769.6 Reinsurance assumed 30.2 33.8 38.4 Reinsurance ceded (114.4 ) (132.9 ) (142.8 ) Premiums collected, net of reinsurance 3,929.2 3,843.6 3,665.2 Change in unearned premiums 19.0 6.2 5.9 Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities (1,445.9 ) (1,386.7 ) (1,241.9 ) Premiums on traditional products with mortality or morbidity risk 2,502.3 2,463.1 2,429.2 Fees and surrender charges on interest-sensitive products 145.0 138.0 126.8 Insurance policy income $ 2,647.3 $ 2,601.1 $ 2,556.0
Schedule of other operating cost and expense	Other operating costs and expenses were as follows (dollars in millions): 2017 2016 2015 Commission expense $ 115.6 $ 110.5 $ 103.8 Salaries and wages 237.3 231.0 205.2 Other 488.6 454.8 430.2 Total other operating costs and expenses $ 841.5 $ 796.3 $ 739.2
Schedule of changes in present value of future insurance profits	Changes in the present value of future profits were as follows (dollars in millions): 2017 2016 2015 Balance, beginning of year $ 401.8 $ 449.0 $ 489.4 Amortization (54.4 ) (62.2 ) (69.1 ) Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale 12.2 15.0 28.7 Balance, end of year $ 359.6 $ 401.8 $ 449.0
Schedule of changes in deferred acquisition costs	Changes in deferred acquisition costs were as follows (dollars in millions): 2017 2016 2015 Balance, beginning of year $ 1,044.7 $ 1,083.3 $ 770.6 Additions 236.1 242.7 246.4 Amortization (184.9 ) (191.1 ) (190.9 ) Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale (69.1 ) (90.2 ) 257.2 Balance, end of year $ 1,026.8 $ 1,044.7 $ 1,083.3

CONSOLIDATED STATEMENT CASH F40

CONSOLIDATED STATEMENT CASH FLOWS (Tables)	12 Months Ended
	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Schedule of the reconciliation for net income provided by operating activities	The following reconciles net income to net cash provided by operating activities (dollars in millions): 2017 2016 2015 Cash flows from operating activities: Net income $ 175.6 $ 358.2 $ 270.7 Adjustments to reconcile net income to net cash from operating activities: Amortization and depreciation 265.4 275.0 283.4 Income taxes 227.5 (11.7 ) 92.9 Insurance liabilities 464.7 332.8 297.4 Accrual and amortization of investment income (321.6 ) (124.2 ) (27.6 ) Deferral of policy acquisition costs (236.1 ) (242.7 ) (246.4 ) Net realized investment (gains) losses (50.3 ) (8.3 ) 36.6 Loss on reinsurance transactions and transition expenses — 75.4 9.0 Cash and cash equivalents received upon recapture of reinsurance — 73.6 — Loss on extinguishment of borrowings related to variable interest entities 9.5 — — Loss on extinguishment of debt — — 32.8 Other 78.4 34.7 (1.0 ) Net cash from operating activities $ 613.1 $ 762.8 $ 747.8
Schedule of other significant noncash transactions	Other non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions): 2017 2016 2015 Stock options, restricted stock and performance units $ 21.4 $ 23.0 $ 17.1 Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe — 431.1 —

STATUTORY INFORMATION (BASED 41

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES) (Tables)	12 Months Ended
	Dec. 31, 2017
Insurance [Abstract]
Schedule of statutory accounting practices	The Company's insurance subsidiaries reported the following amounts to regulatory agencies, after appropriate elimination of intercompany accounts among such subsidiaries (dollars in millions): 2017 2016 Statutory capital and surplus $ 1,904.4 $ 1,956.8 Asset valuation reserve 246.8 253.3 Interest maintenance reserve 487.0 486.9 Total $ 2,638.2 $ 2,697.0

BUSINESS SEGMENTS (Tables)

BUSINESS SEGMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Schedule of segment reporting information by segment	Operating information by segment was as follows (dollars in millions): 2017 2016 2015 Revenues: Bankers Life: Insurance policy income: Annuities $ 20.3 $ 22.0 $ 22.4 Health 1,231.1 1,244.1 1,251.0 Life 415.2 393.0 375.3 Net investment income (a) 1,107.3 936.8 884.7 Fee revenue and other income (a) 44.1 34.4 27.7 Total Bankers Life revenues 2,818.0 2,630.3 2,561.1 Washington National: Insurance policy income: Annuities 2.1 2.9 3.0 Health 642.9 627.9 615.4 Life 26.4 25.0 25.4 Net investment income (a) 270.2 259.3 253.6 Fee revenue and other income (a) 1.0 1.3 1.3 Total Washington National revenues 942.6 916.4 898.7 Colonial Penn: Insurance policy income: Health 2.1 2.6 3.0 Life 289.7 278.8 260.5 Net investment income (a) 44.4 44.2 43.0 Fee revenue and other income (a) 1.3 1.1 1.0 Total Colonial Penn revenues 337.5 326.7 307.5 Long-term care in run-off: Insurance policy income - health 17.5 4.8 — Net investment income (a) 34.6 9.4 — Total Long-term care in run-off revenues 52.1 14.2 — Corporate operations: Net investment income 35.5 16.6 11.3 Fee revenue and other income 8.5 10.0 8.6 Total corporate revenues 44.0 26.6 19.9 Total revenues $ 4,194.2 $ 3,914.2 $ 3,787.2 (continued on next page) (continued from previous page) 2017 2016 2015 Expenses: Bankers Life: Insurance policy benefits $ 1,771.8 $ 1,620.6 $ 1,588.4 Amortization 163.6 176.5 187.1 Interest expense on investment borrowings 19.8 13.2 8.8 Other operating costs and expenses 443.9 422.1 407.2 Total Bankers Life expenses 2,399.1 2,232.4 2,191.5 Washington National: Insurance policy benefits 581.1 561.7 546.6 Amortization 58.8 59.1 55.2 Interest expense on investment borrowings 6.3 3.7 2.0 Other operating costs and expenses 198.1 189.0 183.4 Total Washington National expenses 844.3 813.5 787.2 Colonial Penn: Insurance policy benefits 199.6 201.9 189.0 Amortization 16.3 15.3 14.4 Interest expense on investment borrowings .9 .6 .1 Other operating costs and expenses 98.1 107.2 98.4 Total Colonial Penn expenses 314.9 325.0 301.9 Long-term care in run-off: Insurance policy benefits 47.3 17.6 — Other operating costs and expenses 3.1 .5 — Total Long-term care in run-off expenses 50.4 18.1 — Corporate operations: Interest expense on corporate debt 46.5 45.8 45.0 Interest expense on investment borrowings — — .2 Other operating costs and expenses 84.3 69.1 38.6 Total corporate expenses 130.8 114.9 83.8 Total expenses 3,739.5 3,503.9 3,364.4 Pre-tax operating earnings by segment: Bankers Life 418.9 397.9 369.6 Washington National 98.3 102.9 111.5 Colonial Penn 22.6 1.7 5.6 Long-term care in run-off 1.7 (3.9 ) — Corporate operations (86.8 ) (88.3 ) (63.9 ) Pre-tax operating earnings $ 454.7 $ 410.3 $ 422.8 ___________________ (a) It is not practicable to provide additional components of revenue by product or services.
Reconciliation of operating profit (loss) from segments to consolidated	A reconciliation of segment revenues and expenses to consolidated revenues and expenses and net income is as follows (dollars in millions): 2017 2016 2015 Total segment revenues $ 4,194.2 $ 3,914.2 $ 3,787.2 Net realized investment gains (losses) 50.3 8.3 (36.6 ) Revenues related to certain non-strategic investments and earnings attributable to VIEs 52.7 52.6 36.3 Fee revenue related to transition and support services agreements — 10.0 25.0 Consolidated revenues 4,297.2 3,985.1 3,811.9 Total segment expenses 3,739.5 3,503.9 3,364.4 Insurance policy benefits - fair value changes in embedded derivative liabilities 2.9 (11.3 ) (15.7 ) Amortization related to fair value changes in embedded derivative liabilities (.4 ) 1.7 3.8 Amortization related to net realized investment gains (losses) 1.0 .7 (.5 ) Expenses related to certain non-strategic investments and expenses attributable to VIEs 61.5 54.6 43.0 Fair value changes and amendment related to agent deferred compensation plan 12.2 (3.1 ) (15.1 ) Loss on extinguishment of debt — — 32.8 Loss on reinsurance transaction and transition expenses — 75.4 9.0 Expenses related to transition and support services agreements — 10.0 22.5 Consolidated expenses 3,816.7 3,631.9 3,444.2 Income before tax 480.5 353.2 367.7 Income tax expense: Tax expense on period income 162.8 127.8 129.5 Valuation allowance for deferred tax assets and other tax items 142.1 (132.8 ) (32.5 ) Net income $ 175.6 $ 358.2 $ 270.7
Schedule of balance sheet information, by segment	Segment balance sheet information was as follows (dollars in millions): 2017 2016 Assets: Bankers Life $ 21,134.9 $ 19,876.4 Washington National 7,674.3 7,555.7 Colonial Penn 1,059.3 1,022.9 Long-term care in run-off 692.9 656.2 Corporate operations 2,548.9 2,864.0 Total assets $ 33,110.3 $ 31,975.2 Liabilities: Bankers Life $ 18,031.6 $ 17,144.9 Washington National 6,101.5 6,096.9 Colonial Penn 921.0 898.5 Long-term care in run-off 580.4 562.2 Corporate operations 2,628.3 2,785.8 Total liabilities $ 28,262.8 $ 27,488.3
Schedule of selected financial information, by segment	The following table presents selected financial information of our segments (dollars in millions): Segment Present value of future profits Deferred acquisition costs Insurance liabilities 2017 Bankers Life $ 81.1 $ 606.5 $ 16,541.2 Washington National 243.7 310.8 5,590.7 Colonial Penn 34.8 109.5 834.4 Long-term care in run-off — — 572.7 Total $ 359.6 $ 1,026.8 $ 23,539.0 2016 Bankers Life $ 95.5 $ 646.2 $ 15,702.8 Washington National 266.8 299.9 5,586.7 Colonial Penn 39.5 98.6 809.6 Long-term care in run-off — — 554.7 Total $ 401.8 $ 1,044.7 $ 22,653.8

QUARTERLY FINANCIAL DATA (UNAUD

QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Data [Abstract]
Schedule of quarterly financial information	Quarterly financial data (unaudited) were as follows (dollars in millions, except per share data): 2017 1st Qtr. 2nd Qtr. 3rd Qtr. 4th Qtr. (a) Revenues $ 1,070.7 $ 1,057.1 $ 1,079.3 $ 1,090.1 Income before income taxes $ 96.7 $ 128.5 $ 129.9 $ 125.4 Income tax expense 34.4 45.1 29.1 196.3 Net income (loss) $ 62.3 $ 83.4 $ 100.8 $ (70.9 ) Earnings per common share: Basic: Net income (loss) $ .36 $ .49 $ .60 $ (.42 ) Diluted: Net income (loss) $ .36 $ .48 $ .59 $ (.42 ) 2016 1st Qtr. 2nd Qtr. 3rd Qtr. 4th Qtr. Revenues $ 960.4 $ 1,003.9 $ 1,015.9 $ 1,004.9 Income before income taxes $ 40.5 $ 82.7 $ 49.3 $ 180.7 Income tax expense (benefit) (5.0 ) 22.8 30.7 (53.5 ) Net income $ 45.5 $ 59.9 $ 18.6 $ 234.2 Earnings per common share: Basic: Net income $ .25 $ .34 $ .11 $ 1.35 Diluted: Net income $ .25 $ .33 $ .11 $ 1.34 ___________________ (a) In the fourth quarter of 2017, our net loss reflected the unfavorable impact of $172.5 million related to the Tax Reform Act which was enacted in December 2017.

INVESTMENTS IN VARIABLE INTER44

INVESTMENTS IN VARIABLE INTEREST ENTITIES (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of impact on balance sheet of consolidating variable interest entities	The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated (dollars in millions): December 31, 2017 VIEs Eliminations Net effect on consolidated balance sheet Assets: Investments held by variable interest entities $ 1,526.9 $ — $ 1,526.9 Notes receivable of VIEs held by insurance subsidiaries — (155.5 ) (155.5 ) Cash and cash equivalents held by variable interest entities 178.9 — 178.9 Accrued investment income 2.6 (.1 ) 2.5 Income tax assets, net .7 — .7 Other assets 10.0 (1.5 ) 8.5 Total assets $ 1,719.1 $ (157.1 ) $ 1,562.0 Liabilities: Other liabilities $ 158.3 $ (4.4 ) $ 153.9 Borrowings related to variable interest entities 1,410.7 — 1,410.7 Notes payable of VIEs held by insurance subsidiaries 167.6 (167.6 ) — Total liabilities $ 1,736.6 $ (172.0 ) $ 1,564.6 December 31, 2016 VIEs Eliminations Net effect on consolidated balance sheet Assets: Investments held by variable interest entities $ 1,724.3 $ — $ 1,724.3 Notes receivable of VIEs held by insurance subsidiaries — (204.2 ) (204.2 ) Cash and cash equivalents held by variable interest entities 189.3 — 189.3 Accrued investment income 3.0 (.1 ) 2.9 Income tax assets, net 6.4 (1.3 ) 5.1 Other assets 13.1 (1.8 ) 11.3 Total assets $ 1,936.1 $ (207.4 ) $ 1,728.7 Liabilities: Other liabilities $ 81.8 $ (6.4 ) $ 75.4 Borrowings related to variable interest entities 1,662.8 — 1,662.8 Notes payable of VIEs held by insurance subsidiaries 203.3 (203.3 ) — Total liabilities $ 1,947.9 $ (209.7 ) $ 1,738.2
Supplemental information, revenues and expenses of variable interest entities	The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions): 2017 2016 2015 Revenues: Net investment income – policyholder and other special-purpose portfolios $ 69.8 $ 78.9 $ 62.1 Fee revenue and other income 5.9 6.4 1.6 Total revenues 75.7 85.3 63.7 Expenses: Interest expense 50.2 53.1 38.8 Other operating expenses 1.8 1.5 2.0 Total expenses 52.0 54.6 40.8 Income before net realized investment losses and income taxes 23.7 30.7 22.9 Net realized investment losses (5.6 ) (20.4 ) (6.4 ) Loss on extinguishment of borrowings (9.5 ) — — Income before income taxes $ 8.6 $ 10.3 $ 16.5
Summary of variable interest entities by contractual maturity	The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 11.2 $ 11.2 Due after one year through five years 541.8 542.0 Due after five years through ten years 971.9 973.7 Total $ 1,524.9 $ 1,526.9 The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at December 31, 2017 , by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Amortized cost Estimated fair value (Dollars in millions) Due in one year or less $ 2.4 $ 2.4 Due after one year through five years 178.2 174.3 Due after five years through ten years 299.8 297.1 Total $ 480.4 $ 473.8

BUSINESS AND BASIS OF PRESENT45

BUSINESS AND BASIS OF PRESENTATION (NARRATIVE) (Details)	12 Months Ended
	Dec. 31, 2017distribution_channel
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of product distribution channels	3

SUMMARY OF SIGNIFICANT ACCOUN46

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (PRESENT VALUE OF FUTURE PROFITS) (Details)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Discount rate used to determine present value of future profits	12.00%

SUMMARY OF SIGNIFICANT ACCOUN47

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (REINSURANCE) (Details) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2013USD ($)subsidiary	Dec. 31, 2017USD ($)subsidiary	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2016USD ($)
Accounting Policies [Abstract]
Company retains no more than this amount of mortality risk		$ 0.8
Ceded premiums written		105	$ 123.9	$ 133.6
Reinsurance benefits netted against insurance policy benefits		88.6	130.1	167.7
Assumed premiums written		30.4	34	38.5
Insurance policy benefits related to reinsurance assumed		$ 44.7	$ 47.5	$ 48
Number of insurance subsidiaries | subsidiary	2	3
Percent of coinsurance agreements	100.00%
Ceded long-term reserves	$ 495
Additional premiums paid by subsidiaries to enter into coinsurance agreement	$ 96.9
Over-collateralization rate of market-value trusts	7.00%
Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract]
Market value of investments					$ 504.7
Insurance liabilities					(552.2)
Write-off of reinsurance receivables					(17.9)
Estimated transaction expenses					(10)
Pre-tax loss					(75.4)
Tax benefit					26.4
Increase in valuation allowance for deferred tax assets					(4.1)
After-tax loss					$ (53.1)

SUMMARY OF SIGNIFICANT ACCOUN48

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (INCOME TAXES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Valuation allowance for deferred income tax assets	$ 89.1	$ 255.9	$ 240.2	$ 213.5	$ 246

SUMMARY OF SIGNIFICANT ACCOUN49

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (INVESTMENTS IN VARIABLE INTEREST ENTITIES) (Details) $ in Millions	Dec. 31, 2017USD ($)
Accounting Policies [Abstract]
Investments held in limited partnerships	$ 371.1
Unfunded commitments to limited partnerships	$ 276.5

SUMMARY OF SIGNIFICANT ACCOUN50

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (INVESTMENT BORROWINGS) (Details) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2013subsidiary	Dec. 31, 2017USD ($)subsidiary	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Number of insurance subsidiaries | subsidiary	2	3
Investment borrowings		$ 1,646.7	$ 1,647.4
Interest expense on FHLB borrowings		27	$ 17.5	$ 10.9
Federal Home Loan Bank Advances
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Federal home loan bank stock		71.2
Investment borrowings		1,646.7
Fair value of collateral for borrowings		1,900
Aggregate fee to prepay all fixed rate FHLB borrowings		2.1
Federal Home Loan Bank Advances | Borrowings due January 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Jan. 31, 2019
Interest rate		1.779%
Federal Home Loan Bank Advances | Borrowings due February 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Feb. 28, 2019
Interest rate		1.509%
Federal Home Loan Bank Advances | Borrowings due March 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100
Maturity date		Mar. 31, 2019
Interest rate		1.971%
Federal Home Loan Bank Advances | Borrowings due July 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 21.8
Maturity date		Jul. 31, 2019
Interest rate		2.001%
Federal Home Loan Bank Advances | Borrowings due October 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 15
Maturity date		Oct. 31, 2019
Interest rate		1.887%
Federal Home Loan Bank Advances | Borrowing due May 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		May 31, 2020
Interest rate		1.997%
Federal Home Loan Bank Advances | Borrowings due June 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 21.8
Maturity date		Jun. 30, 2020
Interest rate		1.96%
Federal Home Loan Bank Advances | Borrowing due September 2020, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 25
Maturity date		Sep. 30, 2020
Interest rate		2.30%
Federal Home Loan Bank Advances | Borrowings due September 2020, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100
Maturity date		Sep. 30, 2020
Interest rate		2.212%
Federal Home Loan Bank Advances | Borrowings due September 2020, Rate Three
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Sep. 30, 2020
Interest rate		2.224%
Federal Home Loan Bank Advances | Borrowings due September 2020, Rate Four
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 75
Maturity date		Sep. 30, 2020
Interest rate		1.813%
Federal Home Loan Bank Advances | Borrowings due October 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100
Maturity date		Oct. 31, 2020
Interest rate		1.453%
Federal Home Loan Bank Advances | Borrowings due December 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Dec. 31, 2020
Interest rate		2.072%
Federal Home Loan Bank Advances | Borrowings Due July 2021
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100
Maturity date		Jul. 31, 2021
Interest rate		1.909%
Federal Home Loan Bank Advances | Borrowings due July 2021 Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100
Maturity date		Jul. 31, 2021
Interest rate		1.879%
Federal Home Loan Bank Advances | Borrowings Due August 2021, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 57.7
Maturity date		Aug. 31, 2021
Interest rate		1.921%
Federal Home Loan Bank Advances | Borrowings Due August 2021, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 28.2
Maturity date		Aug. 31, 2021
Interest rate		2.55%
Federal Home Loan Bank Advances | Borrowings Due August 2021, Rate Three
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 125
Maturity date		Aug. 31, 2021
Interest rate		2.032%
Federal Home Loan Bank Advances | Borrowings Due September 2021
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Sep. 30, 2021
Interest rate		2.002%
Federal Home Loan Bank Advances | Borrowings Due May 2022, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 22
Maturity date		May 31, 2022
Interest rate		1.829%
Federal Home Loan Bank Advances | Borrowings Due May 2022, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100
Maturity date		May 31, 2022
Interest rate		1.78%
Federal Home Loan Bank Advances | Borrowings Due June 2022
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 10
Maturity date		Jun. 30, 2022
Interest rate		2.15%
Federal Home Loan Bank Advances | Borrowings Due July 2022 Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Jul. 31, 2022
Interest rate		1.726%
Federal Home Loan Bank Advances | Borrowings Due July 2022 Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Jul. 31, 2022
Interest rate		1.745%
Federal Home Loan Bank Advances | Borrowings Due July 2022 Rate 3
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Jul. 31, 2022
Interest rate		1.758%
Federal Home Loan Bank Advances | Borrowings Due August 2022
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Aug. 31, 2022
Interest rate		1.782%
Federal Home Loan Bank Advances | Borrowings Due December 2022, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Dec. 31, 2022
Interest rate		1.795%
Federal Home Loan Bank Advances | Borrowings Due December 2022, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50
Maturity date		Dec. 31, 2022
Interest rate		1.795%
Federal Home Loan Bank Advances | Borrowings due March 2023
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 24.7
Maturity date		Mar. 31, 2023
Interest rate		2.16%
Federal Home Loan Bank Advances | Borrowings due June 2025
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 20.5
Maturity date		Jun. 30, 2025
Interest rate		2.94%

SUMMARY OF SIGNIFICANT ACCOUN51

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (MULTIBUCKET ANNUITY PRODUCTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Return of premium annual percentage, multibucket annuity	3.00%
Insurance liabilities held, related to multibucket annuity products	$ 32.3	$ 32.8

SUMMARY OF SIGNIFICANT ACCOUN52

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (SALE OF INDUCEMENTS) (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Deferred sales inducements	$ 2	$ 3.4	$ 3.8
Deferred sales inducements, amortization expense	8.9	11.4	$ 13.8
Unamortized deferred sales inducements	42.5	49.4
Insurance liabilities for persistency bonus benefits	$ 0.3	$ 0.5

SUMMARY OF SIGNIFICANT ACCOUN53

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (OUT-OF-PERIOD ADJUSTMENTS) (NARRATIVE) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease to Insurance policy benefits									$ (2,602.7)	$ (2,390.5)	$ (2,308.3)
Other operating costs and expenses									(841.5)	(796.3)	(739.2)
Increase in income tax expense	$ (196.3)	$ (29.1)	$ (45.1)	$ (34.4)	$ 53.5	$ (30.7)	$ (22.8)	$ 5	(304.9)	5	(97)
Out of period adjustment, effect on net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7
Adjustment to earnings per diluted share (in dollars per share)	$ (0.42)	$ 0.59	$ 0.48	$ 0.36	$ 1.34	$ 0.11	$ 0.33	$ 0.25	$ 1.02	$ 2.01	$ 1.39
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease to Insurance policy benefits									$ (4.2)
Other operating costs and expenses									2
Increase in income tax expense									0.8
Out of period adjustment, effect on net income									$ 1.4
Adjustment to earnings per diluted share (in dollars per share)									$ 0.01

SUMMARY OF SIGNIFICANT ACCOUN54

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	$ 0
Cumulative effect of accounting change		$ 0.3
Revenue | Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk, percentage	1.00%
Retained earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	$ (205.4)
Cumulative effect of accounting change		$ (0.6)
Retained earnings | Pro Forma | Accounting Standards Update 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of accounting change	17
Accumulated other comprehensive income
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	205.4
Accumulated other comprehensive income | Pro Forma | Accounting Standards Update 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of accounting change	$ (17)

SUMMARY OF SIGNIFICANT ACCOUN55

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENT BALANCE SHEET iNFO) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets	$ 967.9	$ 1,045.9	$ 1,647.7
Valuation allowance for deferred income tax assets	(89.1)	(255.9)	(240.2)	$ (213.5)	$ (246)
Net deferred tax assets	376.2	790	785.6
Total assets	33,110.3	31,975.5	31,975.2
Additional paid-in capital	3,073.3	3,213	3,212.1
Retained earnings	560.4	650.1	650.7
Total shareholders' equity	4,847.5	4,487.2	4,486.9	$ 4,138.5	$ 4,688.2
Total liabilities and shareholders' equity	$ 33,110.3	31,975.5	$ 31,975.2
Amounts prior to effect of adoption of authoritative guidance
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets		1,029.9
Valuation allowance for deferred income tax assets		(240.2)
Net deferred tax assets		789.7
Total assets		31,975.2
Additional paid-in capital		3,212.1
Retained earnings		650.7
Total shareholders' equity		4,486.9
Total liabilities and shareholders' equity		31,975.2
Election to account for forfeitures as they occur
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets		0.3
Valuation allowance for deferred income tax assets		0
Net deferred tax assets		0.3
Total assets		0.3
Additional paid-in capital		0.9
Retained earnings		(0.6)
Total shareholders' equity		0.3
Total liabilities and shareholders' equity		0.3
Recognition of excess tax benefits
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets		15.7
Valuation allowance for deferred income tax assets		15.7
Net deferred tax assets		0
Total assets		0
Additional paid-in capital		0
Retained earnings		0
Total shareholders' equity		0
Total liabilities and shareholders' equity		$ 0

SUMMARY OF SIGNIFICANT ACCOUN56

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENT CASH FLOW INFO) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Other operating costs	$ (740.9)	$ (747.9)	$ (720.5)
Cash flows from operating activities	613.1	762.8	747.8
Cash flows from financing activities:
Payments to repurchase common stock	(168.3)	(210)	(365.4)
Net cash provided by financing activities	(274)	26.2	142.5
Net increase in cash and cash equivalents	$ 99.5	46.6	(179.3)
Amounts prior to effect of adoption of authoritative guidance
Cash flows from operating activities:
Other operating costs		(751.2)	(724.4)
Cash flows from operating activities		759.5	743.9
Cash flows from financing activities:
Payments to repurchase common stock		(206.7)	(361.5)
Net cash provided by financing activities		29.5	146.4
Net increase in cash and cash equivalents		46.6	(179.3)
Effect of adoption of authoritative guidance
Cash flows from operating activities:
Other operating costs		3.3	3.9
Cash flows from operating activities		3.3	3.9
Cash flows from financing activities:
Payments to repurchase common stock		(3.3)	(3.9)
Net cash provided by financing activities		(3.3)	(3.9)
Net increase in cash and cash equivalents		$ 0	$ 0

INVESTMENTS (SCHEDULE OF FIXED

INVESTMENTS (SCHEDULE OF FIXED MATURITIES FOR AVAILABLE FOR SALE AND EQUITY SECURITIES) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 20,702.1	$ 19,803.1
Gross unrealized gains	2,251.3	1,487.4
Gross unrealized losses	(42.5)	(194.3)
Estimated fair value	22,910.9	21,096.2
Other-than-temporary impairments included in accumulated other comprehensive income	(1)	(8)
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	491.1	580.7
Gross unrealized gains	23.6	11.5
Gross unrealized losses	(3)	(8)
Estimated fair value	511.7	584.2
Investment Grade
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	18,052.7	16,733.1
Gross unrealized gains	2,032.6	1,359.2
Gross unrealized losses	(27.9)	(143.9)
Estimated fair value	20,057.4	17,948.4
Other-than-temporary impairments included in accumulated other comprehensive income	(0.2)	0
Investment Grade | Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	12,419.3	11,582.6
Gross unrealized gains	1,670.7	1,073.9
Gross unrealized losses	(14.6)	(99.8)
Estimated fair value	14,075.4	12,556.7
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | US treasury and government
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	146.4	143.8
Gross unrealized gains	31.5	20.5
Gross unrealized losses	(0.2)	0
Estimated fair value	177.7	164.3
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | States and political subdivisions
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,819.9	1,798.2
Gross unrealized gains	234.8	186.7
Gross unrealized losses	(0.4)	(7.9)
Estimated fair value	2,054.3	1,977
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | Debt securities issued by foreign governments
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	79.5	37.1
Gross unrealized gains	3.8	0.2
Gross unrealized losses	(0.2)	(0.4)
Estimated fair value	83.1	36.9
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,730.7	1,169.6
Gross unrealized gains	39.7	29.2
Gross unrealized losses	(3.2)	(8.7)
Estimated fair value	1,767.2	1,190.1
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | Collateralized debt obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	257.1	227.5
Gross unrealized gains	2.3	1
Gross unrealized losses	0	(0.3)
Estimated fair value	259.4	228.2
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,304.1	1,467.2
Gross unrealized gains	33.2	32.9
Gross unrealized losses	(9.1)	(26.6)
Estimated fair value	1,328.2	1,473.5
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | Mortgage pass-through securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1.8	2.3
Gross unrealized gains	0.2	0.2
Gross unrealized losses	0	0
Estimated fair value	2	2.5
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Investment Grade | Collateralized mortgage obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	293.9	304.8
Gross unrealized gains	16.4	14.6
Gross unrealized losses	(0.2)	(0.2)
Estimated fair value	310.1	319.2
Other-than-temporary impairments included in accumulated other comprehensive income	(0.2)	0
Below-investment grade
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	2,649.4	3,070
Gross unrealized gains	218.7	128.2
Gross unrealized losses	(14.6)	(50.4)
Estimated fair value	2,853.5	3,147.8
Other-than-temporary impairments included in accumulated other comprehensive income	(0.8)	(8)
Below-investment grade | Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	867	967.3
Gross unrealized gains	28.4	26.1
Gross unrealized losses	(12.4)	(39.2)
Estimated fair value	883	954.2
Other-than-temporary impairments included in accumulated other comprehensive income	0	(3.6)
Below-investment grade | States and political subdivisions
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	2	13.6
Gross unrealized gains	0	0
Gross unrealized losses	0	(1.7)
Estimated fair value	2	11.9
Other-than-temporary impairments included in accumulated other comprehensive income	0	(3)
Below-investment grade | Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,355.2	1,471.9
Gross unrealized gains	132.9	55.1
Gross unrealized losses	(0.9)	(6.8)
Estimated fair value	1,487.2	1,520.2
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Below-investment grade | Collateralized debt obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost		2.5
Gross unrealized gains		0
Gross unrealized losses		0
Estimated fair value		2.5
Other-than-temporary impairments included in accumulated other comprehensive income		0
Below-investment grade | Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	49.9	63.8
Gross unrealized gains	0.6	0.2
Gross unrealized losses	(1.2)	(1.3)
Estimated fair value	49.3	62.7
Other-than-temporary impairments included in accumulated other comprehensive income	0	0
Below-investment grade | Collateralized mortgage obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	375.3	550.9
Gross unrealized gains	56.8	46.8
Gross unrealized losses	(0.1)	(1.4)
Estimated fair value	432	596.3
Other-than-temporary impairments included in accumulated other comprehensive income	$ (0.8)	$ (1.4)

INVESTMENTS (SUMMARY OF FIXED M

INVESTMENTS (SUMMARY OF FIXED MATURITY SECURITIES AVAILABLE FOR SALE) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 20,702.1	$ 19,803.1
Estimated fair value	$ 22,910.9	$ 21,096.2
Percentage of total estimated fair value	100.00%
NAIC designation 1
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 9,923.7
Estimated fair value	$ 11,028.5
Percentage of total estimated fair value	48.10%
NAIC designation 2
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 9,821.6
Estimated fair value	$ 10,906.2
Percentage of total estimated fair value	47.60%
Total NAIC Designation 1 and 2
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 19,745.3
Estimated fair value	$ 21,934.7
Percentage of total estimated fair value	95.70%
NAIC designation 3
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 676.2
Estimated fair value	$ 693.8
Percentage of total estimated fair value	3.00%
NAIC designation 4
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 225
Estimated fair value	$ 225.9
Percentage of total estimated fair value	1.00%
NAIC designation 5
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 46.3
Estimated fair value	$ 45.9
Percentage of total estimated fair value	0.20%
NAIC designation 6
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 9.3
Estimated fair value	$ 10.6
Percentage of total estimated fair value	0.10%
Total NAIC Designation 3, 4, 5 and 6
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 956.8
Estimated fair value	$ 976.2
Percentage of total estimated fair value	4.30%

INVESTMENTS (SCHEDULE OF ACCUMU

INVESTMENTS (SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$ 2.6	$ (1.1)
Net unrealized gains on all other investments	2,227.3	1,311.9
Adjustment to present value of future profits	(94)	(106.2)
Adjustment to deferred acquisition costs	(292.6)	(223.5)
Adjustment to insurance liabilities	(295.8)	(13.5)
Deferred income tax liabilities	(335.4)	(345.2)
Accumulated other comprehensive income	$ 1,212.1	$ 622.4

INVESTMENTS (NARRATIVE) (Detail

INVESTMENTS (NARRATIVE) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)investmentstate	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Schedule of Available-for-sale Securities [Line Items]
Premium deficiencies adjustments to present value of future profits	$ (83.8)	$ (94.1)
Reduction to deferred acquisition costs due to unrealized gains that would result in premium deficiency if unrealized gains were realized	(134.9)	(96.4)
Adjustment to insurance liabilities	(295.8)	(13.5)
Increase to deferred tax assets due to unrealized gains that would result in premium deficiency if unrealized gains were realized	111.1	72.5
Fixed maturities, available for sale, amortized cost	20,702.1	19,803.1
Estimated fair value	22,910.9	21,096.2
Carrying value of fixed maturity investments not accruing investment income	2.8
Carrying value mortgage loans not accruing investment income	10.6
Net realized investment gains (losses)	50.3	8.3	$ (36.6)
Net realized investment gains (losses), excluding impairment losses	77.4	47.9	(8)
Gain (loss) on dissolution of variable interest entities	(4.3)	(7.3)	11.3
Net impairment losses recognized	(22.8)	(32.3)	(39.9)
Total other-than-temporary impairment losses	21.9	35.9	42.9
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	$ (0.9)	3.6	3
Number of investments in default or considered nonperforming | investment	1
Fixed maturities in default, aggregate amortized cost	$ 0.5
Fixed maturities in default, carrying value	0.4
Value of available for sale securities sold	427.6	790.2	724.4
Other than temporary impairment losses, losses on other investments following unforeseen events	10.9	5.4	5.4
Other-than-temporary impairments included in accumulated other comprehensive income	1	8
Estimated fair value	$ 5,635.4
Percent of fixed maturities	24.60%
Number of additional states greater than specified percentage of mortgage loan balance | state	0
Mortgage loans in process of foreclosure	$ 10.6
Mortgage loans	1,650.6	1,768
Assets held by insurance regulators	$ 38.5	36.7
Minimum
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	5.00%
California
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	14.00%
Texas
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	12.00%
Maryland
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	8.00%
Florida
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	6.00%
ILLINOIS
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	5.00%
Total fixed maturities, available for sale
Schedule of Available-for-sale Securities [Line Items]
Net realized investment gains (losses)	$ 30.4	30.9	(7.6)
Net impairment losses recognized	(12.5)	(15.2)	(17.9)
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3
Gross realized losses on sale	24.2	95.2	88.4
Embedded Derivative Financial Instruments
Schedule of Available-for-sale Securities [Line Items]
Loss on embedded derivatives		(0.4)	(9.2)
Gain on embedded derivatives	11.5
Coinsurance | Embedded Derivative Financial Instruments
Schedule of Available-for-sale Securities [Line Items]
Loss on embedded derivatives			(7)
Gain on embedded derivatives	2.8	0.8
Marketable Securities
Schedule of Available-for-sale Securities [Line Items]
Net realized investment gains (losses), excluding impairment losses	63.1	47.5	8.2
Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale	16.8	79.2
Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale	3.6	5.8
Other Investments
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale	3.8	4.5
Fixed income investments | Energy Sector
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses	6.7	9.3	10.2
Gross realized losses on sale		63.5	59.7
Direct Loan
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses		3.7
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale		5.7
Preferred Stock
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses		12.7
Commercial bank loans held by VIEs
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses		1.2	16.4
Legacy private company investments
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses			$ 7.9
Mortgage loans
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses	5.2
Non Investment Grade
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 2,649.4	3,070
Percentage of available-for-sale debt securities	13.00%
Estimated fair value	$ 2,853.5	3,147.8
Available-for-sale securities, percentage of amortized cost	108.00%
Other-than-temporary impairments included in accumulated other comprehensive income	$ 0.8	$ 8
Continuous unrealized loss position	20.00%
Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	$ 1,613.5
Total carrying amount | Residential Mortgage
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	37.1
Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	1,640
Estimate of fair value | Residential Mortgage
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	$ 37.3

INVESTMENTS (SCHEDULE OF INVEST

INVESTMENTS (SCHEDULE OF INVESTMENTS CLASSIFIED BY CONTRACTUAL MATURITY DATE) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Available-for-sale Securities, Debt Maturities, Single Maturity Date, Amortized Cost Basis [Abstract]
Due in one year or less	$ 328.1
Due after one year through five years	1,947.3
Due after five years through ten years	1,508.7
Due after ten years	11,550
Subtotal	15,334.1
Structured securities	5,368
Amortized cost	20,702.1	$ 19,803.1
Available-for-sale Securities, Debt Maturities, Single Maturity Date [Abstract]
Due in one year or less	335.1
Due after one year through five years	2,052.3
Due after five years through ten years	1,601.3
Due after ten years	13,286.8
Subtotal	17,275.5
Structured securities	5,635.4
Estimated fair value	$ 22,910.9	$ 21,096.2

INVESTMENTS (SCHEDULE OF INVE62

INVESTMENTS (SCHEDULE OF INVESTMENT INCOME) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Trading Securities and Other Trading Assets [Line Items]
Fixed maturities	$ 1,133.8	$ 1,081.4	$ 1,090.1
Equity securities	25.3	21.5	18.3
Mortgage loans	91.5	91	91.4
Policy loans	7.7	7.3	7.3
Other invested assets	44.4	24.3	17.4
Cash and cash equivalents	5.9	2	0.8
Trading securities	12.8	12.2	10.7
Option income (loss)	110.3	(40.1)	36.5
Change in value of options	52.2	69.3	(72.7)
Other special-purpose portfolios	90.6	79.7	55.5
Gross investment income	1,574.5	1,348.6	1,255.3
Less investment expenses	23.2	23.4	21.7
Net investment income	1,551.3	1,325.2	1,233.6
Investment Income
Schedule of Trading Securities and Other Trading Assets [Line Items]
Increase (decrease) in trading securities	$ 3.8	$ (0.2)	$ 0.4

INVESTMENTS (SCHEDULE OF REALIZ

INVESTMENTS (SCHEDULE OF REALIZED GAIN (LOSS) ON INVESTMENTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Investment [Line Items]
Total other than temporary impairment losses	$ 22.8	$ 32.3	$ 39.9
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3
Net realized investment gains (losses)	50.3	8.3	(36.6)
Gain (loss) on dissolution of variable interest entities	(4.3)	(7.3)	11.3
Total fixed maturities, available for sale
Investment [Line Items]
Gross realized gains on sale	68	137.7	95.7
Gross realized losses on sale	(24.2)	(95.2)	(88.4)
Total other than temporary impairment losses	12.5	15.2	17.9
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3
Net impairment losses recognized	(13.4)	(11.6)	(14.9)
Net realized investment gains (losses)	30.4	30.9	(7.6)
Equity securities
Investment [Line Items]
Net realized investment gains (losses)	11.6	20.9	3.7
Mortgage loans
Investment [Line Items]
Net realized investment gains (losses)	1.1	0	(2.3)
Impairments of preferred stock and other investments [Member]
Investment [Line Items]
Net realized investment gains (losses)	(9.4)	(20.7)	(25)
Other [Member]
Investment [Line Items]
Net realized investment gains (losses)	20.9	(15.5)	(16.7)
Investments
Investment [Line Items]
Change in estimated fair value of trading securities	$ 12.8	$ (0.5)	$ (9.2)

INVESTMENTS (SCHEDULE OF INVE64

INVESTMENTS (SCHEDULE OF INVESTMENTS IN OUR PORTFOLIO WHICH HAVE BEEN CONTINUOUSLY IN AN UNREALIZED LOSS POSITION EXCEEDING 20% OF AMORTIZED COST PRIOR TO SALE (Details) - Fixed Maturities $ in Millions	Dec. 31, 2017USD ($)issuer
Schedule of Available-for-sale Securities [Line Items]
Less than 6 months prior to sale, Number of issuers | issuer	4
Greater than or equal to 6 months and less than 12 months prior to sale, Number of issuers | issuer	1
Greater than or equal to 12 months prior to sale, Number of issuers | issuer	1
Number of issuers, Total | issuer	6
Less than 6 months prior to sale, Amortized cost	$ 17.8
Greater than or equal to 6 months and less than 12 months prior to sale, Amortized cost	2.7
Greater than or equal to 12 months prior to sale, Amortized cost	0.7
Amortized cost, Total	21.2
Less than 6 months prior to sale, Fair value	13
Greater than or equal to 6 months and less than 12 months prior to sale, Fair value	1.9
Greater than or equal to 12 months prior to sale, Fair Value	0.5
Fair value, Total	$ 15.4

INVESTMENTS (SCHEDULE OF CREDIT

INVESTMENTS (SCHEDULE OF CREDIT LOSSES RECOGNIZED IN EARNINGS) (Details) - Available-for-sale securities - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Roll Forward]
Credit losses on fixed maturity securities, available for sale, beginning of period	$ (5.5)	$ (2.6)	$ (1)
Add: credit losses on other-than-temporary impairments not previously recognized	0	(3)	(2)
Less: credit losses on securities sold	4.7	0.1	0.4
Less: credit losses on securities impaired due to intent to sell	0	0	0
Add: credit losses on previously impaired securities	(2)	0	0
Less: increases in cash flows expected on previously impaired securities	0	0	0
Credit losses on fixed maturity securities, available for sale, end of period	$ (2.8)	$ (5.5)	$ (2.6)

INVESTMENTS (SCHEDULE OF INVE66

INVESTMENTS (SCHEDULE OF INVESTMENTS WITH UNREALIZED LOSSES CLASSIFIED BY CONTRACTUAL MATURITY DATE) (Details) $ in Millions	Dec. 31, 2017USD ($)
Amortized cost
Due in one year or less	$ 26.9
Due after one year through five years	195.4
Due after five years through ten years	108.9
Due after ten years	602
Subtotal	933.2
Structured securities	1,268.3
Total	2,201.5
Estimated fair value
Due in one year or less	26.9
Due after one year through five years	193.3
Due after five years through ten years	105.2
Due after ten years	580
Subtotal	905.4
Structured securities	1,253.6
Total	$ 2,159

INVESTMENTS (SCHEDULE OF INVE67

INVESTMENTS (SCHEDULE OF INVESTMENTS IN OUR PORTFOLIO RATED BELOW-INVESTMENT GRADE WHICH HAVE BEEN CONTINUOUSLY IN AN UNREALIZED LOSS POSITION EXCEEDING 20% OF THE COST BASIS (Details) $ in Millions	Dec. 31, 2017USD ($)issuer	Dec. 31, 2016USD ($)
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses, total	$ (42.5)	$ (194.3)
Fair value, total	$ 2,159	$ 4,500.6
Non Investment Grade
Schedule of Available-for-sale Securities [Line Items]
Less than 6 months, Number of issuers | issuer	1
Less than 6 months, Cost basis	$ 9.2
Cost basis, Total	9.2
Less than 6 months, Unrealized loss	(1.9)
Unrealized losses, total	(1.9)
Less than 6 months, Estimated fair value	7.3
Fair value, total	$ 7.3

INVESTMENTS (SCHEDULE OF UNREAL

INVESTMENTS (SCHEDULE OF UNREALIZED LOSS ON INVESTMENTS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	$ 1,426.4	$ 3,440.8
Unrealized losses, less than 12 months	(11.1)	(109.5)
Fair value, twelve months or greater, Fair value	732.6	1,059.8
Unrealized losses, 12 months or greater	(31.4)	(84.8)
Fair value, total	2,159	4,500.6
Unrealized losses, total	(42.5)	(194.3)
US treasury and government
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	28.2	8
Unrealized losses, less than 12 months	(0.2)	0
Fair value, twelve months or greater, Fair value	0.7	0
Unrealized losses, 12 months or greater	0	0
Fair value, total	28.9	8
Unrealized losses, total	(0.2)	0
States and political subdivisions
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	18.3	176.3
Unrealized losses, less than 12 months	(0.1)	(7.8)
Fair value, twelve months or greater, Fair value	14.9	18.3
Unrealized losses, 12 months or greater	(0.3)	(1.8)
Fair value, total	33.2	194.6
Unrealized losses, total	(0.4)	(9.6)
Debt securities issued by foreign governments
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	7.7	18.9
Unrealized losses, less than 12 months	(0.1)	(0.4)
Fair value, twelve months or greater, Fair value	5.4	0
Unrealized losses, 12 months or greater	(0.1)	0
Fair value, total	13.1	18.9
Unrealized losses, total	(0.2)	(0.4)
Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	470.5	1,907.6
Unrealized losses, less than 12 months	(6.8)	(75.5)
Fair value, twelve months or greater, Fair value	359.7	559.6
Unrealized losses, 12 months or greater	(20.2)	(63.5)
Fair value, total	830.2	2,467.2
Unrealized losses, total	(27)	(139)
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	601.4	692.9
Unrealized losses, less than 12 months	(2)	(8.5)
Fair value, twelve months or greater, Fair value	122.2	262.5
Unrealized losses, 12 months or greater	(2.1)	(7)
Fair value, total	723.6	955.4
Unrealized losses, total	(4.1)	(15.5)
Collateralized debt obligations
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	3	38.3
Unrealized losses, less than 12 months	0	(0.1)
Fair value, twelve months or greater, Fair value	0	30.8
Unrealized losses, 12 months or greater	0	(0.2)
Fair value, total	3	69.1
Unrealized losses, total	0	(0.3)
Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	276.8	525.2
Unrealized losses, less than 12 months	(1.7)	(16.6)
Fair value, twelve months or greater, Fair value	218.2	154
Unrealized losses, 12 months or greater	(8.6)	(11.3)
Fair value, total	495	679.2
Unrealized losses, total	(10.3)	(27.9)
Collateralized mortgage obligations
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	20.5	73.6
Unrealized losses, less than 12 months	(0.2)	(0.6)
Fair value, twelve months or greater, Fair value	11.5	34.6
Unrealized losses, 12 months or greater	(0.1)	(1)
Fair value, total	32	108.2
Unrealized losses, total	(0.3)	(1.6)
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	58.7	239.4
Unrealized losses, less than 12 months	(1.7)	(8)
Fair value, twelve months or greater, Fair value	21.2	0
Unrealized losses, 12 months or greater	(1.3)	0
Fair value, total	79.9	239.4
Unrealized losses, total	$ (3)	$ (8)

INVESTMENTS (SCHEDULE OF STRUCT

INVESTMENTS (SCHEDULE OF STRUCTURED SECURITIES) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	$ 5,826
Amortized cost	5,368
Estimated fair value	$ 5,635.4
Percent of fixed maturities	24.60%
Pass-throughs, sequential and equivalent securities[Member]
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 557.7
Estimated fair value	$ 617.2
Percent of fixed maturities	2.70%
Planned amortization classes, target amortization classes and accretion-directed bonds [Member]
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 95.3
Estimated fair value	$ 108.5
Percent of fixed maturities	0.50%
Commercial mortgage-backed securities
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 1,354
Estimated fair value	$ 1,377.5
Percent of fixed maturities	6.00%
Asset-backed securities
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 3,085.9
Estimated fair value	$ 3,254.4
Percent of fixed maturities	14.20%
Collateralized debt obligations
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 257.1
Estimated fair value	$ 259.4
Percent of fixed maturities	1.10%
Other
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 18
Estimated fair value	$ 18.4
Percent of fixed maturities	0.10%
Below 4 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	$ 2,101.7
Amortized cost	1,944.8
Estimated fair value	2,014.9
4 Percent - 5 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	1,656.3
Amortized cost	1,516
Estimated fair value	1,596.5
5 Percent - 6 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	1,407.1
Amortized cost	1,271.8
Estimated fair value	1,362.6
6 Percent - 7 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	286.6
Amortized cost	260.6
Estimated fair value	276.8
7 Percent - 8 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	83
Amortized cost	83.7
Estimated fair value	92.5
8 Percent and Above
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	291.3
Amortized cost	291.1
Estimated fair value	$ 292.1
Minimum | 4 Percent - 5 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	4.00%
Minimum | 5 Percent - 6 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	5.00%
Minimum | 6 Percent - 7 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	6.00%
Minimum | 7 Percent - 8 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	7.00%
Minimum | 8 Percent and Above
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	8.00%
Maximum | Below 4 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	4.00%
Maximum | 4 Percent - 5 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	5.00%
Maximum | 5 Percent - 6 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	6.00%
Maximum | 6 Percent - 7 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	7.00%
Maximum | 7 Percent - 8 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	8.00%

INVESTMENTS (SUMMARY OF WEIGHTE

INVESTMENTS (SUMMARY OF WEIGHTED AVERAGE LOAN-TO-VALUE RATIO FOR OUTSTANDING MORTGAGE LOANS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 1,650.6	$ 1,768
Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	1,613.5
Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	1,640
Collateral	3,292.1
Less than 60% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	944.7
Less than 60% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	960.8
Collateral	$ 2,330.6
Less than 60% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	60.00%
60% to 70% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 439.5
60% to 70% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	440.2
Collateral	$ 671.3
60% to 70% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	60.00%
60% to 70% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	70.00%
Greater than 70% to 80% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 138.4
Greater than 70% to 80% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	145.9
Collateral	$ 188.4
Greater than 70% to 80% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	70.00%
Greater than 70% to 80% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	80.00%
Greater than 80% to 90% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 52.3
Greater than 80% to 90% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	52.9
Collateral	$ 60.1
Greater than 80% to 90% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	80.00%
Greater than 80% to 90% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	90.00%
Greater than 90% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 38.6
Greater than 90% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	40.2
Collateral	$ 41.7
Greater than 90% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	90.00%

FAIR VALUE MEASUREMENTS (NARRAT

FAIR VALUE MEASUREMENTS (NARRATIVE) (Details)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair value of level 3 fixed maturity securities valued using broker quotes, percentage	29.00%
Available for sale fixed maturities classified as level 3, investment grade, percent	52.00%
Available for sale fixed maturities classified as level 3, corporate securities, percent	89.00%

FAIR VALUE MEASUREMENTS (FAIR V

FAIR VALUE MEASUREMENTS (FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS MEASURED ON A RECURRING BASIS - SECURITIES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	$ 22,910.9	$ 21,096.2
Trading securities	284.6	363.4
Investments held by variable interest entities - corporate securities	1,526.9	1,724.3
Assets held in separate accounts	5	4.7
Fair value, measurements, recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	284.6	363.4
Investments held by variable interest entities - corporate securities	1,526.9	1,724.3
Assets held in separate accounts	5	4.7
Total assets carried at fair value by category	25,409.3	23,884.7
Fair value, measurements, recurring | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	170.2	111.9
Fair value, measurements, recurring | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	1,334.8	1,092.3
Fair value, measurements, recurring | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	14,958.4	13,510.9
Equity securities - corporate securities	511.7	584.2
Trading securities	21.6	19
Fair value, measurements, recurring | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	177.7	164.3
Trading securities	0.5	0.5
Fair value, measurements, recurring | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2,056.3	1,988.9
Fair value, measurements, recurring | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	83.1	36.9
Fair value, measurements, recurring | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	3,254.4	2,710.3
Trading securities	95.8	94.3
Fair value, measurements, recurring | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	259.4	230.7
Trading securities	2.7	2.4
Fair value, measurements, recurring | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	1,377.5	1,536.2
Trading securities	92.5	163.9
Fair value, measurements, recurring | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2	2.5
Fair value, measurements, recurring | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	742.1	915.5
Trading securities	68.7	78.4
Fair value, measurements, recurring | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	22,910.9	21,096.2
Fair value, measurements, recurring | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	2.8	4.9
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	2.8	4.9
Investments held by variable interest entities - corporate securities	0	0
Assets held in separate accounts	0	0
Total assets carried at fair value by category	290.6	364.8
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Equity securities - corporate securities	287.8	359.9
Trading securities	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Trading securities	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Trading securities	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Trading securities	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Trading securities	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Trading securities	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	2.8	4.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	281.8	358.5
Investments held by variable interest entities - corporate securities	1,522	1,724.3
Assets held in separate accounts	5	4.7
Total assets carried at fair value by category	24,834.1	23,134.5
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	170.2	111.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	0	0
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	14,728	13,252.4
Equity securities - corporate securities	202.7	199.1
Trading securities	21.6	19
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	177.7	164.3
Trading securities	0.5	0.5
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2,056.3	1,988.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	79.2	33
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	3,230.2	2,649.9
Trading securities	95.8	94.3
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	259.4	225.3
Trading securities	2.7	2.4
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	1,377.5	1,504.2
Trading securities	92.5	163.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2	2.5
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	742.1	915.5
Trading securities	68.7	78.4
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	22,652.4	20,736
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	0	0
Investments held by variable interest entities - corporate securities	4.9	0
Assets held in separate accounts	0	0
Total assets carried at fair value by category	284.6	385.4
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	1,334.8	1,092.3
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	230.4	258.5
Equity securities - corporate securities	21.2	25.2
Trading securities	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Trading securities	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	3.9	3.9
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	24.2	60.4
Trading securities	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	5.4
Trading securities	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	32
Trading securities	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0	0
Trading securities	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	258.5	360.2
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	$ 0	$ 0

FAIR VALUE MEASUREMENTS (FAIR73

FAIR VALUE MEASUREMENTS (FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS MEASURED ON A RECURRING BASIS - FINANCIAL INSTRUMENTS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents - unrestricted	$ 578.4	$ 478.9	$ 432.3	$ 611.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Fair value, measurements, recurring | Total estimated fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	1,677.3	1,800.1
Policy loans	116	112
Company-owned life insurance	182.3	165
Cash and cash equivalents - unrestricted	578.4	478.9
Cash and cash equivalents held by variable interest entities	178.9	189.3
Policyholder account balances	11,220.7	10,912.7
Investment borrowings	1,648.8	1,650
Borrowings related to variable interest entities	1,432.9	1,675.2
Notes payable – direct corporate obligations	962.3	931.9
Fair value, measurements, recurring | Total carrying amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	1,650.6	1,768
Policy loans	116	112
Company-owned life insurance	182.3	165
Cash and cash equivalents - unrestricted	578.4	478.9
Cash and cash equivalents held by variable interest entities	178.9	189.3
Policyholder account balances	11,220.7	10,912.7
Investment borrowings	1,646.7	1,647.4
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable – direct corporate obligations	914.6	912.9
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	0	0
Policy loans	0	0
Company-owned life insurance	0	0
Cash and cash equivalents - unrestricted	578.4	473.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Policyholder account balances	0	0
Investment borrowings	0	0
Borrowings related to variable interest entities	0	0
Notes payable – direct corporate obligations	0	0
Fair value, measurements, recurring | Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	0	0
Policy loans	0	0
Company-owned life insurance	182.3	165
Cash and cash equivalents - unrestricted	0	5.3
Cash and cash equivalents held by variable interest entities	0	0
Policyholder account balances	0	0
Investment borrowings	1,648.8	1,650
Borrowings related to variable interest entities	1,432.9	1,675.2
Notes payable – direct corporate obligations	962.3	931.9
Fair value, measurements, recurring | Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	1,677.3	1,800.1
Policy loans	116	112
Company-owned life insurance	0	0
Cash and cash equivalents - unrestricted	0	0
Cash and cash equivalents held by variable interest entities	0	0
Policyholder account balances	11,220.7	10,912.7
Investment borrowings	0	0
Borrowings related to variable interest entities	0	0
Notes payable – direct corporate obligations	$ 0	$ 0

FAIR VALUE MEASUREMENTS (FAIR74

FAIR VALUE MEASUREMENTS (FAIR VALUE ASSETS AND LIABILITIES MEASURED ON A RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Liabilities:
Cash and cash equivalents - unrestricted	$ 578.4	$ 478.9	$ 432.3	$ 611.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Future policy benefits - embedded derivatives associated with fixed index annuity products
Liabilities:
Purchases, sales, issuances and settlements, net	(267.5)	(96)
Corporate securities
Assets:
Purchases, sales, issuances and settlements, net	(70.4)	76.5
Debt securities issued by foreign governments
Assets:
Purchases, sales, issuances and settlements, net		4
Asset-backed securities
Assets:
Purchases, sales, issuances and settlements, net	(4.3)	9.7
Collateralized debt obligations
Assets:
Purchases, sales, issuances and settlements, net	(2.5)	5.4
Commercial mortgage-backed securities
Assets:
Purchases, sales, issuances and settlements, net	(1.2)	16.9
Mortgage pass-through securities
Assets:
Purchases, sales, issuances and settlements, net		(0.1)
Total fixed maturities, available for sale
Assets:
Purchases, sales, issuances and settlements, net	(78.4)	112.4
Equity securities - corporate securities
Assets:
Purchases, sales, issuances and settlements, net	(8.5)	5.5
Fair Value, Inputs, Level 1 | Fair value, measurements, recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Mortgage Loans on Real Estate, Fair Value	0	0
Liabilities:
Loans Receivable, Fair Value Disclosure	0	0
Company-owned life insurance	0	0
Cash and cash equivalents - unrestricted	578.4	473.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Liabilities For Interest Sensitive Products, Excluding Embedded Derivatives	0	0
Investment Borrowings, Fair Value Disclosure	0	0
Borrowings Related To Variable Interest Entities, Fair Value Disclosure	0	0
Notes Payable, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 | Fair value, measurements, recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Mortgage Loans on Real Estate, Fair Value	0	0
Liabilities:
Loans Receivable, Fair Value Disclosure	0	0
Company-owned life insurance	182.3	165
Cash and cash equivalents - unrestricted	0	5.3
Cash and cash equivalents held by variable interest entities	0	0
Liabilities For Interest Sensitive Products, Excluding Embedded Derivatives	0	0
Investment Borrowings, Fair Value Disclosure	1,648.8	1,650
Borrowings Related To Variable Interest Entities, Fair Value Disclosure	1,432.9	1,675.2
Notes Payable, Fair Value Disclosure	962.3	931.9
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Mortgage Loans on Real Estate, Fair Value	1,677.3	1,800.1
Liabilities:
Loans Receivable, Fair Value Disclosure	116	112
Company-owned life insurance	0	0
Cash and cash equivalents - unrestricted	0	0
Cash and cash equivalents held by variable interest entities	0	0
Liabilities For Interest Sensitive Products, Excluding Embedded Derivatives	11,220.7	10,912.7
Investment Borrowings, Fair Value Disclosure	0	0
Borrowings Related To Variable Interest Entities, Fair Value Disclosure	0	0
Notes Payable, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Future policy benefits - embedded derivatives associated with fixed index annuity products
Liabilities:
Beginning balance	(1,092.3)	(1,057.1)
Purchases, sales, issuances and settlements, net	(267.5)	(96)
Total realized and unrealized gains (losses) included in net income	25	60.8
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0	0
Transfers into level 3	0	0
Transfers out of level 3	0	0
Ending balance	(1,334.8)	(1,092.3)
Amount of total gains (losses) for the year included in our net income related to liabilities still held as of the reporting date	25	60.8
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Corporate securities
Assets:
Beginning balance	258.5	170.4
Purchases, sales, issuances and settlements, net	(70.4)	76.5
Total realized and unrealized gains (losses) included in net income	5.8	(10.7)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	5.3	9.1
Transfers into level 3	31.2	20.3
Transfers out of level 3	0	(7.1)
Ending balance	230.4	258.5
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	(8)	(10.9)
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Debt securities issued by foreign governments
Assets:
Beginning balance	3.9	0
Purchases, sales, issuances and settlements, net	0	4
Total realized and unrealized gains (losses) included in net income	0	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0	(0.1)
Transfers into level 3	0	0
Transfers out of level 3	0	0
Ending balance	3.9	3.9
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0	0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Asset-backed securities
Assets:
Beginning balance	60.4	35.9
Purchases, sales, issuances and settlements, net	(4.3)	9.7
Total realized and unrealized gains (losses) included in net income	0	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.7	2.2
Transfers into level 3	0	26.3
Transfers out of level 3	(32.6)	(13.7)
Ending balance	24.2	60.4
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0	0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Collateralized debt obligations
Assets:
Beginning balance	5.4	0
Purchases, sales, issuances and settlements, net	(2.5)	5.4
Total realized and unrealized gains (losses) included in net income	0	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0	0
Transfers into level 3	0	0
Transfers out of level 3	(2.9)	0
Ending balance	0	5.4
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0	0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Commercial mortgage-backed securities
Assets:
Beginning balance	32	1.1
Purchases, sales, issuances and settlements, net	(1.2)	16.9
Total realized and unrealized gains (losses) included in net income	0.1	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	(0.1)	0.1
Transfers into level 3	0	13.9
Transfers out of level 3	(30.8)	0
Ending balance	0	32
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0	0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Mortgage pass-through securities
Assets:
Beginning balance	0	0.1
Purchases, sales, issuances and settlements, net		(0.1)
Total realized and unrealized gains (losses) included in net income		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		0
Transfers into level 3		0
Transfers out of level 3		0
Ending balance		0
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date		0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Total fixed maturities, available for sale
Assets:
Beginning balance	360.2	207.5
Purchases, sales, issuances and settlements, net	(78.4)	112.4
Total realized and unrealized gains (losses) included in net income	5.9	(10.7)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	5.9	11.3
Transfers into level 3	31.2	60.5
Transfers out of level 3	(66.3)	(20.8)
Ending balance	258.5	360.2
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	(8)	(10.9)
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Equity securities - corporate securities
Assets:
Beginning balance	25.2	32
Purchases, sales, issuances and settlements, net	(8.5)	5.5
Total realized and unrealized gains (losses) included in net income	6.3	(12.7)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	(1.8)	0.4
Transfers into level 3	0	0
Transfers out of level 3	0	0
Ending balance	21.2	25.2
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0	(12.7)
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Trading Securities [Member]
Assets:
Beginning balance	0	39.9
Purchases, sales, issuances and settlements, net		0
Total realized and unrealized gains (losses) included in net income		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		0
Transfers into level 3		0
Transfers out of level 3		(39.9)
Ending balance		0
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date		0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Investments Held By Variable Interest Entities
Assets:
Beginning balance	0
Purchases, sales, issuances and settlements, net	4.9
Total realized and unrealized gains (losses) included in net income	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0
Transfers into level 3	0
Transfers out of level 3	0
Ending balance	4.9	$ 0
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	$ 0

FAIR VALUE MEASUREMENTS (FAIR75

FAIR VALUE MEASUREMENTS (FAIR VALUE ASSETS AND LIABILITIES MEASURED ON A RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION - ACTIVITY) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Corporate securities
Assets:
Purchases	$ 76.6	$ 18.5
Received in reinsurance recapture		89.2
Sales	(147)	(31.2)
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(70.4)	76.5
Debt securities issued by foreign governments
Assets:
Purchases		4
Received in reinsurance recapture		0
Sales		0
Issuances		0
Settlements		0
Purchases, sales, issuances and settlements, net		4
Asset-backed securities
Assets:
Purchases	0	16.9
Received in reinsurance recapture		0
Sales	(4.3)	(7.2)
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(4.3)	9.7
Collateralized debt obligations
Assets:
Purchases	0	5.4
Received in reinsurance recapture		0
Sales	(2.5)	0
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(2.5)	5.4
Commercial mortgage-backed securities
Assets:
Purchases	0	17
Received in reinsurance recapture		0
Sales	(1.2)	(0.1)
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(1.2)	16.9
Mortgage pass-through securities
Assets:
Purchases		0
Received in reinsurance recapture		0
Sales		(0.1)
Issuances		0
Settlements		0
Purchases, sales, issuances and settlements, net		(0.1)
Total fixed maturities, available for sale
Assets:
Purchases	76.6	61.8
Received in reinsurance recapture		89.2
Sales	(155)	(38.6)
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(78.4)	112.4
Equity securities - corporate securities
Assets:
Purchases	0	3.3
Received in reinsurance recapture		2.2
Sales	(8.5)	0
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(8.5)	5.5
Trading securities - corporate securities
Assets:
Purchases		0.2
Received in reinsurance recapture		0
Sales		(0.2)
Issuances		0
Settlements		0
Purchases, sales, issuances and settlements, net		0
Future policy benefits - embedded derivatives associated with fixed index annuity products
Liabilities:
Purchases	(178.9)	(148.3)
Received in reinsurance recapture		0
Sales	5.4	21.2
Issuances	(159.3)	(28.9)
Settlements	65.3	60
Purchases, sales, issuances and settlements, net	(267.5)	$ (96)
Investments Held By Variable Interest Entities | Investments held by variable interest entities - corporate securities
Assets:
Purchases	8.9
Sales	(4)
Issuances	0
Settlements	0
Purchases, sales, issuances and settlements, net	$ 4.9

FAIR VALUE MEASUREMENTS (FAIR76

FAIR VALUE MEASUREMENTS (FAIR VALUE INPUTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 27,854.1	$ 26,237.6
Other invested assets	853.4	589.5
Policyholder account balances	11,220.7	10,912.7
Significant unobservable inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	284.6	385.4
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 149.2	$ 148.5
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	1.45%	1.35%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	71.29%	27.71%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	6.96%	13.52%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 24.2	$ 24
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	1.80%	2.06%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	3.71%	3.64%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	2.67%	2.76%
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 2.8	$ 14.8
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	0.00%	5.00%
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	21.73%	69.00%
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	18.42%	55.00%
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 21.2	$ 25.2
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected cash flows	110.00%	40.00%
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected cash flows	890.00%	620.00%
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected cash flows	110.00%	590.00%
Unadjusted Third-Party Price Source | Significant unobservable inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Other invested assets	$ 87.2	$ 172.9
Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Policyholder account balances	$ 1,334.8	$ 1,092.3
Future policy benefits - embedded derivatives associated with fixed index annuity products | Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3) | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected portfolio yields	5.15%	5.15%
Discount rates	0.92%	0.18%
Surrender rates	1.20%	0.94%
Future policy benefits - embedded derivatives associated with fixed index annuity products | Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3) | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected portfolio yields	5.61%	5.61%
Discount rates	2.51%	3.06%
Surrender rates	46.40%	46.48%
Future policy benefits - embedded derivatives associated with fixed index annuity products | Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3) | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected portfolio yields	5.60%	5.59%
Discount rates	2.00%	2.07%
Surrender rates	12.30%	13.52%

LIABILITIES FOR INSURANCE PRO77

LIABILITIES FOR INSURANCE PRODUCTS (SCHEDULE OF INSURANCE LIABILITIES BY PRODUCT SEGMENT) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Liability for Future Policy Benefit, by Product Segment [Line Items]
Future policy benefits	$ 11,521.3	$ 10,953.3
Policyholder account balance	$ 11,220.7	10,912.7
Long-term care
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	6.00%
Future policy benefits	$ 5,669	5,346.1
Traditional life insurance contracts
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	5.00%
Future policy benefits	$ 2,401.2	2,322.1
Accident and health contracts
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	5.00%
Future policy benefits	$ 2,812	2,695.6
Interest-sensitive life insurance contracts
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	5.00%
Future policy benefits	$ 44.9	52.2
Policyholder account balance	$ 1,094.7	1,046.4
Annuities and supplemental contracts with life contingencies
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	4.00%
Future policy benefits	$ 594.2	537.3
Fixed index annuities
Liability for Future Policy Benefit, by Product Segment [Line Items]
Policyholder account balance	5,942.2	5,324.5
Other annuities
Liability for Future Policy Benefit, by Product Segment [Line Items]
Policyholder account balance	$ 4,183.8	$ 4,541.8

LIABILITIES FOR INSURANCE PRO78

LIABILITIES FOR INSURANCE PRODUCTS (SUMMARY OF LIABILITIES FOR UNPAID CLAIMS ADJUSTMENT EXPENSE) (Details) - Accident and Health Insurance Product Line - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of year	$ 1,777.6	$ 1,731.8	$ 1,679.5
Less reinsurance (receivables) payables	14	(130)	(125)
Net balance, beginning of year	1,791.6	1,601.8	1,554.5
Incurred claims related to:
Current year	1,548.1	1,526.4	1,481
Prior years	(26.7)	96.6	(13.3)
Total incurred	1,521.4	1,623	1,467.7
Interest on claim reserves	78.4	75.3	71
Paid claims related to:
Current year	845.5	837.2	841.8
Prior years	702.6	671.3	649.6
Total paid	1,548.1	1,508.5	1,491.4
Net balance, end of year	1,843.3	1,791.6	1,601.8
Add reinsurance receivables (payables)	(15.1)	(14)	130
Balance, end of year	$ 1,828.2	$ 1,777.6	$ 1,731.8

INCOME TAXES (SCHEDULE OF COMPO

INCOME TAXES (SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current tax expense (benefit)									$ 90.8	$ (45.2)	$ 10.7
Deferred tax expense									72	173	118.6
Valuation allowance applicable to current year income									(15.3)	(14)	0
Income tax expense calculated based on annual effective tax rate									147.5	113.8	129.3
Income tax expense on discrete items:
Change in valuation allowance									(13.4)	40.7	(32.5)
Impact of federal tax reform									310.6	0	0
Impact of federal tax reform									(138.1)	0	0
IRS settlement					$ (118.7)				0	(170.4)	0
Other items									(1.7)	10.9	0.2
Total income tax expense (benefit)	$ 196.3	$ 29.1	$ 45.1	$ 34.4	$ (53.5)	$ 30.7	$ 22.8	$ (5)	$ 304.9	$ (5)	$ 97

INCOME TAXES (NARRATIVE) (Detai

INCOME TAXES (NARRATIVE) (Details) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)position	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jan. 01, 2017USD ($)	Dec. 31, 2014USD ($)	May 11, 2010	Jan. 20, 2009right
Operating Loss Carryforwards [Line Items]
Tax reform provisional income tax expense (benefit)	$ 172.5		$ 172.5
Deferred tax assets more likely than not to be realized through future taxable earnings	376.2	$ 785.6	376.2	$ 785.6		$ 790
Deferred tax assets	465.3	1,025.8	465.3	1,025.8
Valuation allowance for deferred income tax assets	$ 89.1	240.2	$ 89.1	240.2	$ 213.5	$ 255.9	$ 246
Aggregate growth rate for the next five years	3.00%		3.00%
Forecast period of model			5 years
Adjusted average taxable income			$ 345
Adjusted average nonlife taxable income			85
Adjusted average life taxable income			260
Increase (decrease) in valuation allowance			$ 151.1	(26.7)	32.5
Loss limitation based on income of life insurance company, percent	35.00%		35.00%
Loss limitation based on loss of non-life entities, percent	35.00%		35.00%
Federal long-term tax exempt rate	1.96%		1.96%
Ownership change threshold restricting NOL usage	50.00%		50.00%
Ownership percentage threshold relating to company 382 provision, ownership percentage at which transfers of common stock become void (less than)								5.00%
Number of rights for each share | right									1
Ownership percentage threshold relating to company 382 securities									4.99%
Net operating loss carryforwards	$ 2,331.4		$ 2,331.4
Net state operating loss carryforwards	9.3	$ 12.3	9.3	12.3
Number of tax positions settled | position		2
IRS settlement		$ 118.7	0	170.4	0
Reduction in interest recognized from prior periods on alternative minimum tax		3.4
Decrease to income tax accrued			227.5	$ (11.7)	$ 92.9
Future cash tax payments as a percent of life insurance, taxable income due				65.00%
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Valuation allowance for deferred income tax assets	77.4		77.4
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Valuation allowance for deferred income tax assets	11.7		11.7
Life Insurance Related NOLs
Operating Loss Carryforwards [Line Items]
Tax Benefits Recognized On IRS Settlement		280.7
Additional life net operating loss carryforwards		98.2		$ 98.2
Decrease to income tax accrued			(50)
Non-Life Insurance Related NOLs, Classification Of Loss On Investment [Member]
Operating Loss Carryforwards [Line Items]
Tax Benefits Recognized On IRS Settlement		130
Non-Life Insurance Related NOLs, Bad Debt Deduction On Stock Purchase Loan [Member]
Operating Loss Carryforwards [Line Items]
Tax Benefits Recognized On IRS Settlement		66.7
Non-Life Insurance Related NOLs
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		51.7
Additional life net operating loss carryforwards		$ 17.1		$ 17.1
Internal Revenue Service (IRS)
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 2,300		$ 2,300

INCOME TAXES (SCHEDULE OF EFFEC

INCOME TAXES (SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILLIATION) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. statutory corporate rate	35.00%	35.00%	35.00%
Valuation allowance	(6.00%)	7.60%	(8.80%)
Non-taxable income and nondeductible benefits, net	(2.00%)	(1.10%)	(0.20%)
State taxes	0.60%	2.20%	2.10%
Impact of federal tax reform	64.70%	0.00%	0.00%
Change in valuation allowance related to federal tax reform	(28.80%)	0.00%	0.00%
Impact of IRS settlement	0.00%	(48.20%)	0.00%
Other items	0.00%	3.10%	(1.70%)
Effective tax rate	63.50%	(1.40%)	26.40%

INCOME TAXES (SCHEDULE OF DEFER

INCOME TAXES (SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net federal operating loss carryforwards	$ 489.6		$ 882.9
Net state operating loss carryforwards	9.3		12.3
Investments	4.3		17.8
Insurance liabilities	415.8		668.4
Other	48.9		66.3
Gross deferred tax assets	967.9	$ 1,045.9	1,647.7
Deferred tax liabilities:
Present value of future profits and deferred acquisition costs	(165.4)		(277.8)
Accumulated other comprehensive income	(337.2)		(344.1)
Gross deferred tax liabilities	(502.6)		(621.9)
Net deferred tax assets before valuation allowance	465.3		1,025.8
Valuation allowance	(89.1)	(255.9)	(240.2)	$ (213.5)	$ (246)
Net deferred tax assets	376.2	$ 790	785.6
Current income taxes prepaid (accrued)	(9.3)		4.1
Income tax assets, net	$ 366.9		$ 789.7

INCOME TAXES (SUMMARY OF VALUAT

INCOME TAXES (SUMMARY OF VALUATION ALLOWANCE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 01, 2017
Increase (Decrease) in Valuation Allowance [Roll Forward]
Beginning valuation allowance	$ 240.2	$ 213.5	$ 246
Change in valuation allowance	(151.1)	26.7	(32.5)
Decrease in 2017	166.8
Cumulative effect of accounting change	967.9	1,647.7		$ 1,045.9
Ending valuation allowance	89.1	240.2	213.5
Impact of federal tax reform	138.1	$ 0	$ 0
Income Tax Expense (Benefit), change in valuation allowance in taxable income	15.3
Recognition of excess tax benefits
Increase (Decrease) in Valuation Allowance [Roll Forward]
Cumulative effect of accounting change				$ 15.7
Capital Gains
Increase (Decrease) in Valuation Allowance [Roll Forward]
Decrease in 2017	$ 13.4

INCOME TAXES (SUMMARY OF OPERAT

INCOME TAXES (SUMMARY OF OPERATING LOSS CARRYFORWARDS) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 2,331.4
2,023
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2023
Net operating loss carryforwards	$ 1,744.8
2,025
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2025
Net operating loss carryforwards	$ 85.2
2,026
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2026
Net operating loss carryforwards	$ 149.9
2,027
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2027
Net operating loss carryforwards	$ 10.8
2,028
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2028
Net operating loss carryforwards	$ 80.3
2,029
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2029
Net operating loss carryforwards	$ 213.2
2,030
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2030
Net operating loss carryforwards	$ 0.3
2,031
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2031
Net operating loss carryforwards	$ 0.2
2,032
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2032
Net operating loss carryforwards	$ 44.4
2,033
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2033
Net operating loss carryforwards	$ 0.6
2,034
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2034
Net operating loss carryforwards	$ 0.9
2,035
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2035
Net operating loss carryforwards	$ 0.8

INCOME TAXES (RECONCILIATION OF

INCOME TAXES (RECONCILIATION OF UNRECOGNIZED TAX BENEFITS) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 234.2
Increase based on tax positions taken in prior years	3.4
Decrease in unrecognized tax benefits related to settlements with taxing authorities	(237.6)
Balance at end of year	$ 0

NOTES PAYABLE - DIRECT CORPOR86

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (SCHEDULE OF LONG-TERM DEBT INSTRUMENTS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-term debt, gross	$ 925
Unamortized debt issuance costs	(10.4)	$ (12.1)
Direct corporate obligations	914.6	912.9
Senior Notes | 4.500% Senior Notes due May 2020
Debt Instrument [Line Items]
Long-term debt, gross	$ 325	325
Interest rate	4.50%
Senior Notes | 5.250% Senior Notes due May 2025
Debt Instrument [Line Items]
Long-term debt, gross	$ 500	500
Interest rate	5.25%
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 100	$ 100

NOTES PAYABLE - DIRECT CORPOR87

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (NOTES) (Details) - Senior Notes - USD ($)	May 19, 2015	Dec. 31, 2017	Sep. 28, 2012
Debt Instrument [Line Items]
Event of default ownership percentage threshold to declare payment		25.00%
4.500% Senior Notes due May 2020
Debt Instrument [Line Items]
Aggregate principal amount	$ 325,000,000
Interest rate		4.50%
5.250% Senior Notes due May 2025
Debt Instrument [Line Items]
Aggregate principal amount	$ 500,000,000
Interest rate		5.25%
5.250% Senior Notes due May 2025 | On and After February 28, 2025
Debt Instrument [Line Items]
Redemption price, percent	100.00%
5.250% Senior Notes due May 2025 | Change of Control Repurchase Event
Debt Instrument [Line Items]
Redemption price, percent	101.00%
Senior Secured Note 6.375 Percent
Debt Instrument [Line Items]
Interest rate			6.375%

NOTES PAYABLE - DIRECT CORPOR88

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (REVOLVING CREDIT AGREEMENT) (Details) - USD ($) $ in Millions	Oct. 13, 2017	May 19, 2015	Dec. 31, 2017
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 250	$ 150
Debt Instrument, term		4 years
Initial drawing amount		$ 100
Remaining borrowing capacity		50
Potential additional borrowing capacity		$ 100
Interest rate on amounts outstanding at period end			3.44%
Fronting fee as a percent of aggregate face amount of letters of credit outstanding		0.125%
Debt covenant, required minimum debt to total capitalization ratio	35.00%	30.00%
Debt covenant, actual debt to total capitalization ratio at period end			20.30%
Debt covenant, minimum required aggregate total adjusted capital to company action level risk-based capital ratio		250.00%
Debt covenant, actual aggregate total adjusted capital to company action level risk-based capital ratio at period end			446.00%
Debt covenant, minimum required consolidated net worth, component one, amount		$ 2,674
Debt covenant, minimum required consolidated net worth, component two, as a percent of net equity proceeds received from issuance and sale of equity interests		50.00%
Debt covenant, actual consolidated net worth at period end			$ 3,635.4
Debt covenant, required minimum consolidated net worth, amount			$ 2,684.9
Line of Credit | Revolving Credit Facility | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Line of Credit | Bridge Loan
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 5
Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 5
Minimum | Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate	1.375%	1.75%
Minimum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.375%	0.75%
Minimum | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining borrowing capacity		$ 50
Maximum | Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate	2.125%	2.25%
Maximum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.125%	1.25%
Maximum | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining borrowing capacity	$ 100

NOTES PAYABLE - DIRECT CORPOR89

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (LOSS ON EXTINGUISHMENT OF DEBT) (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 28, 2012
Debt Instrument [Line Items]
Loss on extinguishment of debt	$ 0	$ 0	$ 32.8
Senior Notes | Senior Secured Note 6.375 Percent
Debt Instrument [Line Items]
Interest rate				6.375%

NOTES PAYABLE - DIRECT CORPOR90

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (SCHEDULE OF MATURITIES OF LONG-TERM DEBT) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2,018	$ 0
2,019	100
2,020	325
2,021	0
2,022	0
Thereafter	500
Direct corporate obligations	925
Senior Notes | 4.500% Senior Notes due May 2020
Debt Instrument [Line Items]
Direct corporate obligations	$ 325	$ 325
Interest rate	4.50%

LITIGATION AND OTHER LEGAL PR91

LITIGATION AND OTHER LEGAL PROCEEDINGS (NARRATIVE) (Details) $ in Millions	Jun. 19, 2017USD ($)	Dec. 16, 2016USD ($)	Dec. 31, 2017USD ($)stateindividual	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jul. 26, 2017individual
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of individuals appointed to assume immediate control and power over affairs | individual						2
Number of states participating in examination of compliance with unclaimed property laws | state			38
Amount of insurance-related assessment liability			$ 14.1	$ 24.9
Premium tax offset for loss contingency accruals			20	26.7
Insurance-related assessment, expense recognized			11	2.8	$ 1.2
Operating leases and sponsorship agreements, expense			$ 61.4	56.8	$ 48.8
Former Chief Executive Officers
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of Company's former chief executive officers' retirement benefits guaranteed by subsidiaries | individual			2
Deferred compensation arrangement with individual, recorded liability			$ 24.2	$ 25
Compensatory Damages
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Damages awarded to plaintiffs		$ 4.7
Punitive Damages
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Damages awarded to plaintiffs		$ 6
Loss contingency, awarded damages reduced, value	$ 1.5

LITIGATION AND OTHER LEGAL PR92

LITIGATION AND OTHER LEGAL PROCEEDINGS (SCHEDULE OF FUTURE MINIMUM RENTAL PAYMENTS FOR OPERATING LEASES) (Details) $ in Millions	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 33.5
2,019	18.2
2,020	11.8
2,021	8
2,022	5.6
Thereafter	3.6
Total	$ 80.7

AGENT DEFERRED COMPENSATION P93

AGENT DEFERRED COMPENSATION PLAN (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Cost recognized for defined contribution plan	$ 5.5	$ 5.3	$ 5
Nonqualified Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Company-owned life insurance	18	5.1
Deferred compensation arrangement with individual, recorded liability	22.9	11.2
Deferred compensation arrangement contributions by employer	6.6	4.4
Unfunded Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Recognized pre-tax gain related to settlement distributions				$ 6.1
Net periodic benefit cost	18.8	8.1	2.2
Deferred Compensation Arrangement With Individual, Gain (Loss) Recognized	(12.2)	3.1	15.2
Company-owned life insurance	182.3	165
Change in value of corporate or bank owned life insurance	24.6	6.9	$ 0.5
Deferred compensation arrangement with individual, recorded liability	$ 168.2	$ 156.3
Minimum | Nonqualified Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred compensation arrangement vesting period	5 years
Maximum | Nonqualified Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred compensation arrangement vesting period	10 years

AGENT DEFERRED COMPENSATION P94

AGENT DEFERRED COMPENSATION PLAN (SCHEDULE OF ASSUMPTIONS USED) (Details) - Unfunded Plan	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Discount rate - Benefit Obligations	3.75%	4.25%
Discount rate - Net Period Costs	4.25%	4.50%

AGENT DEFERRED COMPENSATION P95

AGENT DEFERRED COMPENSATION PLAN (SCHEDULE OF EXPECTED BENEFIT PAYMENTS) (Details) - Unfunded Plan $ in Millions	Dec. 31, 2017USD ($)
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
2,018	$ 7.4
2,019	7.6
2,020	7.9
2,021	8
2,022	8.3
2023 - 2027	$ 45.2

DERIVATIVES (FAIR VALUE BY BALA

DERIVATIVES (FAIR VALUE BY BALANCE SHEET LOCATION) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Fixed index call options
Derivatives, Fair Value [Line Items]
Gross amounts recognized	$ 170.2	$ 111.9
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross amounts recognized	168.8	107.7
Gross derivative liability	1,334.8	1,092.3
Not Designated as Hedging Instrument | Fixed index call options | Other invested assets:
Derivatives, Fair Value [Line Items]
Gross amounts recognized	170.2	111.9
Not Designated as Hedging Instrument | Reinsurance receivables | Other invested assets:
Derivatives, Fair Value [Line Items]
Gross amounts recognized	(1.4)	(4.2)
Not Designated as Hedging Instrument | Fixed index products | Fixed index products
Derivatives, Fair Value [Line Items]
Gross derivative liability	$ 1,334.8	$ 1,092.3

DERIVATIVES (SCHEDULE OF DERIVA

DERIVATIVES (SCHEDULE OF DERIVATIVE INSTRUMENTS) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)policy
Embedded Derivative Financial Instruments
Derivative Instrument [Roll Forward]
December 31, 2016 | policy	100,812
Additions | policy	11,437
Maturities/terminations | policy	(7,560)
December 31, 2017 | policy	104,689
Fixed index call options
Derivative, Notional Amount [Roll Forward]
December 31, 2016	$ 2,455.1
Additions	3,021.8
Maturities/terminations	(2,471.1)
December 31, 2017	3,005.8
Embedded Derivative Associated With Modified Coinsurance Agreement [Member]
Derivative, Notional Amount [Roll Forward]
Mark to market adjustment on embedded derivatives	$ 126

DERIVATIVES (SCHEDULE PRE-TAX G

DERIVATIVES (SCHEDULE PRE-TAX GAINS (LOSSES) RECOGNIZED IN NET INCOME FOR DERIVATIVE INSTRUMENTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	$ 190.3	$ 89.7	$ (9.6)
Investment Income | Equity Swap
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	162.5	29.2	(36.2)
Gain (Loss) on Investments
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	2.8	(0.3)	(9.7)
Gain (Loss) on Investments | Interest Rate Contract
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	0	(1.1)	(2.7)
Gain (Loss) on Investments | Embedded Derivative Financial Instruments | Coinsurance
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	2.8	0.8	(7)
Insurance Policy Benefits | Embedded Derivative Financial Instruments
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	$ 25	$ 60.8	$ 36.3

DERIVATIVES (DERIVATIVES WITH M

DERIVATIVES (DERIVATIVES WITH MASTER NETTING ARRANGEMENTS) (Details) - Fixed index call options - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Derivative [Line Items]
Gross amounts recognized	$ 170.2	$ 111.9
Gross amounts offset in the balance sheet	0	0
Net amounts of assets presented in the balance sheet	170.2	111.9
Financial instruments	0	0
Cash collateral received	0	0
Net amount	$ 170.2	$ 111.9

SHAREHOLDERS' EQUITY (SCHEDULE

SHAREHOLDERS' EQUITY (SCHEDULE OF COMMON STOCK OUTSTANDING) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Common Stock Outstanding [Roll Forward]
Balance, beginning of year (in shares)	173,753,614
Balance, end of year (in shares)	166,857,931	173,753,614
Number of stock tendered for payment of federal and state taxes owed	103,000	191,000	237,000
Common stock
Common Stock Outstanding [Roll Forward]
Balance, beginning of year (in shares)	173,754,000	184,029,000	203,324,000
Treasury stock purchased and retired (in shares)	(7,808,000)	(11,688,000)	(20,582,000)
Balance, end of year (in shares)	166,858,000	173,754,000	184,029,000
Common stock | Employee Stock Option
Common Stock Outstanding [Roll Forward]
Shares issued under employee benefit compensation plans (in shares)	725,000	978,000	769,000
Common stock | Restricted and Performance Stock
Common Stock Outstanding [Roll Forward]
Shares issued under employee benefit compensation plans (in shares)	187,000	435,000	518,000

SHAREHOLDERS' EQUITY (NARRATIVE

SHAREHOLDERS' EQUITY (NARRATIVE) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	4 Months Ended		8 Months Ended			12 Months Ended			36 Months Ended		60 Months Ended
	May 31, 2017	Apr. 30, 2017	Apr. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2009	Dec. 31, 2014	Jan. 01, 2017	May 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, increase in authorized amount	$ 1,900
Payments to repurchase common stock							$ 168.3	$ 210	$ 365.4
Stock repurchase program, remaining repurchase authorized amount				$ 385.6			385.6			$ 385.6
Common stock dividends paid							$ 59.6	$ 54.8	$ 52
Dividends (in dollars per share)		$ 0.08	$ 0.06	$ 0.09	$ 0.08	$ 0.07	$ 0.35	$ 0.31	$ 0.27
Available for future grant (in shares)				7,488,000	4,620,000	6,882,000	7,488,000	4,620,000	6,882,000	7,488,000
Proceeds from stock options exercised							$ 8.3	$ 8.4	$ 6.3
Additional paid-in capital				$ 3,073.3	$ 3,212.1		3,073.3	3,212.1		$ 3,073.3			$ 3,213
Retained earnings				560.4	650.7		560.4	650.7		560.4			650.1
Income tax assets				$ 967.9	1,647.7		$ 967.9	1,647.7		$ 967.9			1,045.9
Price of junior preferred stock (per 1/1000 of a share)				$ 90			$ 90			$ 90
Junior preferred stock right becomes exercisable when a person or group becomes owner of stated percentage (more than)							4.99%
Series B Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Series B junior participating preferred stock par value (in dollars per share)				$ 0.01			$ 0.01			$ 0.01
Junior preferred stock, purchase right to purchase fractional share (in shares)							0.001
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period							10 years
Allocated share-based compensation expense							$ 6.3	12.2	9.6
Allocated share-based compensation expense, net of tax							$ 4.1	$ 7.9	$ 6.2
Compensation expense related to stock options reduced both basic and diluted earnings per share (in dollars per share)							$ (0.02)	$ (0.04)	$ (0.03)
Unrecognized compensation expense				$ 4.2			$ 4.2			$ 4.2
Weighted average recognition period							1 year 5 months 24 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period										3 years
Allocated share-based compensation expense							$ 6.1	$ 3.1	$ 2.2
Unrecognized compensation expense				5.5	5		$ 5.5	$ 5		$ 5.5
Weighted average recognition period							1 year 9 months 24 days
Granted (in shares)							330,000
Granted (in dollars per share)							$ 20.87	$ 18.17	$ 17.59
Grant date fair value of performance shares awarded				6.9	7.3	$ 1.7	$ 6.9	$ 7.3	$ 1.7	6.9
Fair value of vested shares							$ 2.7	$ 2.1	$ 2.7
Restricted Stock | Directors, Officers, and Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)							300,000	400,000	100,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense							$ 9	$ 7.7	$ 5.3
Granted (in shares)							452,900	507,976	516,660
Grant date fair value of performance shares awarded				$ 11.2	$ 10.3		$ 11.2	$ 10.3		$ 11.2
Performance period							3 years
Performance unit payout							200.00%	150.00%
Years 2007 Through 2009 | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period											5 years
Vesting period											3 years
Years 2010 and Thereafter | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period												7 years
Vesting period												3 years
2015 | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period										10 years
Vesting period										3 years
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock purchased and retired (in shares)							7,808,000	11,688,000	20,582,000
Common Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount														$ 100
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments to repurchase common stock							$ 167.1	$ 203	$ 365.2
Election to account for forfeitures as they occur
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional paid-in capital													0.9
Retained earnings													(0.6)
Income tax assets													$ 0.3

SHAREHOLDERS' EQUITY (SCHEDU102

SHAREHOLDERS' EQUITY (SCHEDULE OF SHARE-BASED COMPENSATION) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at the beginning of the year (in shares)	5,354	5,199	5,011
Options granted (in shares)	729	1,706	1,361
Exercised (in shares)	(237)	(978)	(769)
Forfeited or terminated (in shares)	(725)	(573)	(404)
Outstanding at the end of the year (in shares)	5,121	5,354	5,199
Options exercisable at the end of the year (in shares)	2,440	2,187	2,399
Available for future grant (in shares)	7,488	4,620	6,882
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at the beginning of the year (in dollars per share)	$ 14.73	$ 13.32	$ 12.04
Options granted (in dollars per share)	21.06	17.45	16.45
Exercised (in dollars per share)	(17.81)	(8.70)	(8.20)
Forfeited or terminated (in dollars per share)	(11.43)	(20.41)	(17.70)
Outstanding at the end of the year (in dollars per share)	$ 15.95	$ 14.73	$ 13.32
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Options outstanding, weighted average remaining life	5 years 4 months 24 days	5 years 10 months 24 days	4 years 9 months 24 days
Options exercisable at the end of the year, weighted average remaining life	3 years	2 years 8 months 24 days	2 years 5 months 24 days
Options exercised, aggregate intrinsic value	$ 5.2	$ 6.1	$ 4.8
Options outstanding, aggregate intrinsic value	37.2	37.1	38.4
Options exercisable at the end of the year, aggregate intrinsic value	$ 19.2	$ 15.1	$ 15.3

SHAREHOLDERS' EQUITY (SCHEDU103

SHAREHOLDERS' EQUITY (SCHEDULE OF VALUATION ASSUMPTIONS ON PAYMENT AWARDS) (Details) - Employee Stock Option - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rates	2.20%	1.40%	1.70%
Weighted average dividend yields	1.50%	1.60%	1.50%
Volatility factors	32.00%	36.00%	85.00%
Weighted average expected life (in years)	6 years 3 months 24 days	6 years 3 months 24 days	6 years 3 months 24 days
Weighted average fair value per share (in dollars per share)	$ 6.20	$ 5.48	$ 10.83

SHAREHOLDERS' EQUITY (SCHEDU104

SHAREHOLDERS' EQUITY (SCHEDULE OF SHARE-BASED COMPENSATION BY EXERCISE PRICE RANGE) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number outstanding (in shares) | shares	5,121
Number exercisable (in shares) | shares	2,440
Range of exercise prices: $6.77 - $7.51
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower range limit (in dollars per share)	$ 6.77
Exercise price range, upper range limit (in dollars per share)	$ 7.51
Number outstanding (in shares) | shares	605
Remaining life (in years)	10 months 24 days
Average exercise price (in dollars per share)	$ 7.47
Number exercisable (in shares) | shares	605
Average exercise price (in dollars per share)	$ 7.47
Range of exercise prices: $10.88 - $16.22
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower range limit (in dollars per share)	10.88
Exercise price range, upper range limit (in dollars per share)	$ 16.22
Number outstanding (in shares) | shares	683
Remaining life (in years)	2 years 3 months 24 days
Average exercise price (in dollars per share)	$ 11.12
Number exercisable (in shares) | shares	670
Average exercise price (in dollars per share)	$ 11.02
Range of exercise prices: $16.42 - $21.48
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower range limit (in dollars per share)	16.42
Exercise price range, upper range limit (in dollars per share)	$ 21.48
Number outstanding (in shares) | shares	3,833
Remaining life (in years)	6 years 8 months 24 days
Average exercise price (in dollars per share)	$ 18.15
Number exercisable (in shares) | shares	1,165
Average exercise price (in dollars per share)	$ 18.04

SHAREHOLDERS' EQUITY (SCHEDU105

SHAREHOLDERS' EQUITY (SCHEDULE OF NONVESTED SHARE ACTIVITY) (Details) - Restricted Stock - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares, beginning of year (in shares)	369
Granted (in shares)	330
Vested (in shares)	(147)
Forfeited (in shares)	(17)
Non-vested shares, end of year (in shares)	535	369
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares, beginning of year (in dollars per share)	$ 18.10
Granted (in dollars per share)	20.87	$ 18.17	$ 17.59
Vested (in dollars per share)	(18.38)
Forfeited (in dollars per share)	(20.59)
Non-vested shares, end of year (in dollars per share)	$ 19.65	$ 18.10

SHAREHOLDERS' EQUITY (SCHEDU106

SHAREHOLDERS' EQUITY (SCHEDULE OF PERFORMANCE SHARE-BASED COMPENSATION) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total shareholder return awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Awards outstanding, beginning of period (in units)	570	549	519
Granted (in units)	226	254	258
Additional shares issued pursuant to achieving certain performance criteria (in units)	0	87	85
Vested (in units)	0	(261)	(260)
Forfeited (in units)	(167)	(59)	(53)
Awards outstanding, end of period (in units)	629	570	549
Performance unit payout	150.00%
Operating return on equity awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Awards outstanding, beginning of period (in units)	570	549	343
Granted (in units)	226	254	258
Additional shares issued pursuant to achieving certain performance criteria (in units)	30	65	0
Vested (in units)	(144)	(239)	0
Forfeited (in units)	(53)	(59)	(52)
Awards outstanding, end of period (in units)	629	570	549
Pre-tax operating income awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Awards outstanding, beginning of period (in units)	0	0	176
Granted (in units)	0	0	0
Additional shares issued pursuant to achieving certain performance criteria (in units)	0	0	85
Vested (in units)	0	0	(260)
Forfeited (in units)	0	0	(1)
Awards outstanding, end of period (in units)	0	0	0

SHAREHOLDERS' EQUITY (SCHEDU107

SHAREHOLDERS' EQUITY (SCHEDULE OF EARNINGS PER SHARE RECONCILIATION) (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Net income (loss) for diluted earnings per share	$ 175.6	$ 358.2	$ 270.7
Shares:
Weighted average shares outstanding for basic earnings per share (in dollars per share)	170,025	176,638	193,054
Effect of dilutive securities on weighted average shares:
Stock options, restricted stock and performance units (in shares)	2,119	1,685	2,112
Weighted average shares outstanding for diluted earnings per share (in shares)	172,144	178,323	195,166

OTHER OPERATING STATEMENT DA108

OTHER OPERATING STATEMENT DATA (SCHEDULE OF INSURANCE POLICY INCOME) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Insurance [Abstract]
Direct premiums collected	$ 4,013.4	$ 3,942.7	$ 3,769.6
Reinsurance assumed	30.2	33.8	38.4
Reinsurance ceded	(114.4)	(132.9)	(142.8)
Premiums collected, net of reinsurance	3,929.2	3,843.6	3,665.2
Change in unearned premiums	19	6.2	5.9
Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities	(1,445.9)	(1,386.7)	(1,241.9)
Premiums on traditional products with mortality or morbidity risk	2,502.3	2,463.1	2,429.2
Fees and surrender charges on interest-sensitive products	145	138	126.8
Insurance policy income	$ 2,647.3	$ 2,601.1	$ 2,556

OTHER OPERATING STATEMENT DA109

OTHER OPERATING STATEMENT DATA (NARRATIVE) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Present Value of Future Insurance Profits, Percentage of Amortization Expense, Next Five Years [Abstract]
2,018	11.00%
2,019	10.00%
2,020	9.00%
2,021	7.00%
2,022	7.00%
Average interest accrual rate associated with amortization method of present value of future insurance profits	5.00%	5.00%	5.00%
Florida
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	10.00%
Pennsylvania
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	6.00%
Texas
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	6.00%
California
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	5.00%

OTHER OPERATING STATEMENT DA110

OTHER OPERATING STATEMENT DATA (SCHEDULE OF OTHER OPERATING COST AND EXPENSE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Expenses:
Commission expense	$ 115.6	$ 110.5	$ 103.8
Salaries and wages	237.3	231	205.2
Other	488.6	454.8	430.2
Total other operating costs and expenses	$ 841.5	$ 796.3	$ 739.2

OTHER OPERATING STATEMENT DA111

OTHER OPERATING STATEMENT DATA (SCHEDULE OF CHANGES IN PRESENT VALUE OF FUTURE INSURANCE PROFITS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement in Present Value of Future Insurance Profits [Roll Forward]
Balance, beginning of year	$ 401.8	$ 449	$ 489.4
Amortization	(54.4)	(62.2)	(69.1)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	12.2	15	28.7
Balance, end of year	$ 359.6	$ 401.8	$ 449

OTHER OPERATING STATEMENT DA112

OTHER OPERATING STATEMENT DATA (SCHEDULE OF CHANGES IN DEFERRED ACQUISITION COSTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Balance, beginning of year	$ 1,044.7	$ 1,083.3	$ 770.6
Additions	236.1	242.7	246.4
Amortization	(184.9)	(191.1)	(190.9)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	(69.1)	(90.2)	257.2
Balance, end of year	$ 1,026.8	$ 1,044.7	$ 1,083.3

CONSOLIDATED STATEMENT CASH 113

CONSOLIDATED STATEMENT CASH FLOWS (SCHEDULE OF THE RECONCILIATION FOR NET INCOME PROVIDED BY OPERATING ACTIVITIES) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7
Adjustments to reconcile net income to net cash from operating activities:
Amortization and depreciation									265.4	275	283.4
Income taxes									227.5	(11.7)	92.9
Insurance liabilities									464.7	332.8	297.4
Accrual and amortization of investment income									(321.6)	(124.2)	(27.6)
Deferral of policy acquisition costs									(236.1)	(242.7)	(246.4)
Net realized investment (gains) losses									(50.3)	(8.3)	36.6
Loss on reinsurance transaction and transition expenses									0	75.4	9
Cash and cash equivalents received upon recapture of reinsurance									0	73.6	0
Loss on extinguishment of borrowings related to variable interest entities									9.5	0	0
Loss on extinguishment of debt									0	0	32.8
Other									78.4	34.7	(1)
Net cash from operating activities									$ 613.1	$ 762.8	$ 747.8

CONSOLIDATED STATEMENT CASH 114

CONSOLIDATED STATEMENT CASH FLOWS (SCHEDULE OF OTHER SIGNIFICANT NONCASH TRANSACTIONS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Stock options, restricted stock and performance units	$ 21.4	$ 23	$ 17.1
Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe	$ 0	$ 431.1	$ 0

STATUTORY INFORMATION (BASED115

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES) (SCHEDULE OF STATUTORY ACCOUNTING PRACTICES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Insurance [Abstract]
Statutory capital and surplus	$ 1,904.4	$ 1,956.8
Asset valuation reserve	246.8	253.3
Interest maintenance reserve	487	486.9
Total	$ 2,638.2	$ 2,697

STATUTORY INFORMATION (BASED116

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES) (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statutory Accounting Practices [Line Items]
Statutory capital and surplus included investments in upstream affiliates	$ 42.6	$ 42.6
Statutory accounting practices, statutory net income, amount	352.3	256.6	$ 332.6
Statutory accounting practices loss on recapture of long-term care business		110
Statutory accounting practices, net realized capital gain (loss), net of income taxes	(9.9)	(29.7)	(18)
Statutory accounting practices, pre-tax amounts for fees and interest paid	$ 158.3	$ 153.9	$ 154.2
Percentage of statutory capital and surplus, available for dividend distribution without prior approval from regulatory agency	10.00%
Amount of dividends paid by insurance subsidiaries	$ 357.7
Adjusted capital to risk-based capital ratio	95.00%
Maximum | Company Plan for Improving Capital Position
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	100.00%
Maximum | Regulatory Authority Special Examination
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	75.00%
Maximum | Regulatory Authority, Any Action Deemed Necessary
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	50.00%
Maximum | Regulatory Authority Control
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	35.00%
Maximum | Trend Test
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	150.00%
Minimum | Company Plan for Improving Capital Position
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	75.00%
Minimum | Regulatory Authority Special Examination
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	50.00%
Minimum | Regulatory Authority, Any Action Deemed Necessary
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	35.00%
Minimum | Trend Test
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	100.00%

BUSINESS SEGMENTS (SCHEDULE OF

BUSINESS SEGMENTS (SCHEDULE OF SEGMENT REPORTING INFORMATION BY SEGMENT) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Net investment income	$ 1,551.3	$ 1,325.2	$ 1,233.6
Fee revenue and other income	48.3	50.5	58.9
Total revenues	4,194.2	3,914.2	3,787.2
Benefits and expenses:
Insurance policy benefits	2,602.7	2,390.5	2,308.3
Other operating costs and expenses	841.5	796.3	739.2
Total expenses	3,739.5	3,503.9	3,364.4
Pre-tax operating earnings by segment	454.7	410.3	422.8
Bankers Life:
Revenues:
Insurance policy income, Annuities	20.3	22	22.4
Insurance policy income, Health	1,231.1	1,244.1	1,251
Insurance policy income, Life	415.2	393	375.3
Net investment income	1,107.3	936.8	884.7
Fee revenue and other income	44.1	34.4	27.7
Total revenues	2,818	2,630.3	2,561.1
Benefits and expenses:
Insurance policy benefits	1,771.8	1,620.6	1,588.4
Amortization	163.6	176.5	187.1
Interest expense on investment borrowings	19.8	13.2	8.8
Other operating costs and expenses	443.9	422.1	407.2
Total expenses	2,399.1	2,232.4	2,191.5
Pre-tax operating earnings by segment	418.9	397.9	369.6
Washington National:
Revenues:
Insurance policy income, Annuities	2.1	2.9	3
Insurance policy income, Health	642.9	627.9	615.4
Insurance policy income, Life	26.4	25	25.4
Net investment income	270.2	259.3	253.6
Fee revenue and other income	1	1.3	1.3
Total revenues	942.6	916.4	898.7
Benefits and expenses:
Insurance policy benefits	581.1	561.7	546.6
Amortization	58.8	59.1	55.2
Interest expense on investment borrowings	6.3	3.7	2
Other operating costs and expenses	198.1	189	183.4
Total expenses	844.3	813.5	787.2
Pre-tax operating earnings by segment	98.3	102.9	111.5
Colonial Penn:
Revenues:
Insurance policy income, Health	2.1	2.6	3
Insurance policy income, Life	289.7	278.8	260.5
Net investment income	44.4	44.2	43
Fee revenue and other income	1.3	1.1	1
Total revenues	337.5	326.7	307.5
Benefits and expenses:
Insurance policy benefits	199.6	201.9	189
Amortization	16.3	15.3	14.4
Interest expense on investment borrowings	0.9	0.6	0.1
Other operating costs and expenses	98.1	107.2	98.4
Total expenses	314.9	325	301.9
Pre-tax operating earnings by segment	22.6	1.7	5.6
Long-term care in run-off:
Revenues:
Insurance policy income, Health	17.5	4.8	0
Net investment income	34.6	9.4	0
Total revenues	52.1	14.2	0
Benefits and expenses:
Insurance policy benefits	47.3	17.6	0
Other operating costs and expenses	3.1	0.5	0
Total expenses	50.4	18.1	0
Pre-tax operating earnings by segment	1.7	(3.9)	0
Corporate operations:
Revenues:
Net investment income	35.5	16.6	11.3
Fee revenue and other income	8.5	10	8.6
Total revenues	44	26.6	19.9
Benefits and expenses:
Interest expense on investment borrowings	0	0	0.2
Other operating costs and expenses	84.3	69.1	38.6
Interest expense on corporate debt	46.5	45.8	45
Total expenses	130.8	114.9	83.8
Pre-tax operating earnings by segment	$ (86.8)	$ (88.3)	$ (63.9)

BUSINESS SEGMENTS (RECONCILIATI

BUSINESS SEGMENTS (RECONCILIATION OF OPERATING PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting [Abstract]
Total segment revenues									$ 4,194.2	$ 3,914.2	$ 3,787.2
Net realized investment gains (losses)									50.3	8.3	(36.6)
Revenues related to certain non-strategic investments and earnings attributable to VIEs									52.7	52.6	36.3
Fee revenue related to transition and support services agreements									0	10	25
Total revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	4,297.2	3,985.1	3,811.9
Total segment expenses									3,739.5	3,503.9	3,364.4
Insurance policy benefits - fair value changes in embedded derivative liabilities									2.9	(11.3)	(15.7)
Amortization related to fair value changes in embedded derivative liabilities									(0.4)	1.7	3.8
Amortization related to net realized investment gains (losses)									1	0.7	(0.5)
Expenses related to certain non-strategic investments and expenses attributable to VIEs									61.5	54.6	43
Fair value changes and amendment related to agent deferred compensation plan									12.2	(3.1)	(15.1)
Loss on extinguishment of debt									0	0	32.8
Loss on reinsurance transaction and transition expenses									0	75.4	9
Expenses related to transition and support services agreements									0	10	22.5
Total benefits and expenses									3,816.7	3,631.9	3,444.2
Income before income taxes	125.4	129.9	128.5	96.7	180.7	49.3	82.7	40.5	480.5	353.2	367.7
Tax expense on period income									162.8	127.8	129.5
Valuation allowance for deferred tax assets and other tax items									142.1	(132.8)	(32.5)
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7

BUSINESS SEGMENTS (SCHEDULE 119

BUSINESS SEGMENTS (SCHEDULE OF BALANCE SHEET INFORMATION, BY SEGMENT) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Total assets	$ 33,110.3	$ 31,975.5	$ 31,975.2
Total liabilities	28,262.8		27,488.3
Bankers Life:
Segment Reporting Information [Line Items]
Total assets	21,134.9		19,876.4
Total liabilities	18,031.6		17,144.9
Washington National:
Segment Reporting Information [Line Items]
Total assets	7,674.3		7,555.7
Total liabilities	6,101.5		6,096.9
Colonial Penn:
Segment Reporting Information [Line Items]
Total assets	1,059.3		1,022.9
Total liabilities	921		898.5
Long-term care
Segment Reporting Information [Line Items]
Total assets	692.9		656.2
Total liabilities	580.4		562.2
Corporate operations:
Segment Reporting Information [Line Items]
Total assets	2,548.9		2,864
Total liabilities	$ 2,628.3		$ 2,785.8

BUSINESS SEGMENTS (SCHEDULE 120

BUSINESS SEGMENTS (SCHEDULE OF SELECTED FINANCIAL INFORMATION, BY SEGMENT) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Present value of future profits	$ 359.6	$ 401.8	$ 449	$ 489.4
Deferred acquisition costs	1,026.8	1,044.7
Insurance liabilities	23,539	22,653.8
Bankers Life:
Segment Reporting Information [Line Items]
Present value of future profits	81.1	95.5
Deferred acquisition costs	606.5	646.2
Insurance liabilities	16,541.2	15,702.8
Washington National:
Segment Reporting Information [Line Items]
Present value of future profits	243.7	266.8
Deferred acquisition costs	310.8	299.9
Insurance liabilities	5,590.7	5,586.7
Colonial Penn:
Segment Reporting Information [Line Items]
Present value of future profits	34.8	39.5
Deferred acquisition costs	109.5	98.6
Insurance liabilities	834.4	809.6
Long-term care
Segment Reporting Information [Line Items]
Present value of future profits	0	0
Deferred acquisition costs	0	0
Insurance liabilities	$ 572.7	$ 554.7

QUARTERLY FINANCIAL DATA (UN121

QUARTERLY FINANCIAL DATA (UNAUDITED) (SCHEDULE OF QUARTERLY FINANCIAL INFORMATION) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	$ 4,297.2	$ 3,985.1	$ 3,811.9
Income before income taxes	125.4	129.9	128.5	96.7	180.7	49.3	82.7	40.5	480.5	353.2	367.7
Income tax expense (benefit)	196.3	29.1	45.1	34.4	(53.5)	30.7	22.8	(5)	304.9	(5)	97
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7
Basic:
Net income (loss) (in dollars per share)	$ (0.42)	$ 0.60	$ 0.49	$ 0.36	$ 1.35	$ 0.11	$ 0.34	$ 0.25	$ 1.03	$ 2.03	$ 1.40
Diluted:
Net income (in dollars per share)	$ (0.42)	$ 0.59	$ 0.48	$ 0.36	$ 1.34	$ 0.11	$ 0.33	$ 0.25	$ 1.02	$ 2.01	$ 1.39
Tax reform provisional income tax expense (benefit)	$ 172.5								$ 172.5

INVESTMENTS IN VARIABLE INTE122

INVESTMENTS IN VARIABLE INTEREST ENTITIES (NARRATIVE) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)entity	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Variable Interest Entity [Line Items]
Gain (loss) on dissolution of variable interest entities	$ (4.3)	$ (7.3)	$ 11.3
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2018	3
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2019	3.6
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2020	2.1
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2021	1.3
Repayments of investment borrowings related to variable interest entities, amounts due in 2028	539.9
Repayments of investment borrowings related to variable interest entities, amounts due in 2030	878
Variable interest entity amortized cost securities held	1,524.9
Variable interest entity, gross unrealized gains fixed maturity securities	8.6
Variable interest entity gross unrealized losses fixed maturity securities	(6.6)
Variable interest entity, estimated fair value of securities held	1,526.9
Variable interest entities net realized gain (loss) on investments	(5.6)	(20.4)	(6.4)
Variable interest entities, net losses from the sales of fixed maturities	1.2	(11.9)	(1.3)
Writedowns of investments for other than temporary declines in fair value recognized through net income	$ (2.5)	(1.2)	(16.4)
Number of VIEs in default | entity	0
Investments held by VIEs and sold	$ 109.6	192.2	46.1
Variable interest entity, gross investment losses from sale	3	20.3	$ 1.8
Less than twelve months
Variable Interest Entity [Line Items]
Fair value investments held by variable interest entity that had been in an unrealized loss position	445.4	93.8
Gross unrealized gain (loss) on investments held by VIEs	(4.9)	(0.9)
Greater than twelve months
Variable Interest Entity [Line Items]
Fair value investments held by variable interest entity that had been in an unrealized loss position	28.4	143.9
Gross unrealized gain (loss) on investments held by VIEs	$ (1.7)	$ (2.9)

INVESTMENTS IN VARIABLE INTE123

INVESTMENTS IN VARIABLE INTEREST ENTITIES (SCHEDULE OF IMPACT ON BALANCE SHEET OF CONSOLIDATING VARIABLE INTEREST ENTITIES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Assets [Abstract]
Investments held by variable interest entities	$ 1,526.9	$ 1,724.3
Cash and cash equivalents held by variable interest entities	178.9	189.3
Liabilities:
Borrowings related to variable interest entities	1,410.7	1,662.8
VIEs
Assets [Abstract]
Investments held by variable interest entities	1,526.9	1,724.3
Notes receivable of VIEs held by insurance subsidiaries	0	0
Cash and cash equivalents held by variable interest entities	178.9	189.3
Accrued investment income	2.6	3
Income tax assets, net	0.7	6.4
Other assets	10	13.1
Total assets	1,719.1	1,936.1
Liabilities:
Other liabilities	158.3	81.8
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable of VIEs held by insurance subsidiaries	167.6	203.3
Total liabilities	1,736.6	1,947.9
Eliminations
Assets [Abstract]
Investments held by variable interest entities	0	0
Notes receivable of VIEs held by insurance subsidiaries	(155.5)	(204.2)
Cash and cash equivalents held by variable interest entities	0	0
Accrued investment income	(0.1)	(0.1)
Income tax assets, net	0	(1.3)
Other assets	(1.5)	(1.8)
Total assets	(157.1)	(207.4)
Liabilities:
Other liabilities	(4.4)	(6.4)
Borrowings related to variable interest entities	0	0
Notes payable of VIEs held by insurance subsidiaries	(167.6)	(203.3)
Total liabilities	(172)	(209.7)
Net effect on consolidated balance sheet
Assets [Abstract]
Investments held by variable interest entities	1,526.9	1,724.3
Notes receivable of VIEs held by insurance subsidiaries	(155.5)	(204.2)
Cash and cash equivalents held by variable interest entities	178.9	189.3
Accrued investment income	2.5	2.9
Income tax assets, net	0.7	5.1
Other assets	8.5	11.3
Total assets	1,562	1,728.7
Liabilities:
Other liabilities	153.9	75.4
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable of VIEs held by insurance subsidiaries	0	0
Total liabilities	$ 1,564.6	$ 1,738.2

INVESTMENTS IN VARIABLE INTE124

INVESTMENTS IN VARIABLE INTEREST ENTITIES (SUPPLEMENTAL INFORMATION, REVENUES AND EXPENSES OF VARIABLE INTEREST ENTITIES) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Policyholder and other special-purpose portfolios									$ 265.9	$ 121.1	$ 30
Fee revenue and other income									48.3	50.5	58.9
Total revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	4,297.2	3,985.1	3,811.9
Expenses:
Interest expense									123.7	116.4	94.9
Other operating costs and expenses									841.5	796.3	739.2
Total benefits and expenses									3,816.7	3,631.9	3,444.2
Net realized investment losses									50.3	8.3	(36.6)
Loss on extinguishment of borrowings									(9.5)	0	0
Income before income taxes	$ 125.4	$ 129.9	$ 128.5	$ 96.7	$ 180.7	$ 49.3	$ 82.7	$ 40.5	480.5	353.2	367.7
Variable Interest Entity, Primary Beneficiary
Revenues:
Policyholder and other special-purpose portfolios									69.8	78.9	62.1
Fee revenue and other income									5.9	6.4	1.6
Total revenues									75.7	85.3	63.7
Expenses:
Interest expense									50.2	53.1	38.8
Other operating costs and expenses									1.8	1.5	2
Total benefits and expenses									52	54.6	40.8
Income before net realized investment losses and income taxes									23.7	30.7	22.9
Net realized investment losses									(5.6)	(20.4)	(6.4)
Loss on extinguishment of borrowings									(9.5)	0	0
Income before income taxes									$ 8.6	$ 10.3	$ 16.5

INVESTMENTS IN VARIABLE INTE125

INVESTMENTS IN VARIABLE INTEREST ENTITIES (SUMMARY OF VARIABLE INTEREST ENTITIES BY CONTRACTUAL MATURITY) (Details) $ in Millions	Dec. 31, 2017USD ($)
Variable Interest Entity [Line Items]
Total, Amortized Cost	$ 1,524.9
Total, Estimated Fair Value	1,526.9
Amortized cost
Variable Interest Entity [Line Items]
Due in one year or less	11.2
Due after one year through five years	541.8
Due after five years through ten years	971.9
Total, Amortized Cost	1,524.9
Due in one year or less	2.4
Due after one year through five years	178.2
Due after five years through ten years	299.8
Total, Amortized Cost	480.4
Estimated fair value
Variable Interest Entity [Line Items]
Due in one year or less	11.2
Due after one year through five years	542
Due after five years through ten years	973.7
Total, Estimated Fair Value	1,526.9
Due in one year or less	2.4
Due after one year through five years	174.3
Due after five years through ten years	297.1
Total, Estimated Fair Value	$ 473.8

SCHEDULE II - BALANCE SHEET (De

SCHEDULE II - BALANCE SHEET (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Assets [Abstract]
Cash and cash equivalents - unrestricted	$ 578.4		$ 478.9	$ 432.3	$ 611.6
Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5)	511.7		584.2
Income tax assets, net	366.9		789.7
Other assets	319.5		328.5
Total assets	33,110.3	$ 31,975.5	31,975.2
Liabilities:
Notes payable	914.6		912.9
Other liabilities	751.8		611.4
Total liabilities	28,262.8		27,488.3
Commitments and Contingencies
Shareholders' equity:
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4	650.1	650.7
Total shareholders' equity	4,847.5	4,487.2	4,486.9	4,138.5	4,688.2
Total liabilities and shareholders' equity	33,110.3	$ 31,975.5	31,975.2
Parent Company
Assets [Abstract]
Cash and cash equivalents - unrestricted	161.1		106.1	$ 128.9	$ 86.6
Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5)	243.6		167.9
Investment in wholly-owned subsidiaries (eliminated in consolidation)	5,440.7		5,220.3
Income tax assets, net	129.6		99.5
Receivable from subsidiaries (eliminated in consolidation)	6.3		2
Other assets	12.7		1.8
Total assets	5,994		5,597.6
Liabilities:
Notes payable	914.6		912.9
Payable to subsidiaries (eliminated in consolidation)	143		128.4
Other liabilities	88.9		69.4
Total liabilities	1,146.5		1,110.7
Commitments and Contingencies
Shareholders' equity:
Common stock and additional paid-in capital ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)	3,075		3,213.8
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4		650.7
Total shareholders' equity	4,847.5		4,486.9
Total liabilities and shareholders' equity	$ 5,994		$ 5,597.6

SCHEDULE II - BALANCE SHEET ADD

SCHEDULE II - BALANCE SHEET ADDITIONAL INFORMATION (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Condensed Financial Statements, Captions [Line Items]
Equity securities cost	$ 491.1	$ 580.7
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000,000	8,000,000,000
Common stock, shares issued (in shares)	166,857,931	173,753,614
Common stock, shares outstanding (in shares)	166,857,931	173,753,614
Parent Company
Condensed Financial Statements, Captions [Line Items]
Equity securities cost	$ 225.7	$ 166.5
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000,000	8,000,000,000
Common stock, shares issued (in shares)	166,857,931	173,753,614
Common stock, shares outstanding (in shares)	166,857,931	173,753,614

SCHEDULE II - STATEMENT OF OPER

SCHEDULE II - STATEMENT OF OPERATIONS (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Net investment income									$ 1,551.3	$ 1,325.2	$ 1,233.6
Net realized investment gains (losses)									50.3	8.3	(36.6)
Total revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	4,297.2	3,985.1	3,811.9
Expenses:
Interest expense									123.7	116.4	94.9
Loss on extinguishment of debt									0	0	32.8
Income before income taxes	125.4	129.9	128.5	96.7	180.7	49.3	82.7	40.5	480.5	353.2	367.7
Income tax expense (benefit)	196.3	29.1	45.1	34.4	(53.5)	30.7	22.8	(5)	304.9	(5)	97
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	175.6	358.2	270.7
Parent Company
Revenues:
Net investment income									14.2	15.6	16.9
Net realized investment gains (losses)									2.4	17.7	3.5
Intercompany losses (eliminated in consolidation)									0	0	(1.5)
Total revenues									16.6	33.3	18.9
Expenses:
Interest expense									46.5	45.8	45.2
Intercompany expenses (eliminated in consolidation)									1.7	0.9	0.4
Operating costs and expenses									75.4	48.2	21
Loss on extinguishment of debt									0	0	32.8
Total expenses									123.6	94.9	99.4
Income before income taxes									(107)	(61.6)	(80.5)
Income tax expense (benefit)									27.4	(54.6)	(37.9)
Loss before equity in undistributed earnings of subsidiaries									(134.4)	(7)	(42.6)
Equity in undistributed earnings of subsidiaries (eliminated in consolidation)									310	365.2	313.3
Net income									$ 175.6	$ 358.2	$ 270.7

SCHEDULE II - STATEMENT OF CASH

SCHEDULE II - STATEMENT OF CASH FLOWS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Cash flows from operating activities	$ 613.1	$ 762.8	$ 747.8
Cash flows from investing activities:
Sales of investments	2,487.4	2,841.8	2,177.6
Purchases of investments	(6,141)	(6,159.8)	(4,767.2)
Net sales of trading securities	108.9	(84.2)	(12.3)
Net cash provided (used) by investing activities	(239.6)	(742.4)	(1,069.6)
Cash flows from financing activities:
Issuance of notes payable, net	0	0	910
Payments on notes payable	0	0	(797.1)
Expenses related to extinguishment of debt	0	0	(17.8)
Issuance of common stock	8.3	8.4	6.3
Payments to repurchase common stock	(168.3)	(210)	(365.4)
Net cash provided (used) by financing activities	(274)	26.2	142.5
Net increase (decrease) in cash and cash equivalents	99.5	46.6	(179.3)
Cash and cash equivalents, beginning of year	478.9	432.3	611.6
Cash and cash equivalents, end of year	578.4	478.9	432.3
Parent Company
Condensed Financial Statements, Captions [Line Items]
Cash flows from operating activities	(181.8)	(110.7)	(51.2)
Cash flows from investing activities:
Sales of investments	54.9	305	66.5
Sales of investments - affiliated	0	0	16
Maturities and redemptions of investments - affiliated	0	0	8.3
Purchases of investments	(123.6)	(198.4)	(68.6)
Purchases of investments - affiliated	0	0	(3.4)
Net sales of trading securities	9.1	12	11.8
Dividends received from consolidated subsidiary, net of capital contributions of nil in 2017, $200.0 in 2016 and nil in 2015	363.5	92.5	269.7
Net cash provided (used) by investing activities	303.9	211.1	300.3
Cash flows from financing activities:
Issuance of notes payable, net	0	0	910
Payments on notes payable	0	0	(797.1)
Expenses related to extinguishment of debt	0	0	(17.8)
Issuance of common stock	8.3	8.4	6.3
Payments to repurchase common stock	(168.3)	(210)	(365.4)
Common stock dividends paid	(59.6)	(54.8)	(52)
Investment borrowings - repurchase agreements, net	0	0	(20.4)
Issuance of notes payable to affiliates	310.8	217.1	234.4
Payments on notes payable to affiliates	(158.3)	(83.9)	(104.8)
Net cash provided (used) by financing activities	(67.1)	(123.2)	(206.8)
Net increase (decrease) in cash and cash equivalents	55	(22.8)	42.3
Cash and cash equivalents, beginning of year	106.1	128.9	86.6
Cash and cash equivalents, end of year	$ 161.1	$ 106.1	$ 128.9

SCHEDULE II - STATEMENT OF C130

SCHEDULE II - STATEMENT OF CASH FLOWS ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Parent Company
Condensed Financial Statements, Captions [Line Items]
Capital contributions	$ 0	$ 200	$ 0

SCHEDULE IV (Details)

SCHEDULE IV (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Assumed premiums earned	$ 30.2	$ 33.8	$ 38.4
Reinsurance ceded	(114.4)	(132.9)	(142.8)
Insurance policy income	2,647.3	2,601.1	2,556
Life insurance inforce:
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Direct	27,154.3	27,048.1	25,807
Assumed	120.5	128.7	137.4
Ceded	(3,452.6)	(3,604)	(3,780.8)
Net insurance inforce	$ 23,822.2	$ 23,572.8	$ 22,163.6
Percentage of assumed to net	0.50%	0.50%	0.60%
Insurance policy income:
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Direct premiums earned	$ 2,576.9	$ 2,553	$ 2,524.3
Assumed premiums earned	30.4	34	38.5
Reinsurance ceded	(105)	(123.9)	(133.6)
Insurance policy income	$ 2,502.3	$ 2,463.1	$ 2,429.2
Premiums, percentage of assumed to net	1.20%	1.40%	1.60%